REMARKS

By this Amendment, claims 1, 9 and 12 are amended; claims 4 and 11 are canceled; and new claims 17-23 are added. Thus, claims 1-3, 5-10 and 12-23 are pending in the application. Claims 1, 9 and 17 are the only independent claims. A Supplemental IDS on Form 1449 accompanies this Amendment. A Declaration is submitted herewith under 37 CFR §1.131. It is submitted that no new matter has been added to this application by way of this Amendment.

Remarks Regarding Priority

It is asserted that Applicant has not complied with conditions for receiving the benefit of an earlier filing date under 35 U.S.C. §119(e) because the application does not contain a specific reference to the prior applications in the first sentence of the specification. The specification is hereby amended to comply with the requirement in accordance with 37 CFR §1.78(a)(2) and therefore Applicant requests acknowledgement of its entitlement to receive the benefit of an earlier filing date under 35 U.S.C. §119(e).

It is further asserted that the inventions described in the provisional application Serial Nos. 60/138,173 and 60/144,314 are "significantly narrower than the instant invention" and that "consequently, the claimed invention does not meet the written description requirement for obtaining benefit of priority."

According to the MPEP, a 'broad, genus' claim is supported by 'narrower, species' examples:

> For a claimed genus, representative examples together with a statement applicable to the genus as a whole will ordinarily be sufficient if one skilled in the art (in view of level of skill, state of the art and the information in the specification) would expect the claimed genus could be used in that manner without undue experimentation. MPEP 2164.02

In the instant case, representative examples of specific vectors are detailed in the body of each of two provisional applications, Serial Nos. 60/138,173 and 60/144,314, along with a statement applicable to the genus as a whole, present at least in claim 1 of each provisional application.

Applicant submits that the claims of the present application are supported by the provisional applications Serial Nos. 60/138,173 and 60/144,314, and is entitled to obtain benefit of the priority date of both referenced provisional applications. Applicant therefore requests acknowledgement of its entitlement to receive the benefit of an earlier filing date under 35 U.S.C. §119(e).

Remarks Regarding Specification

An abstract of the disclosure is required on a separate sheet under 37 CFR §1.52(b)(4). Accordingly, a new abstract is submitted in compliance with these requirements.

Remarks Regarding Drawings

New formal drawings were required. Applicant submits corrected drawings in reply to the April 3, 2003 Office Action in order to "avoid abandonment of the application" by filing in a separate letter to the draftsperson as required by the Office Action and in compliance with MPEP 608.02(r) cited by the Examiner.

Remarks Directed Toward Claim Rejections

Rejection Under 35 U.S.C. §102(e) as Anticipated by Wechsler et al.

Claims 1-5, 9-11 and 13-15 were held to lack novelty under 35 U.S.C. §102(e) as being anticipated by Wechsler et al., US 2002/0098170.

Wechsler et al. is cited as teaching a "composition comprising substantially aneurovirulent replication-competent HSV-1 whose genome comprises deletion of both

copies of the γ34.5 gene and LAT coding sequence and a nucleic acid sequence encoding IL-12 or GM-CSF operably linked to a LAT promoter." (Paper No. 7, page 4)

Firstly, it is noted that Wechsler et al. is not cited as describing a composition including a nucleic acid sequence encoding cytosine deaminase as taught by Applicant, and Applicant finds no apparent teaching of this composition in Wechsler et al. Accordingly, new independent claim 17, and claims 18-23 depending therefrom, which include this limitation are submitted herewith.

Next, Applicant notes that a rejection based on 35 U.S.C. §102(e) can be overcome by: ...(F) Perfecting priority under 35 U.S.C. §119(e) or 120 by amending the specification of the application to contain a specific reference to a prior application or by filing an application data sheet under 37 CFR §1.76 which contains a specific reference to a prior application in accordance with 37 CFR §1.78(a). [MPEP 8th Ed., 706.02(b)]

The current specification has been amended to include a reference to related PCT and provisional applications in accordance with 37 CFR §1.78(a) as required. The referenced PCT application permits Applicant to claim benefit of priority as of June 8, 2000. Further, the referenced provisional applications are submitted to allow Applicant to claim benefit of priority dates of June 8, 1999 and July 16, 1999.

In conjunction with the above established priority dates, Applicant notes that a rejection based on 102(e) can be overcome by "(D) Filing an affidavit or declaration under 37 CFR §1.131 showing prior invention, if the reference is not a U.S. patent (or application in the case of a provisional rejection) claiming the same patentable invention...." [MPEP 706.02(b)] Applicant therefore submits herewith a declaration under 37 CFR §1.131. The declaration shows evidence of Applicant's invention of vectors described in the independent claims rejected under §102(e) as cited above, prior to the priority date claimed by Wechsler et

al., i.e. April 26, 1999. Specifically, notarized copies of dated lab notebook pages showing an IL-12 expressing HSV vector as described in independent claims 1 and 9 was in Applicant's hands at least as of August 21, 1998. Further, notarized copies of dated lab notebook pages are submitted to show a GM-CSF expressing HSV vector as described in independent claims 1 and 9 at least as of March 24, 1999. Applicant submits that evidence presented in the declaration is evidence of prior invention as compared to the priority date claimed by the Wechsler et al. application. Applicant reserves the right to submit further factual evidence showing earlier dates relating to the present inventions.

In view of these arguments and the evidence presented, it is submitted that claims 1-5, 9-11 and 13-15 are not anticipated by Wechsler et al., US 2002/0098170 under 35 U.S.C. §102(e). Applicant respectfully requests withdrawal of the rejection.

Rejection Under 35 U.S.C. §102 (a), (b) & (e) as Anticipated by DeLuca

Claims 9, 10 and 15 were held to lack novelty under 35 U.S.C. §102(a), (b) & (e) as being anticipated by DeLuca, US Patent No. 5,804,413.

A rejection based on 35 U.S.C. §102 (b) can be overcome by: Perfecting priority under 35 U.S.C. §119(e) or 120 by amending the specification of the application to contain a specific reference to a prior application or by filing an application data sheet under 37 CFR §1.76 which contains a specific reference to a prior application in accordance with 37 CFR 1.78(a). [MPEP 8th Ed., 706.02(b)]

The current specification has been amended to include a reference to PCT and provisional applications in accordance with 37 CFR §1.78(a) as required. The referenced provisional applications are submitted to allow Applicant to claim benefit of priority dates of June 8, 1999 and July 16, 1999. Further, the referenced PCT application permits Applicant to claim benefit of priority as of June 8, 2000. In contrast, DeLuca was filed on 5/22/96 and

issued 9/8/98. In order to reject the instant application under 35 U.S.C. §102(b) the instant invention must have been "patented or described in a printed publication ... more than one year prior to the date of the application for patent in the United States." [35 U.S.C. §102(b)] Since DeLuca was not patented or published before the priority date established for the instant invention, it is submitted that claims 9, 10 and 15 are not anticipated by DeLuca under 35 U.S.C. §102(b). Applicant respectfully requests withdrawal of the rejection.

Further, even if DeLuca were patented or published before the priority date established for the instant invention, Applicant submits that DeLuca is not believed to anticipate the present invention under any of 35 U.S.C. §102(a), (b) or (e). In order for the cited reference to have anticipated Applicant's invention 35 U.S.C. §102(a), (b) or (e), the reference must teach every element of the claim. (MPEP, 8th Ed., 2131)

DeLuca is cited as disclosing a "substantially aneurovirulent HSV comprising an expression construct encoding cytosine deaminase." (April 3, 2003 Office Action, p.5)

Independent claim 9 has been amended to define over the prior art. In contrast to the present invention, DeLuca does not appear to teach a replication competent HSV vector.

On the basis of these arguments and the amendments, it is submitted that claims 9, 10 and 15 are not anticipated under 35 U.S.C. §102(a), (b) or (e) by DeLuca. Thus, it is respectfully requested that the rejection of claims 9, 10 and 15 as anticipated by DeLuca be withdrawn.

Rejection under 35 U.S.C. §102(e) as Anticipated by Boursnell et al.

Claims 1, 2, 4, 9, 11 and 15 were held to lack novelty under 35 U.S.C. §102(e) as being anticipated by Boursnell et al., US Patent No. 6,287,557.

In order for the cited reference to have anticipated Applicant's invention, the reference must teach every element of the claim. (MPEP, 8th Ed., 2131)

Boursnell et al. is cited as teaching an HSV in which "[I]nasmuch as loss of the gH gene...in the HSV results in the production of non-infectious particles, the virus is replication competent." (April 3, 2003 Office Action, p.5)

Independent claims 1 and 9 have been amended to define over the prior art. In contrast to the present invention, Boursnell et al. does not appear to teach a replication competent HSV vector competent to produce infectious particles.

On the basis of these arguments and the amendment, it is submitted that claims 1, 2, 4, 9, 11 and 15 are not anticipated under 35 U.S.C. §102(e) by Boursnell et al. Thus, it is respectfully requested that the rejection of claims 1, 2, 4, 9, 11 and 15 as anticipated by Boursnell et al. be withdrawn.

Rejection under 35 U.S.C. §102(b) as Anticipated by Inglis et al.

Claims 1, 2, 4, 9, 11 and 15 were held to lack novelty under 35 U.S.C. §102(b) as being anticipated by Inglis et al., WO 96/26267

In order for the cited reference to have anticipated Applicant's invention, the reference must teach every element of the claim. (MPEP, 8th Ed., 2131)

Inglis et al. is cited as teaching an HSV in which "[I]nasmuch as loss of the gH gene...in the HSV results in the production of non-infectious particles, the virus is replication competent." (April 3, 2003 Office Action, p.5)

Independent claims 1 and 9 have been amended to define over the prior art. In contrast to the present invention, Inglis et al. does not appear to teach a replication competent HSV vector competent to produce infectious particles.

On the basis of these arguments and the amendment, it is submitted that claims 1, 2, 4, 9, 11 and 15 are not anticipated under 35 U.S.C. §102(b) by Inglis et al. Thus, it is

respectfully requested that the rejection of claims 1, 2, 4, 9, 11 and 15 as anticipated by Inglis et al. be withdrawn.

Rejection under 35 U.S.C. §102(a) as Anticipated by Todryk et al.

Claims 1, 2, 4, 9, 11 and 15 were held to lack novelty under 35 U.S.C. §102(a) as being anticipated by Todryk et al., Hum. Gene Ther. 10(17):2757-2768, 20 Nov. 1999.

A rejection based on 35 U.S.C. §102(a) can be overcome by: ...(F) Perfecting priority under 35 U.S.C. §119(e) or 120 by amending the specification of the application to contain a specific reference to a prior application or by filing an application data sheet under 37 CFR §1.76 which contains a specific reference to a prior application in accordance with 37 CFR §1.78(a). [MPEP 8th Ed., 706.02(b)]

The current specification has been amended to include a reference to PCT and provisional applications in accordance with 37 CFR §1.78(a) as required. The referenced provisional applications are submitted to allow Applicant to claim benefit of priority dates of June 8, 1999 and July 16, 1999. Further, the referenced PCT application permits Applicant to claim benefit of priority as of June 8, 2000. In contrast, Todryk et al. was published on 11/20/99. In order to reject the instant application under 35 U.S.C. §102(a) the instant invention must have been "...described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent..." [35 U.S.C. §102(a)] Since Todryk et al. was not published before the priority date established for the instant invention, it is submitted that claims 1, 2, 4, 9, 11 and 15 are not anticipated by Todryk et al. under 35 U.S.C. §102(a). Applicant respectfully requests withdrawal of the rejection.

Further, even if Todryk et al. were patented or published before the priority date established for the instant invention, Applicant submits that Todryk et al. is not believed to anticipate the present invention. In order for the cited reference to have anticipated

Applicant's invention, the reference must teach every element of the claim. (MPEP, 8th Ed., 2131)

Todryk et al. is cited as teaching an HSV in which "[I]nasmuch as loss of the gH gene...in the HSV results in the production of non-infectious particles, the virus is replication competent." (April 3, 2003 Office Action, p.6)

Independent claims 1 and 9 have been amended to define over the prior art. In contrast to the present invention, Todryk et al. does not appear to teach a replication competent HSV vector competent to produce infectious particles.

On the basis of these arguments and the amendment, it is submitted that claim 1 is not anticipated under 35 U.S.C. §102(a) by Todryk et al. Thus, it is respectfully requested that the rejection of claims 1, 2, 4, 9, 11 and 15 as anticipated by Todryk et al. be withdrawn.

Rejection under 35 U.S.C. §102(b) as Anticipated by Toda et al.

Claims 1-3, 9, 10 and 15 were held to lack novelty under 35 U.S.C. §102(b) as being anticipated by Toda et al., J. Immunol. 160(9):4457-44655, May 1998.

In order for the cited reference to have anticipated Applicant's invention, the reference must teach every element of the claim. (MPEP, 8th Ed., 2131)

Independent claims 1 and 9 describe an HSV vector competent to replicate and produce infectious particles and comprising a nucleic acid sequence encoding for a compound selected from the group consisting of IL-12, GM-CSF, and CD.

Toda et al. is cited as teaching "a pharmaceutical composition comprising replication competent HSV-1 helper virus and a replication defective HSV-1 which comprises multiple copies of an expression construct ..." (April 3, 2003 Office Action, p.6)

Independent claims 1 and 9 have been amended to define over the prior art. In contrast to the present invention, Toda et al. does not appear to teach a composition

comprising a replication competent HSV vector comprising a nucleic acid sequence encoding for a compound selected from the group consisting of IL-12, GM-CSF, and CD.

On the basis of these arguments and the amendment, it is submitted that claims 1-3, 9, 10 and 15 are not anticipated under 35 U.S.C. §102(b) by Toda et al. Thus, it is respectfully requested that the rejection of claims 1-3, 9, 10 and 15 as anticipated by Toda et al. be withdrawn.

Rejection under 35 U.S.C. §103(a) over Wechsler et al. in view of Toda et al.

Claims 9, 12 and 13 are held to be unpatentable under 35 U.S.C. §103(a) as being obvious over Wechsler et al. US 2002/0098170 in view of Toda et al. (J. Immunol. 160(9):4457-44655, May 1998).

> A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. 35 U.S.C. §103 (a), emphasis added.

It is asserted that "it would have been obvious to one of skill in the art at the time the invention was made to have constructed the HSV-1 of Wechsler which expressed IL-12 under control of the LAT promoter [and] utilize the construct as taught by Toda..." (April 3, 2003 Office Action, p.7)

However, Wechsler et al. apparently claims an effective filing date of April 26, 1999, establishing that it was unavailable as of the earlier dates, described above, which Applicant submits as evidence of prior invention. Thus, the combination of Wechsler et al. and Toda et al. would not have been obvious to one of skill in the art at the time the invention was made as required by the statute. It is therefore respectfully requested that the rejection of claims 9, 12 and 13 under 35 U.S.C. §103(a) be withdrawn.

Rejection under 35 U.S.C. §103(a) over Andreansky et al. in view of Toda et al.

Claims 1-15 are held to be unpatentable under 35 U.S.C. §103(a) as being obvious over Andreansky et al. (Gene Therapy 5(1):121-130, Jan. 1998) in view of Toda et al. (J. Immunol. 160(9):4457-44655, May 1998).

> The teaching or suggestion to make the claimed combination and the reasonable expectation of success must both be found in the prior art, not in applicant's disclosure. *In re Vaeck*, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir. 1991).

It is asserted that Andreansky et al. "...suggested that other genes encoding other immune modulat[ors] could be used..." (April 3, 2003 Office Action, p.9) However, the reference teaches that "intracerebral inoculation of HSV expressing either IL-4 or IL-10 into syngeneic murine glioma GL-261 cells implanted in the brains of immunocompetent C57BL/6 mice produced dramatically opposite physiologic responses. The IL-4 HSV significantly prolonged survival of tumor bearers, whereas tumor-bearing mice that received the IL-10 HSV had a median survival that was identical to that of saline treated controls" (Andreansky et al., Abstract). Thus, Andreansky et al., does not appear to teach that substitution of one immune modulator for another allows for a reasonable expectation of success in a method of treating tumor-bearing mice.

It is further asserted that Toda et al. teaches "that IL-12 expression in combination with a cytotoxic replication-competent HSV-1 enhanced the antitumor activity of the HSV-1." (April 3, 2003 Office Action, p.9) However, Toda et al. teach the expression of IL-12 only from a defective HSV-1 vector in combination with a replication-competent helper virus. The reference teaches that the "presence of IL-12 in particles separate from the helper virus and the large number of copies of IL-12 delivered in each defective particle may account for the significant antitumor effect seen both in established inoculated tumors and

distal non-inoculated tumors." (Toda et al., p. 4463, c.1, last para. before Acknowledgments) Thus, the Toda et al. reference teaches away from a replication-competent HSV vector that encodes IL-12, suggesting instead that their vector system is successful because the IL-12 gene is encoded by a defective vector.

In summary, Applicant submits that teaching or suggestion to make the claimed combination and the reasonable expectation of success are not found in the cited prior art references as required for rejection under 35 U.S.C. §103(a). Further, the references are believed to teach away from the claimed invention, as described above.

In view of these remarks and claim amendments, it is respectfully requested that the rejection of claims 1-15 under 35 U.S.C. §103(a) be withdrawn.

Summary

Claims 1-3, 5-10 and 12-23 are the pending claims in this application. Each claim is believed to be in proper form and directed to allowable and patentable subject matter. Reconsideration and allowance of the claims is requested.

Respectfully submitted,

Avery N. Goldstein
Registration No. 39,204
Gifford, Krass, Groh, Sprinkle,
Anderson & Citkowski, P.C.
280 N. Old Woodward, Suite 400
Birmingham, MI 48009
(248) 647-6000

Attorney for Applicant

Date: 8/29/03

JKS/sh/gs
GS–W:\Word Processing\Jks\UAB16102 amd.doc

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER EV 339616233 US

DATE OF DEPOSIT August 29, 2003

I hereby certify that this paper or fee (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office To Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janice R. Kuehn

Attorney Docket No. UAB-16102/22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Richard J. Whitley et al.

Serial No.: 10/009,972 Group Art Unit: 1632

Filing Date: February 14, 2002 Examiner: S. D. Priebe

For: HERPES SIMPLEX VIRUS EXPRESSING FOREIGN GENES AND METHOD FOR TREATING CANCERS THEREWITH

DECLARATION OF RICHARD J. WHITLEY UNDER 37 CFR 1.131

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

I, Richard J. Whitley, declare as follows:

1. I am a co-inventor of the invention disclosed in the above-identified application for patent.

2. My curriculum vitae is attached detailing my experiences in basic and therapeutic virus research.

3. I have reviewed and am familiar with the U.S. Patent Application No. 2002/0098170 listing Wechsler et al. as inventors.

4. I understand that claims 1-5, 9-11 and 13-15 of the application have been rejected under 35 USC 102(e) as being anticipated by Wechsler et al.. It is my understanding that Wechsler et al. is cited for teaching a pharmaceutical composition comprising substantially aneurovirulent replication-competent HSV-1 whose genome comprises deletion of both copies of the γ34.5 gene and LAT coding sequence and a nucleic acid sequence encoding IL-12 or GM-CSF operably linked to a LAT promoter. I understand that Wechsler et al. is also cited as

teaching a method for treating cancer in a subject by administering a therapeutically effective amount of the HSV directly to the tumor by injection.

5. I understand that Wechsler et al. filed their U.S. Patent Application 2002/0098170 on November 29, 2001 and, further, that U.S. Patent Application 2002/0098170 was filed claiming priority as a divisional application to application No. 09/299,817, filed April 26, 1999.

6. I state that a composition of the present invention including a replication competent herpes simplex virus vector comprising a nucleic acid sequence encoding interleukin-12, granulocyte macrophage colony stimulating factor or cytosine deaminase, operatively linked to a promoter was in fact invented by myself and my co-inventors before April 26, 1999.

7. I state that a method for treating a subject suffering from cancer, including the step of administering to a subject a therapeutically effective amount of a replication competent herpes simplex virus comprising a nucleic acid sequence encoding interleukin-12, granulocyte macrophage colony stimulating factor, or cytosine deaminase, such that an anti-cancer response is induced in the subject., was in fact invented by myself and my co-inventors before April 26, 1999.

8. I submit herewith notarized copies of lab notebook pages and a summary sheet describing the contents of some of the lab notebook pages as evidence that inventions described in my application were in fact invented before April 26,1999.

9. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Richard J. Whitley

Date AUG. 21, 2007

CURRICULUM VITAE

Richard James Whitley, M.D.
Department of Pediatrics
University of Alabama at Birmingham
Suite CHB 303
1600 7th Avenue South
Birmingham, Alabama 35233
(205) 934-5316

DATE OF BIRTH September 15, 1945

PLACE OF BIRTH Newark, New Jersey

MARITAL STATUS Married, four children
(Kevin 07/16/76, Christopher 02/16/81,
Jennifer 04/13/85 and Katherine 04/13/85)

EDUCATION

Nutley High School, Nutley, N.J., June, 1963.
Duke University, Durham, N.C.; May, 1967.
(Chemistry)
George Washington University School of Medicine,
Washington, D.C.; May, 1971. (M.D.)

POST GRADUATE TRAINING

1973-1976 Fellow, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama (Special Fellowship NIAID #F22AI704)

1972-1973 Pediatric Resident, University of Alabama at Birmingham, Birmingham, Alabama

1971-1972 Pediatric Intern, University of Alabama at Birmingham, Birmingham, Alabama

PRESENT POSITION

2003 Loeb Eminent Scholar Chair in Pediatrics;
Professor of Pediatrics, Microbiology, Medicine and Neurosurgery;
Director, University of Alabama Center for Biodefense and Emerging Infections;
Director, Division of Pediatric Infectious Diseases;
Vice-Chairman, Department of Pediatrics;
Senior Scientist, Department of Gene Therapy;
Scientist, Cancer Research and Training Center;
Associate Director for Clinical Studies, Center for AIDS Research.
Faculty, Gene Therapy Center
University of Alabama at Birmingham, Birmingham, Alabama

PAST POSITIONS

2002-2003 Loeb Eminent Scholar Chair in Pediatrics;
Professor of Pediatrics, Microbiology, Medicine
Director, University of Alabama Center for Biodefense and Emerging Infections;
Director, Division of Pediatric Infectious Diseases;
Vice-Chairman, Department of Pediatrics;
Senior Scientist, Department of Gene Therapy;
Scientist, Cancer Research and Training Center;
Associate Director for Clinical Studies, Center for AIDS Research;
Faculty, Gene Therapy Center;
University of Alabama at Birmingham, Birmingham, Alabama.

2001 Loeb Eminent Scholar Chair in Pediatrics;
Professor of Pediatrics, Microbiology and Medicine;
Director, Division of Pediatric Infectious Diseases;
Vice-Chairman, Department of Pediatrics;
Senior Scientist, Department of Gene Therapy;
Scientist, Cancer Research and Training Center;
Associate Director for Clinical Studies, Center for AIDS Research;
Faculty, Gene Therapy Center;
University of Alabama at Birmingham, Birmingham, Alabama.

2000 Loeb Eminent Scholar Chair in Pediatrics;

Professor of Pediatrics, Microbiology and Medicine;
Director, Division of Pediatric Infectious Diseases;
Vice-Chairman, Department of Pediatrics;
Scientist, Cancer Research and Training Center;
Associate Director for Clinical Studies, Center for AIDS Research;
Faculty, Gene Therapy Center;
University of Alabama at Birmingham, Birmingham, Alabama.

1994-1999

Loeb Eminent Scholar Chair in Pediatrics;
Professor of Pediatrics, Microbiology and Medicine;
Vice-Chairman, Department of Pediatrics;
Scientist, Cancer Research and Training Center;
Associate Director for Clinical Studies, Center for AIDS Research;
Faculty, Gene Therapy Center;
University of Alabama at Birmingham, Birmingham, Alabama.

1993

Loeb Eminent Scholar Chair in Pediatrics;
Professor of Pediatrics, Microbiology and Medicine;
Scientist, Cancer Research and Training Center;
Associate Director for Clinical Studies, Center for AIDS Research;
Vice-Chairman, Department of Pediatrics;
University of Alabama at Birmingham, Birmingham, Alabama.

1992

Loeb Eminent Scholar Chair in Pediatrics;
Professor of Pediatrics, Microbiology and Medicine;
Scientist, Cancer Research and Training Center;
Associate Director, Center for AIDS Research;
Vice-Chairman, Department of Pediatrics;
University of Alabama at Birmingham, Birmingham, Alabama.

1990-1991

Professor of Pediatrics, Microbiology and Medicine;
Scientist, Cancer Research and Training Center;
Associate Director, Center for AIDS Research;
Vice-Chairman, Department of Pediatrics;
University of Alabama at Birmingham, Birmingham,

Alabama

1989-1990	Professor of Pediatrics, Microbiology and Medicine; Scientist, Cancer Research and Training Center; Associate Director, Center of AIDS Research; University of Alabama at Birmingham, Birmingham, Alabama
1987-1989	Professor of Pediatrics, Microbiology; Scientist, Cancer Research and Training Center; Associate Director, Center of AIDS Research; University of Alabama at Birmingham, Birmingham, Alabama
1985-1987	Professor of Pediatrics, Microbiology; Scientist, Cancer Research and Training Center; Director, Clinical Research Unit; University of Alabama at Birmingham, Birmingham, Alabama
1984-1985	Professor of Pediatrics, Associate Professor of Microbiology; Scientist, Cancer Research and Training Center; Director, Clinical Research Unit; University of Alabama at Birmingham, Birmingham, Alabama
1983-1984	Professor and Acting Chairman, Department of Pediatrics; Associate Professor of Microbiology; Scientist, Cancer Research and Training Center; Director, Clinical Research Unit; University of Alabama at Birmingham, Birmingham, Alabama
1981-1983	Professor and Vice Chairman, Department of Pediatrics; Associate Professor of Microbiology; Scientist, Cancer Research and Training Center; Director, Clinical Research Unit; University Hospital; University of Alabama at Birmingham, Birmingham, Alabama
1978-1980	Associate Professor of Pediatrics, Assistant Professor of Microbiology;

	Scientist, Cancer Research and Training Center; Director, Clinical Research Unit; University Hospital; University of Alabama at Birmingham, Birmingham, Alabama
1977-1978	Assistant Professor of Pediatrics and Microbiology; Associate Scientist, Cancer Research and Training Center; University of Alabama at Birmingham, Birmingham, Alabama
1976-1977 1976-1978	Assistant Professor Pediatrics and Microbiology; University of Alabama at Birmingham, Birmingham, Alabama

EDITORIAL BOARDS

1987-Present	Editor, Antiviral Research.
1985-1991	Section Editor, Intervirology.
1988-Present	Editorial Board, Journal Infectious Diseases.
1989-1997	Editorial Board, Pediatric Infectious Diseases Journal.
1990-Present	Editorial Board, Sexually Transmitted Diseases.
1990-Present	Editorial Board, Reviews in Medical Virology.
1991-1997	Editorial Board, Pediatrics
1991-Present	Editorial Board, Antimicrobial Agents and Chemotherapy
1991-1999	Editorial Board, Infectious Diseases in Clinical Practice
1991-1998	Senior Editor, Infectious Agents and Disease
1992-1998	Editorial Advisory Board, Virus and Life
1993-Present	Editorial Advisory Board, Infectious Diseases Watch for Pediatricians
1994-Present	Editorial Board, Antiviral Chemistry and Chemotherapy
1995-Present	Section Editor, Antiviral Therapy
1997-Present	Editorial Board, Seminars in Pediatric Infectious Diseases
1995-Present	Editorial Board, Gene Therapy
1999-2002	Editorial Advisory Board, Medscape Infectious Disease
2001	External Review Board, Glaser Pediatric Research Network (GPRN)
2002	APGO Educational Series on Women's Health Issues: Sexually Transmitted Infections

AWARDS AND HONORS

1967	Dean's Scholar
1967	Who's Who in American Colleges and Universities
1971	William Beaumont Research Society
1972	Best Teaching Intern, University of Alabama at Birmingham, School of Medicine
1974	Commencement Speaker, Graduation
1977	Award of Commendation, Board of Trustee, University of Alabama at Birmingham
1981	Society for Pediatric Research
1981	Infectious Diseases Society
1982	Alpha Omega Alpha
1982	Arnold Welch Visiting Professor of Pharmacology (Yale University)
1983	Award of Commendation, Board of Trustees, The Children's Hospital
1983	Transplantation Society, 1983-present.
1986	Who's Who in America
1989	Elected American Society for Clinical Investigation
1990	Wellcome Visiting Professor (The University of Cincinnati)
1991	Pediatric Infectious Diseases Journal Visiting Professor (Duke and The University of North Carolina)
1991	Award for Excellence in Pediatric Research, American Academy of Pediatrics (Former Mead Johnson Award)
1991	Canon Eley Lecturer, Harvard School of Medicine, Children's Hospital; Boston, Massachusetts
1991	Best Doctors in America
1991	Elected American Pediatric Society -- 1991
1992	1992 S. Stanley Schneierson Memorial Lecturer, Mt. Sinai Medical Center
1992	1992 Erwin Netter Memorial Professor, University of Buffalo
1992	1992 MacLaughlin Visiting Professor, University of Texas, Galveston
1993	Best Doctors in America
1994	1994 Bristol Myers Squibb Unrestricted Grant Award (1994-1999)
1994	1994 Tinsley Harrison Award (University of Alabama at Birmingham)
1994	1994 Achievement Award, International Antiviral

	Research Symposium, Nice, France
1995	Best Doctors in America
1996	Best Doctors in America
1996	Elected, Association of American Physicians
1996	Clinical Virology Award, Pan American Society for Virology
1997	Elected Fellow, American Academy of Microbiology
1998	March of Dimes Visiting Professor, New York Chapter
1998	Award for Distinguished Scientific Accomplishment, International Society for Antiviral Research
1998	Chairman's Award, Department of Pediatrics, University of Alabama
1998	Distinguished Faculty Lecturer, University of Alabama at Birmingham
1999	Ashley Weech Visiting Professor, University of Cincinnati
1999	Robert Ward Visiting Professor, University of Southern California
1999	Best Doctors in America
2000	Distinguished Alumnus Award, The Children's Hospital of Alabama, The university of Alabama at Birmingham
2000	Hugh C. Dillon Memorial Lecturer, University of Alabama at Birmingham
2000	Appointed, Board of Scientific Counselor for NIAID
2000	John Enders Lecturer, Infectious Diseases Society of America
2000	Aventis Award, American Society of Microbiology
2001	John Soothill Lecture. University of York, England, April 4, 2001
2001	American Association Pharmaceutical Physicians Distinguished Service Award
2001	Medical Student Research Day Lecturer, University of Alabama at Birmingham
2001	Best Doctors in America
2003	Pediatric Research Day Visting Professor, Mount Sinai, New York, NY.

MEDICAL LICENSURE AND CERTIFICATION

1994 American Board of Pediatrics, Recertification
1994 American Board of Pediatrics, Subspecialty: Infectious Diseases
Pediatric Board Certification, 1976.
Diplomate American Board Medical Examiners,

1973 Alabama (License #6475).
Staff Physician, The Children's Hospital, Birmingham, Alabama.
Staff Physician, University of Alabama at Birmingham Hospitals and Clinics, Birmingham, Alabama.

SOCIETIES

American Society for Microbiology
Jefferson County Medical Society
American Medical Association
Jefferson County Pediatric Society
Executive Committee, 1976-1985.
President, 1984-1985.
American Academy of Pediatrics
Society of Health and Human Values
American Society for Virology
Pediatric Infectious Diseases Society
Phi Beta Delta Honor Society, 1992
The American Society of Gene Therapy (ASGT), 1997
Society of Pediatric Research
American Pediatric Society

NATIONAL COMMITTEES

ICAAC Program Committee, 1988-1991; 1991-1994.
Mead Johnson Award, American Academy of Pediatrics, 1982-1985.
Chairman, 1984-1985.
NIH Virology Study Section, 1985-1989.
NIH AIDS Executive Advisory Committee, 1986-1987.
NIH AIDS Clinical Trials Committee, 1987.
NIH AIDS Data Safety & Monitoring Board, Chairman, 1987-1995
FDA/IDSA Treatment Guidelines Committee, 1989-1990.
American Society for Virology, Council, 1989-1991.
NIH NIAID DMID Advisory Committee, 1990-1991.
Program Committee - Infectious Disease Society's Scientific Program, 1992, 1993.
American Board of Pediatrics, Sub-Board Infectious

Diseases, 1991-1998.
Review Committee, Clinical Research, National Foundation March of Dimes, January, 1994 to December, 2000.
Subcommittee of Medical Knowledge Self-Assessment Program in the Subspecialty of infectious Diseases, American College of Physicians, 1992-1994.
Chair, International Herpes Management Forum, 1993-Present.
SOCA, Data Policy Committee, 1993-Present
Office of AIDS Research Executive Advisory Committee, 1995-1998
United States Pharmacopeial (USP) Committee of Revision, 1995-2000
American Academy of Pediatrics Committee on Infectious Diseases, 1995-2000
National Institute of Health--OAR Clinical Trials Area Review Panel, Chair, 1995-1996
National Board of Medical Examination Sept 1, 1995-1998
Council, Infectious Diseases Society of America, 1996-1999.
National Advisory Committee—Stopping the Spread of Herpes Campaign" ASHA, 1998-2001
Chair, VA-VZV Vaccine DSMB, 1999-
March of Dimes Foundation, Basil O'Connor Award Committee, 2000-2006.
Immunizing Agents Expert Committee for United States Pharmacopeial (USP), 2000.
NIH/NIAID Board of Scientific Counselors 2000-2005
ID Web Advisory Board Member, 2001.
Committee on Infectious Diseases, Chicago, March 30, 2001
FDA/CBER Committee for Vaccine Evaluation, 2001-
Bionet Working Group Meeting, Bethesda, MD. March 20, 2002.
Drug Information Association (DIA). Data Monitoring Committee/Institutional Review Board Conference. Bethesda, MD. January 28-29, 2002.
Co-Chair, Virology Section, National Institute of Allergy and Infectious Diseases Blue Ribbon Panel on Bioterrorism. February, 2002.
Chair of Pathogenesis and Host Response Mechanisms Fellowship Recruitment Committee, American Academy

of Microbiology, July 1, 2002-June 30, 2005.
Chair, Board of Scientific Councilors, National Institute of Allergy and Infectious Diseases, 2002-2005.
IDSA Program Committee, 2003 Annual Meeting, San Diego, CA, 2003.

INTERNATIONAL COMMITTEES

International Society for Antiviral Research, President, 1988-1990.
Board of Directors, International Society for Antiviral Research, 1988-Present
Chair, International Program Committee, International Society for Antiviral Research, 1988-Present
Council, International Society for Infectious Diseases, 1996-2002
Advisory Committee for the International Congress of Virology, 2000

UNIVERSITY COMMITTEES

Comprehensive Cancer Review, 1977-1980, 1984-1987, 1988-1991.
Faculty Council, 1980-1984.
Chairman, 1983-1984.
Joint Faculty Sciences Committee, 1985-present.
Self-Study, Research Subcommittee, 1982-1983.
Faculty Search Committees
Radiology, 1981-1982.
Microbiology, 1982, 1985.
Genetics (Chair), 1996
Comprehensive Cancer Center Advisory, 1982.
Clinical Pharmacology Advisory, 1982.
Department of Pediatrics
Housestaff Selections, 1978-present.
Faculty Promotions, 1980-present.
Department of Microbiology
Faculty Promotions, 1984-1987.
Faculty Council, 1992-1995.
Executive Committee, Comprehensive Cancer Center, 1992-Present.
University Grievance Committee, 1993-Present
Obstetrics & Gynecology Search Committee, 1994
School of Medicine Research Advisory Committee,

1994-1998.
University Research Advisory Group, 1995-
Ireland Award for Scholarly Distinction Committee, 1999-2002.
Interdisciplinary Advisory Committee (IAC) of the UAB Center for Disaster Preparedness (CDP), 2001-

CHILDREN'S HOSPITAL

Critical Care, 1979-present.
Co-Chairman, 1983.
Infection Control, 1982-present.
Co-Chairman, 1984-present.
Board of Trustees Development Committee, 1983.
Medical Executive Committee, 1983.
Hospital Task Force, 1987-1988.
TCH Research Institute Committee, 1997-present

CIVIC ORGANIZATIONS

Alabama School of Fine Arts Board, 1982-1990.

PATENTS

Weichselbaum R, Roizman B, Whitley RJ, Newman PNl. Treatment of tumors with genetically engineered herpes virus. Publication No. US-2002-0019362-A1. February 14, 2002.

ORGANIZING COMMITTEES FOR NATIONAL AND INTERNATIONAL MEETINGS

American Society for Clinical Investigations, Washington, D.C., 1983.
Second International Conference on Immunobiology and Prophylaxis of Human Herpesvirus Infections, Ft. Lauderdale, FL, 1985.
Society for Pediatric Research, Washington, D.C., 1985.
Eleventh International Herpesvirus Workshop, Leeds, England, 1986.
Vaccine Workshop, 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1986.

Antiviral Workshop, 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1986.
Third International Conference on Immunobiology and Prophylaxis of Human Herpesvirus Infections, Marcos Island, FL, 1986.
International Conference on AIDS in Children, Adolescents, and Heterosexual Adults: An Interdisciplinary Approach to Prevention, Atlanta, GA, 1987.
International Society for Antiviral Research, Williamsburg, VA, 1988.
Vaccine Workshop, 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, 1989.
Fourth International Conference on Immunobiology of Prophylaxis and Human Herpesvirus Infections, Japan, 1989.
Third International Conference on Antiviral Research, Brussels, 1990.
Fourth International Conference on Antiviral Research, New Orleans, 1991.
Fifth International Conference on Immunobiology and Prophylaxis of Human Herpesvirus Infections, Tampa, Florida, 1991.
Fifth International Conference on Antiviral Research, Vancouver, 1992.
NIH/CDC Meeting, March, 1992.
Sixth International Conference on Antiviral Research, Venice, Italy, 1993.
National Academy of Sciences Colloquium on Changes in Human Ecology and Behavior: Effects on Infectious Diseases, Washington, D.C., September, 1993.
Sixth International Conference on Immunobiology and Prophylaxis of Human Herpesvirus Infections, Sopporo, Japan, 1993
First IHMF Annual Meeting Co-Organizer, Monte Carlo, 1993
Second IHMF Annual Meeting Co-Organizer, San Francisco, 1994
Antiviral Resistance Meeting, Bermuda, December

8-11, 1994
Seventh International Conference on Antiviral Research, Santa Fe, NM, 1995
Seventh International Conference on Immunobiology and Prophylaxis of Herpesvirus Infections, Tampa, FL, 1995
Third IHMF Annual Meeting Co-Organizer, Istanbul, Turkey, 1995
American Academy of Pediatrics, Committee on Infectious Diseases, Red Book Review Meeting, Chicago, IL April 13-14, 1996
Eighth International Conference of Antiviral Research, Ursandi, Japan, 1996
Fourth IHMF Annual Meeting Co-Organizer, Barcelona, Spain, 1996
Eighth International Conference on Immunobiology and Prophylaxis of Herpesvirus Infections, Mishima, Japan, 1997
Ninth ISAR Meeting, Japan, 1997
Fifth IHMF Annual Meeting Co-Organizer, Cannes, Frances, 1997
Tenth ISAR Meeting, Atlanta, GA, 1998
Sixth IHMF Annual Meeting Co-Organizer, Marrakech, Morocco, 1998
Ninth International Conference on Immunobiology and Prophylaxis of Herpesvirus Infections, Ciscco, Italy, 1999
Eleventh ISAR Meeting, San Diego, CA, 1999
Twelfth ISAR Meeting, Jerusalem, Israel, 1999
Seventh IHMF Annual Meeting Co-Organizer, Seville, Spain, 1999
Thirteenth ISAR Meeting, Baltimore, MD, 2000
Tenth International Conference on Immunobiology and Prophylaxis of Herpesvirus Infections, 2000
Eighth IHMF Annual Meeting Co-Organizer, St. Julian Bay, Malta, 2000
Fourteenth ISAR Meeting, Seattle, WA, 2001
IHMF 2001 Workshop Co-Organizer. San Diego, CA. March 6-7, 2001.
Keystone Symposia on Molecular and Cellular Biology Co-Organizer. "Control of Viral Latency and Persistence", Breckenridge, CO, March, 2001
ECCMID, Istanbul, Turkey, April 1, 2001
14th International Conference of Antiviral Research. Seattle WA, April 7-13, 2001

LAMIDS meeting chairman, Louisiana. "Herpes Simplex Virus Infections of the CNS" lecture, April 20-22, 2001
4th Annual Conference on Vaccine Research. Arlington, VA,. "Engineered Herpes Simplex Vaccine Implications Viruses Expressing IL-12 or GM- CSG: Gene Therapy and vaccine Implications", April 23-25, 2001
IHMF 2001 Workshop, Berlin, Germany, June 28-29, 2001
Keystone Symposia for the Identification and Development of Novel Antimicrobial Agents B1. Santa Fe, NM January 31 – February 5, 2002
IHMF CNS Workshop, Denver, Colorado, April 21-22, 2002
IHMF Transmission of HSV Workshop, San Diego, California, September 25, 2002
Workshop for Therapeutics for West Nile Virus. Washington, D.C., November 20-21, 2002
Conflicts and Controversies in the Operation of Clinical Trials Monitoring Committee, Washington, D.C., January 16-18, 2003
IHMF Annual Meeting, Paris France, February 26-March 2, 2003
IHMF Workshop, Organizing Committee, Seattle, Wshington, May 5-6, 2003.

BOOK EDITORS/CO-EDITORS

Antiviral Agents and Viral Diseases of Man. Galasso G, Merigan TC, and Whitley RJ, Editors. Raven Press, 1990

Immunobiology and Prophylaxis of Human Herpesvirus Infections. Lopez C, Mori R, Roizman B, and Whitley RJ, Editors. Plenum Publishing Corporation, 1990

Infections of the Central Nervous System. Scheld WM, Durack DT, and Whitley RJ, Editors. Raven Press, 1991

Seminars in Pediatric Infectious Diseases. Feigin RD and Whitley RJ, Editors. W. B. Saunders Company, 1991

The Human Herpesviruses: Biology, Pathogenesis and Treatment. Roizman B, Whitley RJ, and Lopez C, Editors.

Raven Press, 1993

Practical Diagnosis of Viral Infections. Galasso G, Whitley RJ, and Merigan TC, Editors. Raven Press, 1992

Acyclovir: The Landmark Papers. Whitley RJ and Gnann J, Editors. Science Press, 1993

A Color Atlas of Herpesviruses Infections. Vols 1-6. Whitley RJ, Hayden FG, Richman DD, Editors. Churchill Communications Japan, 1996

Clinical Virology. Richman DD, Whitley RJ, Hayden FG, Editors. Churchill Livingstone, 1997

Antiviral Agents and Viral Diseases of Man. Galasso G, Merigan TC, and Whitley RJ, Editors. Lippincott-Raven Publishers, 1997

Infections of the Central Nervous System. Scheld WM, Durack DT, and Whitley RJ, Editors. Lippincott-Raven Publishers, 1997

O*ptimizing the Management of Genital Herpes*. Whitley RJ, Editor. The Royal Society of Medicine Press Ltd, 2000

Clinical Virology. Richman DD, Whitley RJ, Hayden FG, Eds. ASM Press, 2002

A Practical Guide to Clinical Virology, 2nd Edition. Haaheim L, Pattison, J, Whitley R, Eds. Wiley & Sons, Ltd. West Sussex, England 2002

Antibiotic and Chemotherapy, 8th Edition. Finch RG, Greenwood D, Norrby SR, Whitley RJ, Eds., 2003

Human Herpesvirus: Biology, Therapy & Immunoprophylaxis. Whitley RJ. In: Arvin AM, Roizman B, Whitley R, Mocarski E, Campadelli-Fiume G, Yamanishi K. Cambridge University Press. In Press

Infections of the Central Nervous System. Scheld WM, Mara, C. and Whitley RJ, Editors. Lippincott-Raven

Publishers, In Press

Federal Site Visits and Consultations:

1. Ara-AMP Contractor's Meeting, Bethesda, Maryland, September 1, 1976.
2. Infectious Diseases Committee Meeting, Bethesda, Maryland, October 1, 1976.
3. Project Officers Meeting, NIH, Bethesda, Maryland, April 22, 1977.
4. NIH Clinical Center, Bethesda, Maryland, June 1-3, 1977.
5. NIH Antiviral Substances Program Contractor's Meeting, New York, October 13, 1977.
6. NIH Contractor's Meeting, Bethesda, Maryland, November 17-18, 1977.
7. NIH Herpesvirus Workshop, Bethesda, Maryland, December 2, 1977.
8. Microbiology and Infectious Diseases Advisory Committee, Ad Hoc Reviewer, May 31, 1978.
9. Workshop on Development of Antivirals, NIH; Bethesda, Maryland, June 29-30, 1978.
10. NIAID Antiviral Substances Program Annual Contractor's Meeting, Atlanta, Georgia, October 3, 1978.
11. Joint discussion with NIH and Burroughs Wellcome and Company, Durham, North Carolina, November 29-December 1, 1978.
12. Mount Sinai School of Medicine Site Visit, NCI, New York, March 7-9, 1979.
13. NIH Contractor's Meeting, Bethesda, Maryland, June 25-27, 1979.
14. Clinical Research Subpanel, Bethesda, Maryland, January 7, 1980.
15. Stanford University Site Visit, NIAID, Palo Alto, California, June 23-25, 1980.
16. NIH Antiviral Therapy of Chronic Active Hepatitis B, Bethesda, Maryland, September 9-11, 1980.
17. NIH Control of Genital Herpes Simplex Virus Infections, Bethesda, Maryland, February 2-3, 1981.
18. Microbiology and Infectious Diseases Advisory Committee, Ad Hoc Reviewer, Dallas, Texas, March 6, 1981.

19. NIH Genital Herpes, Bethesda, Maryland, May 12-13, 1981.

20. University of Minnesota clinical Research Center Site Visit, Minneapolis, Minnesota, October 6-7, 1981.

21. University of California in Los Angeles Site Visit, Los Angeles, California, May 18-19, 1982.

22. Beth Israel Hospital Site Visit, Boston, Massachusetts, June 3-4, 1982.

23. Microbiology and Infectious Diseases Advisory Committee, NIH, Bethesda, Maryland, June 27-29, 1982.

24. University of Washington in Seattle Site Visit, Seattle, Washington, September 29-30, 1982.

25. Special Study Section Meeting, NIH, Bethesda, Maryland, December 15-18, 1982.

26. University of California in Los Angeles Site Visit, Los Angeles, California, February 29-March 1, 1983.

27. University of California, San Francisco Site Visit, San Francisco, California, March 2-4, 1983.

28. University of New York Medical Center Site Visit, New York, New York, March 13-15, 1983.

29. NIH Conference Call. Dr. Robert E. Slitzel, Chairperson, November 7, 1983.

30. NIH Ad Hoc Committee, Dr. Richard J. Whitley, Chairperson, Bethesda, Maryland, March 16, 1984.

31. American Cancer Society Site Visit, Chapel Hill, North Carolina, April 18, 1984.

32. Source Selection Meeting, NIH, Bethesda, Maryland, May 30, 1984.

33. Food and Drug Administration, Clinical Use of Oral Acyclovir in Normal Host, November 29, 1984.

34. NIAID Workshop, "Evaluation of Antivirals and Interferon in Herpesvirus Animal Models", NIH, Bethesda, Maryland, May 16-17, 1985.

35. Virology Study Section, NIH, Bethesda, Maryland, June 6-8, 1985.

36. Virology Study Section, NIH, Bethesda, Maryland, October 10-12, 1985.

37. Virology Study Section, NIH, Bethesda, Maryland, March 6-8, 1986.

38. University of Rochester Site Visit, Rochester, New York, May 8-9, 1986.

39. Virology Study Section, NIH, Bethesda, Maryland, June 11-13, 1986.

40. NIAID Workshop, "AIDS Vaccines", NIH, Bethesda, Maryland, July 28-29, 1986.

41. University of Colorado Site Visit, Denver, Colorado, August 28-29, 1986.

42. Virology Study Section, NIH, Bethesda, Maryland, October 16-17, 1986.

43. Virology Study Section, NIH, Bethesda, Maryland, March 4-6, 1987.

44. Virology Study Section, NIH, Bethesda, Maryland, June 25-27, 1987.

45. Virology Study Section, NIH, Bethesda, Maryland, October 8-10, 1987.

46. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, December 15-18, 1987.

47. Virology Study Section, NIH, Bethesda, Maryland, February 26-28, 1988.

48. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, March 28, 1988.

49. AIDS Advisory Committee, Washington, D.C., July 7-8, 1988.

50. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, September 3, 1988.

51. National Cooperative Drug Discovery Group Meeting, San Francisco, California, November, 1988.

52. Virology Study Section, NIH, Bethesda, Maryland, February 23, 1989.

53. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, March 3, 1989.

54. Drug Review Aids Program, Bethesda, Maryland, April 10, 1990.

55. Antiviral Data, Safety, Monitoring Committee Meeting, May 9-10, 1989.

56. NIH Clinical Research Meeting, Bethesda, Maryland, May 15-16, 1989.

57. Virology Study Section, NIH, Bethesda, Maryland, June 15-16, 1989.

58. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, August 2-3, 1989.

59. National Institute Child Health Development Meeting. Review of SIDS Proposal. Bethesda, Maryland, August, 1989.

60. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, November 2, 1989.

61. CDC/IDSA CMV Workshop, Centers for Disease Control, Atlanta, Georgia, January 22-23, 1990.

62. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, February 1-2, 1990.

63. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, May, 1990.

64. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, August 1, 1990.

65. Advisory Council for NIAID, September 24-25, 1990.

66. NIAID IFDA Resistance Meeting, October 1-2, 1990.

67. NIAID Collaborative Antiviral Study Group Meeting, October 3-4, 1990.

68. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, November 10-11, 1990.

69. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, February 10-11, 1991.

70. NIAID Collaborative Antiviral Study Group Meeting, Bethesda, Maryland, February 12, 1991.

71. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, May 1-2, 1991.

72. NIAID Collaborative Antiviral Study Group Meeting, Bethesda, Maryland, June 25, 1991.

73. NIAID STD Vaccine Workshop, Hamilton, Montana, July 29 - August 2, 1991.

74. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, August 28-29, 1991.

75. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, November 7-8, 1991.

76. FDA Combination Therapy Meeting, Rockville, Maryland, November 18 - 21, 1991.

77. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, February 13-14, 1992.

78. Fifth National Forum on AIDS, Hepatitis, and Other Blood-Borne Diseases, Atlanta, Georgia, March 29-April 1, 1992.

79. AIDS Data, Safety, Monitoring Board Meeting, Bethesda, Maryland, May 7-8, 1992.

80. ICAAC Committee Meeting, Washington, DC, June 4-5, 1992.

81. NIH/FDA Advisory Committee Review of Ribavirin, Bethesda, Maryland, June 30, 1992.

82. AIDS Data, Safety, Monitoring Board Meeting, Washington, DC, August 20-21, 1992.

83. AIDS Data, Safety, Monitoring Board Meeting, Washington, DC, November 16-17, 1992.

84. CDC, STD Treatment Guidelines Committee, Atlanta, Georgia, January 19-21, 1993.

85. NIAID/DSMB Meeting, Washington, D. C., February 11-12, 1993.

86. NIH/DRG Pathogenesis Study Section Consent Review, Washington, D.C., May 12, 1993.

87. NIAID/DSMB Meeting, Washington, D. C., May 20-21, 1993.

88. NIAID/CDC Hantavirus Committee, August, 1993.

89. NIAID/DSMB Meeting, Washington, D. C., September, 1993.

90. NIAID/DSMB Meeting, Washington, D. C., November, 1993.

91. NIAID/CASG, Bethesda, Maryland, December, 1993.

92. NIH Reunion Task Force, Mind/Body Interactions and Psychoneuroimmunological Aspects of Health and Disease, Washington, D. C., Jan. 12-14, 1994

93. NIAID DSMB, Washington, D. C., February 17-18, 1994.

94. NIAID Adolescents and STD, April 12-14, 1994.

95. NIAID/DSMB Meeting, Washington, D. C., May 17-18, 1994.

96. Update, CDC/NIH/IDSA, AIDS OI Committee, Atlanta, Georgia, September 26-27, 1994.

97. NIAID/DAIDS, Statistical Issues in HIV/AIDS Research Symposium, Bethesda, Maryland, June 12-13, 1995.

98. NIH AIDS Program Evaluation Work Group Meeting, Bethesda, MD, August 10-11, 1995.

99. NIH/DMID Adolescents and STD Meeting, August 14-16, 1995.

100. OAR Meeting, Clinical Trials, Bethesda, MD, September 28, 1995.

101. OAR Meeting, Clinical Trials, Bethesda, MD, October 10-11, 1995.

102. NIH AIDS Program Evaluation Working Group, Bethesda, MD, October 12-13, 1995.

103. NIH/DMID Focus Group Meeting, Bethesda, MD, December 8, 1995.

104. Institute of Medicine Vaccine Advisory Committee, December 11, 1995.

105. NIH/DMID Adolescents and STD Meeting, Bethesda MD, January 22, 1996.

106. NIH AIDS Program Evaluation Work Group Meeting, Bethesda, MD, February 15-16, 1996.

107. NIH AIDS Research Program Evaluation Clinical Trials Area Review Panel.

108. NIH OAR Research Advisory Council, Rockville, MD, March 13, 1996

109. NIH Special Emphasis Panel. Coordination of Rare Diseases Research, 1999.

110. CDC Encephalitis Working Group Member. 1999.

111. NIH Special Emphasis Panel. HIV Vaccine Trials Network Clinical Trials Units Review. Washington, D. C. February 10, 2000.

112. NIH/NIAID Board of Scientific Counselors. Rockville, MD, June 4-5, 2000.

113. CDC Workshop on CMV Vaccine Development. October 25, 2000.

114. NIH/NIAID Board of Scientific Counselors. Rockville, MD, December 11-13, 2000.

115. NIH/NIAID Board of Scientific Counselors. Bethesda, MD, June 11-13, 2000.

116. FDA. Vaccines and Related Biological Products Advisory Committee. Bethesda, MD, September 13-14, 2001.

117. FDA. Vaccines and Related Biological Products Advisory Committee. Bethesda, MD, January 30, 2002.

118. FDA. Vaccines and Related Biological Products Advisory Committee. Bethesda, MD, May 21, 2002.

119. NIAID Board of Scientific Counselors. Hamilton, Montana, June 10-12, 2002.

120. Joint Working Committee on Downselecting, Department of Health and Human Services, October 15, 2002.

120. NIAID Blue Ribbon Panel on Bioterrorism Related Research. Bethesda, MD, October 22-22, 2002.

121. NIAID Board of Scientific Counselors. Besthesda, Maryland, December 8-11, 2002.

122. FDA, NCI Biological Resource Branch Oversight Committee. Telecommunications, Frederick, Maryland, December 16, 2002.

123. FDA-Center for Biologics Evaluation and Research (CBER) Labor of Mycobacterial Diseases and Cellular Immunology (LMDCI), Bethesda, Maryland, January 7, 2002.

124. NIAID Board of Scientific Counselors. Besthesda, Maryland, June 9-10, 2003.

Original Articles

1. Ch'ien LT, Cannon NJ, Charamella LJ, Dismukes WE, Whitley RJ, Buchanan RA and Alford CA Jr: Effect of adenine arabinoside on severe herpesvirus hominis infections in man. Preliminary Report. J Infect Dis. 128:658-663, 1973.

2. Ch'ien LT, Cannon JJ, Whitley RJ, Diethelm AG, Dismukes WE, Scott CW, Buchanan RA and Alford CA Jr: Effect of adenine arabinoside on cytomegalovirus infections. J Infect Dis. 130:32-39, 1974.

3. Boston Interhospital Virus Study Group and the NIAID Sponsored Cooperative Antiviral Clinical Study (Alford, Chien, Whitley, et al.): Failure of high dose 5-iodo-2'-deoxyuridine in the therapy of herpes simplex virus encephalitis: Evidence of unacceptable toxicity. N Engl J Med. 292:600-603, 1975.

4. Ch'ien LT, Whitley RJ, Nahmias AJ, Levin EB, Linnemann CC Jr, Frenkel LD, Bellanti JA Buchanan RA, and Alford CA Jr: Antiviral chemotherapy and neonatal herpes simplex virus infection, A pilot study: Experience with adenine arabinoside (ara-A). Pediatrics. 55:678-685, 1975.

5. Whitley RJ, Ch'ien LT, Buchanan RA, and Alford CA Jr: Studies on adenine arabinoside - a model for antiviral chemotherapeutics. In: Antiviral Mechanisms - Perspectives in Virology IX, Morris Pollard (ed), Academic Press (New York), Chapter 18, 1975, 315-335.

6. Alford CA Jr, and Whitley RJ: Therapy of herpetic infections in man - a status report. In: Cancer Biology III: Herpes Virus Epidemiology, Molecular Events, Oncogenicity and Therapy, Carmia Borek and Donald West King (eds), Stratton Intercontinental Medical Book Corp (New York), 1976, 159-172.

7. Ceballos R, Chien LT, and Whitley RJ: Cerebellar hypoplasia in an infant with congenital cytomegalovirus infection. Pediatrics. 57:155-157, 1976.

8. Whitley RJ, Ch'ien LT, Dolin R, Galasso GJ, Alford CA Jr, and the Collaborative Antiviral Study Group: Adenine arabinoside therapy of herpes zoster in the immunosuppressed: NIAID Collaborative Antiviral Study. N Engl J Med. 294:1193-1199, 1976.

9. Alford CA Jr. and Whitley RJ: Treatment of infections due to herpesvirus in humans: A critical review of the state of the art. J Infect Dis. 133:A101-A108, 1976.

10. Ch'ien LT, Whitley RJ, Alford CA Jr, Galasso GJ, and the Collaborative Study Group: Adenine arabinoside for therapy of herpes zoster in immunosuppressed patients: Preliminary results of a collaborative study. J Infect Dis. 133:A184-A191, 1976.

11. Whitley RJ, Brasfield D, Reynolds DW, Stagno S, Tiller RE and Alford CA Jr: Protracted pneumonitis in young infants associated with perinatally acquired cytomegaloviral infection. J Pediatr. 80:16-22, 1976.

12. Whitley RJ, Soong SJ, Dolin R, Galasso GJ, Chien LT, Alford CA and the Collaborative Study Group: Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis: National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study. N Engl J Med. 297:289-294, 1977.

13. Pass RF, Long WF, Whitley RJ, Soong SJ, Diethelm AG, Reynolds DW and Alford CA Jr: Productive infection with cytomegalovirus and herpes simplex virus in renal transplant recipients: role of source of kidney. J Infect Dis. 137:556-563, 1978.

14. Whitley RJ and Alford CA Jr: Developmental aspects of selected antiviral chemotherapeutic agents. Annu Rev Microbiol. 32:285-300, 1978.

15. Whitley RJ and Alford CA Jr: Current status of antiviral chemotherapy. South Med J. 71:1134-1140, 1978.

16. Tucker BA, Doekel RC Jr, Whitley RJ, and Dismukes WE: Herpes simplex virus encephalitis: an atypical presentation. South Med J. 71:1431-1433, 1978.

17. Chen AB, Ben-Porat T, Whitley RJ and Kaplan AS: Purification and characterization of proteins excreted by cells infected with herpes simplex virus and their use in diagnosis. Virology. 91:234-242, 1978.

18. Dolin R, Reichman RC, Mazur MH and Whitley RJ: Herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med. 89:375-388, 1978.

19. Pass RF, Whitley RJ, Diethelm AG, Whelchel JD, Reynolds DW and Alford CA JR: Outcome of renal transplantation in patients with primary cytomegalovirus infection. Transplant Proc. 11:1288-1290, 1979.

20. Pass RF, Whitley RJ, Whelchel JD, Diethelm AG, Reynolds DW and Alford CA Jr: Identification of patients with increased risk of herpes simplex virus after renal transplantation. J Infect Dis. 140:487-492, 1979.

21. Mazur, MH, Whitley RJ and Dolin R: Serum antibody levels as risk factors in the dissemination of herpes zoster. Arch Intern Med. 139:1341-1345, 1979.

22. Whitley RJ and Alford CA JR: Developmental aspects of adenine arabinoside for parenteral therapy of human herpesvirus infections. Adv Ophthalmol. 38:288-296, 1979.

23. de Miranda P, Whitley RJ, Blum MR, Keeney RE, Barton N, Cocchetto DM, Good S, Hemstreet GP, Kirk LE, Page DA and Elion GB: Acyclovir kinetics after intravenous infusion. Clin Pharmacol Ther. 26:718-728, 1979.

24. Whelchel JD, Pass RJ, Diethelm AG, Whitley RJ and Alford CA Jr: Effect of primary and recurrent cytomegalovirus infections upon graft and patient survival after renal transplantation. Transplantation. 28:443-446, 1979.

25. Dworsky M, Whitley RJ and Alford CA Jr: Herpes zoster in early infancy. Am J Dis Child. 134:618-619, 1980.

26. Pass RJ, Whitley RJ, Diethelm AG, Whelchel JD, Reynolds DW and Alford CA JR: Cytomegalovirus infection in renal transplant patients: potentiation by antithymocyte globulin and an incompatible graft. J Infect Dis. 142:9-17, 1980.

27. Whitley RJ and Alford CA Jr: Herpes simplex encephalitis: need for accurate diagnosis. JAMA. 24:371-372, 1980.

28. Buchanan RA, Kinkel AW, Whitley RJ and Alford CA Jr: Plasma levels and urinary excretion of vidarabine after repeated dosing. Clin Pharmacol Ther. 27:690-696, 1980.

29. Whitley RJ, Nahmias AJ, Visintine AM, Fleming CL, Alford CA Jr and the NIAID Collaborative Antiviral Study Group with special assistance from A Yeager, A Arvin, R Haynes, M Hilty, and J Luby: The natural history of herpes simplex virus infection of mother and newborn. Pediatrics. 66:489-494, 1980.

30. Whitley RJ, Nahmias AJ, Soong SJ, Galasso GG, Fleming CL, Alford CA Jr and the NIAID Collaborative Antiviral Study Group with special assistance from J Connor, Y Bryson and C Linnemann: Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics. 66:495-501, 1980.

31. Whitley RJ, Tucker BC, Kinkel AW, Barton NH, Pass RF, Whelchel JD, Cobbs CG, Diethelm AG and Buchanan RA: Pharmacology, tolerance and antiviral activity of vidarabine monophosphate in humans. Antimicrob Agents Chemother. 18:709-715, 1980.

32. Whitley RJ, Alford C, Hess F and Buchanan R: Vidarabine: a preliminary review of its pharmacological properties and therapeutic use. Drugs. 20:267-282, 1980.

33. Whitley RJ, Soong, SJ, Hirsch MS, Karchmer AW, Dolin R, Galasso G, Dunnick JK, Alford CA Jr and the NIAID Collaborative Antiviral Study Group: Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med. 304:313-318,

1981.

34. Whitley RJ: Virologic findings in progressive multifocal leuko-encephalopathy. Ala J Med Sci. 18:68, 1981.

35. Nahmias AJ and Whitley RJ: Herpes simplex virus encephalitis in pediatrics. Pediatr Rev. 2:259-261, 1981.

36. Whitley RJ: Diagnosis and treatment of herpes simplex encephalitis. Ann Rev Med. 32:335-340, 1981.

37. Whitley RJ and Alford CA: Antiviral agents: clinical status report. Hosp Pract. 16:109-121, 1981.

38. Stagno S, Brasfield DM, Brown MB, Cassell GH, Pifer LL, Whitley RJ and Tiller RE: Infant pneumonitis associated with cytomegalovirus, chlamydia, pneumocystis, and ureaplasma: a prospective study. Pediatrics. 68:322-329, 1981.

39. Whitley RJ and Alford CA Jr: Preventive and therapeutic approaches to the newborn infant with perinatal viral and toxoplasma infections. Clin Perinatol. 8:591-604, 1981.

40. Pass RF, Dworsky ME, Whitley RJ, August AM, Stagno S and Alford CA Jr: Specific lymphocyte blastogenic responses in children with cytomegalovirus and herpes simplex virus infections acquired early in infancy. Infect Immun. 34:166-170, 1981.

41. Lee FK, Takei Y, Dannenbarger J, Visintine A, Whitley RJ and Nahmias A: Rapid detection of viruses in biopsy or autopsy specimens by the pseudoreplica method of

42. De Clercq E, Whitley RJ, Helgstrand E, Keeney RE, Crumpacker C, Young CW, Kern ER and Galasso G: Antiherpes Chemotherapy. Current Chemother Immunother. 1:1053-1059, 1981.

43. Whitley RJ, Tilles J, Linneman C Jr, Liu C, Pazin G, Hilty M, Overall J, Visintine A, Soong SJ, Alford CA Jr and the NIAID Collaborative Antiviral Study Group: Herpes simplex encephalitis: clinical assessment, JAMA. 247:317-320, 1982.

44. Nahmias AJ, Whitley RJ, Visintine AN, Takei Y, Alford CA Jr and the NIAID Collaborative Antiviral Study Group: Herpes simplex encephalitis: laboratory evaluations and their diagnostic significance. J Infect Dis. 145:829-836, 1982.

45. Whitley RJ: Herpes simplex virus infections of the central nervous system in children. Semin Neurol. 2:87-97, 1982.

46. Whitley RJ, Hilty M, Haynes R, Bryson Y, Connor JD, Soong SJ, Alford CA Jr and the NIAID Collaborative Antiviral Study Group: Vidarabine therapy of varicella in immunosuppressed patients. J Pediatr. 101:125-131, 1982.

47. Whitley RJ, Blum MR, Barton N and de Miranda P: The pharmacokinetics of acyclovir in humans following intravenous administration: a model for the development of parenterally administered antivirals. Am J Med. 73:165-171, 1982.

48. Whitley RJ, Barton N, Collins E, Welchel J and Diethelm AG: Mucocutaneous herpes simplex virus infections in immunocompromised patients: a model for evaluation of topical antiviral agents. Am J Med. 73:236-240, 1982.

49. Whitley RJ, Soong SJ, Dolin R, Betts R, Linnemann C Jr, Alford CA Jr and the NIAID Collaborative Antiviral Study Group: Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med. 307:971-975, 1982.

50. Whitley RJ, Lakeman AD, Nahmias A, Roizman B: DNA restriction-enzyme analysis of herpes simplex virus isolates obtained from patients with encephalitis. N Engl J Med. 307:1060-1062, 1982.

51. Whitley RJ and Alford CA Jr: Herpesvirus infections in childhood: diagnostic dilemmas and therapy. Ped Infect Dis. 1:81-84, 1982.

52. Whitley RJ and Alford CA Jr: Towards therapy and prevention of herpetic infections. Semin Perinatol. 7:64-81, 1983.

53. Whitley RJ and Crist WM: Management of infections. Pediatr Ann. 12:445-449, 1983.

54. Volpi A, Whitley RJ, Ceballos R, Pereira L and Stagno S: Rapid diagnosis of cytomegalovirus pneumonia by specific monoclonal antibodies. J Infect Dis. 147:1119-1120, 1983.

55. Morawetz RB, Whitley RJ and Murphy DM: Experience with brain biopsy for suspected herpes encephalitis - a review of forty consecutive cases. Neurosurgery. 12:654-657, 1983.

56. Gnann JW Jr, Barton NH and Whitley RJ: Acyclovir - Mechanism of Action, Pharmacokinetics, Safety and clinical applications. Evaluations of new drugs. Pharmacotherapy. 3:275-283, 1983.

57. Whitley RJ and the NIAID Collaborative Antiviral Study Group: Interim summary of mortality in herpes simplex encephalitis and neonatal herpes simplex virus infections.

Vidarabine versus acyclovir. J Antimicrob Chemother. 12:105-112, 1983.

58. Coleman RM, Bailey PD, Whitley RJ, Keyserling H, Nahmias AJ: Elisa for the detection of HSV antigens in the cerebrospinal fluid of patients with encephalitis. J Virol Methods. 7:117-125, 1983.

59. Grissom JR, Durant JR, Whitley RJ and Flint A: Thymic hyperplasia in a case of Hodgkin's disease. South Med J. 76:1189-1192, 1983.

60. Gnann JW Jr and Whitley RJ: Current status of antiviral chemotherapy. IM-Internal Medicine for the Specialist. 4:49-61, 1983.

61. Whitley RJ, Yeager A, Kartus P, Bryson Y, Connor JD, Nahmias AJ, Soong SJ and the NIAID Collaborative Antiviral Study Group: Neonatal herpes simplex virus infection: follow-up evaluation of vidarabine therapy. Pediatrics. 72:778-785, 1983.

62. Whitley RJ, Spruance S, Hayden FG, Overall J, Alford CA Jr, Gwaltney JM Jr, Soong SJ and the NIAID Collaborative Antiviral Study Group: Vidarabine therapy of mucocutaneous herpes simplex virus infections in the immunocompromised host. J Infect Dis. 149:1-8, 1984.

63. Whitley RJ, Gnann JW Jr and Alford CA Jr: Approaches to the parenteral therapy of herpesvirus infections. 1983 International Symposium on Medical Virology. Elsevier, North Holland, 1984.

64. Chatterjee S, Lakeman AD, Whitley RJ and Hunter E: Effect of cloned human interferons on the replication of and cell fusion induced by herpes simplex virus. Virus Res. 1:81-87, 1984.

65. Dworksy M, Pass RF, Stagno S, and Whitley RJ: Therapeutic approaches to the control of cytomegalovirus infections. Birth Defects: Orig Artic Ser. 20:345-352, 1984.

66. Whitley RJ: Treatment of human herpesvirus infections with special reference to encephalitis. J Antimicrob Chemother. 13:1-18, 1984.

67. Garcia JH, Colon LE, Whitley RJ, and Wilmes FJ: Diagnosis of viral encephalitis by brain biopsy. Semin Diagn Pathol. 1:71-81, 1984.

68. Whitley RJ, Levin M, Barton N, Hershey BJ, Davis G, Keeney RE, Welchel J, Diethelm AG, Kartus P, and Soong SJ: Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy. J Infect Dis. 150:323-329, 1984.

69. Kelly JP, and Whitley RJ: Viral infections and acquired immune deficiency syndrome: practical and theoretical approaches to therapy. In: Acquired Immune Deficiency Syndrome, Michael S Gottlieb and Jerome E Groopman, eds, Alan R Liss, Inc., New York, 1984, pp 377-395.

70. Whitley RJ: Herpes simplex virus infections of the central nervous system. In: Herpesviruses, Fred Rapp, ed. Alan R Liss, Inc., New York, 1984, pp 71-90.

71. Overall JC, Whitley RJ, Yeager AS, McCracken GH Jr and Nelson JD: Prophylactic or anticipatory antiviral therapy for newborns exposed to herpes simplex infection. Pediatr Infect Dis. 3: 193-195, 1984.

72. Garcia JH, Sekar BC and Whitley RJ: Medical Pathology Conference: Headache, fever, abnormal behavior, and dysphasia in an elderly man. Ala J Med Scie. 21:399-407, 1984.

73. Whitley RJ and the NIAID Collaborative Antiviral Study Group: Herpes simplex virus infections of the central nervous system. In: 13th International Congress of Chemotherapy Proceedings. HJ Field and J Wallin, eds, 1984.

74. Ginsburg B, Beaver PC, Wilson ER, and Whitley RJ: Dermatitis due to larvae of a soil nematode, Pelodera Strongyloides. Pediatr Dermatol. 2:33-37, 1984.

75. Whitley RJ: Therapy for human herpesvirus infections: a perspective. Al J Med. 22:193-207, 1985.

76. McCann WP, Hall LM, Siler W, Barton N and Whitley RJ: High pressure liquid chromatographic methods for determining arabinosyladenine-5'-monophosphate, arabionosyladenine and arabinosylhypoxanthine in plasma and urine. Antimicrob Agents Chemother. 28:265-273, 1985.

77. Whitley RJ and Hutto C: Neonatal herpes simplex virus infections. Pediatr Rev. 7:119-126, 1985.

78. Chatterjee S, Hunter E and Whitley RJ: Effect of cloned human interferons on protein synthesis and morphogenesis of herpes simplex virus. J Virol. 56:419-425, 1985.

79. Schlitt M, Lakeman FD and Whitley RJ: Psychosis and herpes simplex encephalitis. South Med J. 78:1347-1352, 1985.

80. Whitley RJ: Chickenpox in the immunocompromised host. In: Advances in Therapy Against Herpesvirus Infections in Immunocompromised Hosts. Proceedings of a symposium conducted by the University of Minnesota, Park Row Publishers, 1985, pp25-

30.

81. Whitley RJ: Approaches to the development of new drugs for the control of herpes viral infections in the immunocompromised host. In: Advances in Therapy Against Herpesvirus Infections in Immunocompromised Hosts. Proceedings of a symposium conducted by the University of Minnesota, Park Row Publisher, 1985, pp 65-70.

82. Stagno S and Whitley RJ: Herpesvirus Infections of Pregnancy. I. Cytomegalovirus and Epstein-Barr virus infections. N Engl J Med. 313:1270-1273, 1985.

83. Stagno S and Whitley RJ: Herpesvirus Infections of Pregnancy. II. Herpes simplex virus and varicella-zoster virus infections. N Engl J Med. 313:1327-1329, 1985.

84. Whitley RJ, Nahmias AJ and the NIAID Collaborative Antiviral Study Group: Therapeutic challenges of neonatal herpes simplex virus infection. Scand J Infect Dis. 47:97-106, 1985.

85. Whitley RJ, Alford CA Jr, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias AJ and the NIAID Collaborative Antiviral Study Group: Vidarabine versus acyclovir therapy of herpes simplex encephalitis. N Engl J Med. 314:144-149, 1986.

86. Kahlon J, Lakeman FD, Ackermann M and Whitley RJ: Human antibody response to herpes simplex virus specified polypeptides following primary and recurrent infection. J Clin Microbiol. 23:725-730, 1986.

87. Schlitt M, Lakeman AD, Wilson ER, To A, Acoff RW, Harsh GR and Whitley RJ: A rabbit model of focal herpes simplex encephalitis. J Infect Dis. 153:732-735, 1986.

88. Schlitt M, Morawetz RB, Bonnin J, Chandra-Sekar B, Curtiss JJ, Diethelm, AG, Whelchel JD and Whitley RJ: Progressive multifocal leukoencephalopathy: three patients diagnosed by brain biopsy, with prolonged survival in two. Neurosurg. 18:407-414, 1986.

89. Lakeman FD, Nahmias AJ and Whitley RJ: Analysis of DNA from recurrent genital herpes simplex virus isolates by restriction endonuclease digestion. Sex Transm Dis. 13:61-66, 1986.

90. Whitley RJ: Neonatal herpes simplex virus infections. J Reprod Med. 31:426-432, 1986.

91. Collaborative DHPG Treatment Study Group: Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl) guanine in patients with AIDS and other immunodeficiencies. N Engl J Med. 314:801-805, 1986.

92. Cauda R, Chatterjee S, Tilden AB, Grossi CE and Whitley RJ: Replication of varicella zoster virus in Raji cells. Virus Res. 4:337-342, 1986.

93. Koga J, Chatterjee S and Whitley RJ: Studies on herpes simplex virus type-1 glycoproteins using monoclonal antibodies. Virology. 151:385-389, 1986.

94. Tilden AB, Cauda R, Grossi CE, Balch CM, Lakeman AD and Whitley RJ: Demonstration of NK-cell mediated lysis of varicella-zoster virus (VZV) infected cells: characterization of the effector cells. J Immunology. 136:4243-4246, 1986.

95. Cauda R, Laghi V, Ortona L and Whitley RJ: Delta Hepatitis. An overview. Ala J Med Sci. 23:433-436, 1986.

96. Kahlon J, Chatterjee S, Lakeman FD, Lee F, Nahmias AJ and Whitley RJ: Detection of antibodies to herpes simplex virus in the cerebrospinal fluid of patients with herpes simplex encephalitis. J Infect Dis. 155:38-44, 1987.

97. Brasfield DM, Stagno S, Whitley RJ, Cloud G, Cassell G and Tiller RE: Infant pneumonitis associated with cytomegalovirus, chlamydia, pneumocystis, and ureaplasma: follow-up. Pediatrics. 79:76-83, 1987.

98. Metcalf JF and Whitley RJ: Protective immunity against herpetic ocular disease in an outbred mouse model. Curr Eye Res. 6:167-171, 1987.

99. Metcalf JF, Koga J, Chatterjee S and Whitley RJ: Passive immunization with monoclonal antibodies against herpes simplex virus glycoproteins protects mice against herpetic ocular disease. Curr Eye Res. 6:173-177, 1987.

100. Hutto C, Arvin A, Jacobs R, Steele R, Stagno S, Lyrene R, Willett L, Powell D, Anderson R, Wetherman J, Ratliff G, Nahmias AJ and Whitley RJ: Intrauterine herpes simplex virus infections. J Pediatr. 110:97-101, 1987.

101. Cauda R, Grossi CE, Whitley RJ and Tilden AB: Analysis of immune function in herpes zoster patients: demonstration and characterization of suppressor cells. J Immunol. 138:1229-1233, 1987.

102. Barnes DW and Whitley RJ: Antiviral therapy and pulmonary disease. Chest. 91:246-251, 1987.

103. Lakeman FD, Koga J, Whitley RJ and the NIAID Collaborative Antiviral Study Group: Detection of antigen to herpes simplex virus in cerebrospinal fluid from patients with herpes simplex encephalitis. J Infect Dis. 155:1172-1178, 1987.

104. Longnecker R, Chatterjee S, Whitley RJ and Roizman B.: Identification of a novel herpes simplex virus 1 glycoprotein gene within a gene cluster dispensable for growth in cell culture. Proc Natl Acad Sci (USA). 84:4303-4307, 1987.

105. Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley, D, Nahmias AJ, Soong SJ and the NIAID Collaborative Antiviral Study Group: Factors indicative of outcome in a comparison trial of acyclovir and vidarabine for biopsy-proven herpes simplex encephalitis. Infection. 15:3-8, 1987.

106. Barnes DW and Whitley RJ: Herpes simplex infections in immunocompromised patients. Primary Care and Cancer. 7:33-41, 1987.

107. Cauda R, Tyring SK, Grossi CE, Tilden AB, Hatch KD, Sams WD, Baron S and Whitley RJ: Patients with condyloma acuminatum exhibit decreased Interleukin 2 and interferon gamma production and depressed natural killer activity. J Clin Immunology. 7:304-311, 1987.

108. Tyring SK, Cauda R, Baron S and Whitley RJ: Condyloma acuminatum: epidemiological, clinical and therapeutic aspects. European J Epidemiol. 3:209-215, 1987.

109. Petty BG, Whitley RJ, Liao S, Krasny HC, Rocco LE, Davis LG and Leitman PS: Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers. Antimicrob Agents Chemother. 31:1317-1322, 1987.

110. Cauda R, Prasthofer EF, Tilden AB, Whitley RJ and Grossi CE: T-cell imbalances and natural killer activity in varicella-zoster virus infections. Viral Immunol. 1:145-152, 1987.

111. Hanley DF, Johnson RT and Whitley RJ: Controversies in neurology: yes, brain biopsy should be a prerequisite for herpes simplex encephalitis treatment. Arch Neurol. 44:1289-1290, 1987.

112. Metcalf JF, Koga J, Chatterjee S and Whitley RJ: Protection against herpetic ocular disease by immunotherapy with monoclonal antibodies to HSV glycoproteins. Intervirology. 185:1-11, 1987.

113. Cauda R, Prasthofer EF, Grossi CE, Whitley RJ and Pass RF: Congenital cytomegalovirus: immunological alterations. J Med Virol. 23:41-49, 1987.

114. Corey L, Whitley RJ, Stone F and Mohan K: Differences between herpes simplex virus type 1 and type 2 encephalitis in neonatal neurological outcome. Lancet. 29:1-4, 1988.

115. Whitley RJ: Antiviral treatment of a serious herpes simplex infection: encephalitis. J Am Acad Dermatol. 18:209-211, 1988.

116. Schlitt M, Bucher AP, Stroop WG, Pindak F, Bastian FO, Jennings RA, Lakeman AD and Whitley RJ: Mortality in an experimental focal herpes encephalitis: relationship to seizures. Brain Res. 440:293-298, 1988.

117. Whitley RJ, Corey L, Arvin A, Lakeman FD, Sumaya CV, Wright PF, Dunkle LM, Steele RW, Soong SJ, Nahmias AJ, Alford CA and the NIAID Collaborative Antiviral Study Group: Changing presentation of neonatal herpes simplex virus infection. J Infect Dis. 158:109-116, 1988.

118. Baldwin S, Stagno S, Odrezin GT, Kelly DR and Whitley RJ: Isolated cryptococcus neoforms osteomyelitis in an immunocompetent child. Pediatr Infect Dis. 7:289-292, 1988.

119. Kahlon J and Whitley RJ: Antibody response of the newborn after herpes simplex virus infection. J Infect Dis. 158:925-933, 1988.

120. Whitley RJ: Herpes simplex virus infections of the central nervous system: A review. Am J Med. 85:61-67, 1988.

121. Peacock JE, Kaplowitz LG, Sparling PF, Durack DT, Gnann JW, Whitley RJ, Lovett M, Bryson YJ, Klein RJ, Friedman-Kien AE, Knowlton GM and Davis LG: Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial. Am J Med. 85:301-306, 1988.

122. Whitley RJ: Lessons learned from therapy of human herpesvirus infection. A discussion. In: Frontiers of Infectious Diseases New Antiviral Strategies, S. R. Norrby, J. Mills, E. Norrby, L. J. Whitton, eds, Churchill Livingstone, New York, 1988, pp 91-95.

123. Reichman RC, Oakes D, Bonnez W, Greisberger C, Tyring S, Miller L, Whitley R, Carveth H, Widner M, Krueger G, Yorkey L, Roberts NJ and Dolin R: Treatment of condyloma acuminatum with three different interferons administered intralesionally: a multicentered, placebo-controlled trial. Ann Int Med. 108:675-679, 1988.

124. Grimaldi LME, Roos RP, Manservigi R, Spear PG, Lakeman FD and Whitley RJ: An isoelectric focusing study in herpes simplex virus encephalitis. Ann Neurol. 24:227-232, 1988.

125. Chatterjee S, Whitley RJ: Effect of recombinant human interferon on replication and morphogenesis of HSV-1 in monkey cells. Virus Res. 12:33-42, 1989.

126. Cauda R, Laghi V, Tumbarella M, Ortona L, and Whitley RJ: Immunological alterations associated with recurrent herpes simplex genitalis. Clin Immunol Immunopathol. 51:294-302, 1989.

127. Baldwin S and Whitley RJ: Intrauterine herpes simplex virus infection. Teratology. 39:1-10, 1989.

128. Whitley RJ, Cobbs CG, Alford CA, Soong SJ, Morawetz R, Benton JW, Hirsch MS, Reichman RC, Aoki FY, Connor J, Oxman M, Corey L, Hanley DF, Wright PF, Levin M, Nahmias A, Powell DA and the NIAID Collaborative Antiviral Study Group: Diseases that mimic herpes simplex encephalitis: diagnosis, presentation and outcome. JAMA. 262:234-239, 1989.

129. Whitley RJ, Cobbs CG, Alford CA, Soong SJ, Morawetz R, Benton JW, Hirsch MS, Reichman RC, Aoki FY, Connor J, Oxman M, Corey L, Hanley DF, Wright PF, Levin M, Nahmias A, Powell DA and the NIAID Collaborative Antiviral Study Group: Diseases that mimic herpes simplex encephalitis: diagnosis, presentation and outcome. JAMA Southeast Asia. 5:33-40, 1989.

130. Whitley RJ, Cobbs CG, Alford CA, Soong SJ, Morawetz R, Benton JW, Hirsch MS, Reichman RC, Aoki FY, Connor J, Oxman M, Corey L, Hanley DF, Wright PF, Levin M, Nahmias A, Powell DA and the NIAID Collaborative Antiviral Study Group: Diseases that mimic herpes simplex encephalitis: diagnosis, presentation and outcome. JAMA Turkish Edition. 12:924-933, 1989.

131. Chatterjee S, Koga J, and Whitley RJ: Role of HSV type 1 glycoprotein E in induction of cell fusion. J Gen Virol. 70:2157-2162, 1989.

132. Ortona L, Cauda R, and Whitley RJ: Herpes Zoster. Aggiornamento del Medico. 13: 133. 7, 1989.

133. Rowley A, Lakeman F, Whitley R, Wolinsky S: Rapid detection of herpes simplex virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis. Lancet. 335:440-441, 1990.

134. Chatterjee S, Nishimuro S, Whitley RJ: Expression of HSV-1 glycoproteins in tunicamycin-treated monkey kidney cells. Biochem Biophys Res Commun. 167:1139-1145, 1990.

135. Gordon B, Selnes OA, Hart J, Hanley DF, and Whitley RJ: Long-term cognitive sequelae of acyclovir-treated herpes simplex encephalitis. Arch Neurol. 47:646-647, 1990.

136. Whitley RJ: Viral encephalitis. N Engl J Med. 323:242-250, 1990.

137. Meignier B, Martin B, Whitley R, and Roizman B: In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis. 162:313-321, 1990.

138. Chou J, Kern ER, Whitley RJ, and Roizman B: Mapping of neurovirulence to protein 34.5 encoded by a diploid herpes simplex virus 1 gene non essential for growth in cell culture. Science. 250:1262-1266, 1990.

139. Reichman RC, Oakes D, Bonnez W, Brown D, Mattison HR, Bailey-Farchione A, Stoler MH, Tyring S, Miller L, Whitley RJ, Carveth H, Weidner M, Krueger G, and Yorkey L: Treatment of condyloma acuminatum with three different alpha interferon preparations administered parenterally: A double-blind, placebo-controlled trial. J Infect Dis. 162:248-258, 1990.

140. Canessa A, Chatterjee S, Whitley RJ, Prasthofer EF, Grossi CE, Tilden AB. Individual NK cell clones lyse both tumor cell targets and herpes simplex virus-infected fibroblasts in the absence of interferon. Viral Immunol. 3:217-224, 1990.

141. Whitley RJ, Connell J, Markiewicz MA, and Sommadossi JP: Novel pharmacological strategies in the treatment of life-threatening cytomegalovirus infections: Clinical experience with continuous infusion 9-(1,3-dihydroxy-2-propoxymethyl) guanine. Ann NY Acad Sci. 616:452-460, 1990.

142. Soong SJ, Watson NE, Caddell GR, Alford CA Jr, Whitley RJ, and the NIAID Collaborative Antiviral Study Group: Use of brain biopsy for diagnostic evaluation of patients with suspected herpes simplex encephalitis: A statistical model and its clinical implications. J Infect Dis. 163:17-22, 1991.

143. Whitley RJ, Arvin A, Prober C, Burchett S, Corey L, Powell D, Plotkin S, Starr S, Alford C, Connor J, Jacobs RF, Nahmias AJ, Soong SJ, and the NIAID Collaborative Antiviral Study Group: A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med. 324:444-449, 1991.

144. Whitley RJ, Arvin A, Prober C, Lawrence C, Burchett S, Plotkin S, Starr SE, Jacobs RF, Powell DA, Nahmias AJ, Sumaya C, Edwards C, Alford C, Caddell G, Soong SJ, and the NIAID Collaborative Antiviral Study Group: Predictors of morbidity and mortality in neonates with herpes simplex virus infections. N Engl J Med. 324:450-454, 1991.

145. Co MS, Deschamps M, and Whitley RJ, Queen C: Humanized antibodies for antiviral therapy. Proc Natl Acad Sci (USA). 88:2869-2873, 1991.

146. Report of the Committee on Infectious Diseases. Varicella-zoster virus, herpes simplex virus, and cytomegalovirus infections. In: Red Book, 22nd Edition. Committee on Infectious Diseases, American Academy of Pediatrics. Georges Peter, ed. pp 75-76, 1991.

147. Gnann J, Whitley RJ: Natural history and treatment of varicella-zoster in high risk populations. J Hosp Infect. 18:317-329, 1991.

148. Whitley RJ. Herpes simplex virus infection of the newborn. In: The Term Newborn Infant: A Current Look. The 100th Ross Conference on Pediatric Research, May 20-23, 1990, Ross Laboratories Publisher, pp 61-67, 1991.

149. Saag MS, Decker WD, Campbell-Hill S, Crain M, Robinson S, Brown WE, Leuther M, Whitley RJ, Hahn BH, Shaw GM: High level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and $CD4^+$ lymphocyte levels. J Infect Dis. 164:72-80, 1991.

150. Whitley RJ. Perinatal herpes simplex virus infections. Rev Med Virol. 1:101-110, 1991.

151. Sanchez-Martinez D, Schmid DS, Whittington W, Brown D, Reeves WC, Chatterjee S, Whitley RJ, Pellett P. Evaluation of a test based on baculovirus-expressed glycoprotein G for detection of herpes simplex virus type specific antibodies. J Infect Dis. 164:1196-1199, 1991.

152. Nielsen LN, Whitley RJ, Chatterjee S. Apical expression of herpes simplex type-2 glycoproteins in human neuroblastoma cells. Virology. 185:908-910, 1991.

153. Laughlin CA, Black RJ, Feinberg J, Freeman DJ, Ramsey J, Ussery MA, Whitley RJ: Resistance to Antiviral Drugs. ASM News. 57:512-517, 1991.

154. Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM, Feldman S, Gershon AA, Levy ML, Hayden GF, McGuirt PV, Harris J, Balfour HH Jr. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med. 325:1539-1544, 1991.

155. Whitley RJ, Gnann JW, Hinthorn D, Chein L, Pollard RB, Hayden F, Mertz GJ, Oxman M, Soong S-J, and the NIAID Collaborative Antiviral Study Group. Disseminated herpes zoster in the immunocompromised host: A comparative trial of acyclovir and vidarabine. J Infect Dis. 165:450-455, 1992

156. Rodu B, Tate AL, Lakeman AF, Mattingly G, Russell CM, Whitley RJ. Prevalence of herpes simplex virus antibodies in dental students. J Dent Educ. 56:206-208, 1992.

157. Balfour HH Jr, Rotbart HA, Feldman S, Dunkle LM, Feder HM, Prober CG, Hayden GF, Steinberg S, Whitley RJ, Goldberg L, McGuirt PV. Acyclovir treatment of varicella in otherwise healthy adolescents. J Peds. 120:627-633, 1992.

158. Whitley RJ. Therapeutic approaches to varicella zoster virus infections. J Infect Dis. 166:S51-S57, 1992.

159. Whitley RJ, Gnann JW Jr. Acyclovir: A decade later. N Engl J Med. 327:782-789, 1992.

160. Chatterjee S, Burns P, Whitley RJ, Kern ER. Effect of (S)-1-[(3-hydroxy-2-phosphonyl methoxy) propyl] cytosine on the replication and morphogenesis of herpes simplex virus type 1. Antiviral Res. 19:181-192, 1992.

161. Prober CG, Corey L, Brown ZA, Hensleigh PA, Frenkel LM, Bryson YJ, Whitley RJ, Arvin AM. The management of pregnancies complicated by genital herpes simplex virus infections. Clin Infect Dis. 15:1031-1038, 1992.

162. Perl TM, Haugen TH, Pfaller MA, Hollis R, Lakeman FD, Whitley RJ, Nicholson D, Hunter GA, Wenzel RP. Transmission of herpes simplex virus type 1 in an intensive care unit. Ann Intern Med. 117:584-586, 1992.

163. Whitley RJ. Neonatal herpes simplex virus infections: Pathogenesis and therapy. Pathol Biol. 40:729-734, 1992.

164. McCracken GH, Sande MA, Lentnek A, Whitley RJ, Scheld WM. Evaluation of new anti-infective drugs for the treatment acute bacterial meningitis. Clin Infect Dis. 15(Supp 1):S182-188, 1992.

165. Lentnek A, Sande MA, Whitley RJ, McCracken GH, Scheld WM. Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis. Clin Infect Dis. 15(Supp 1):S189-194, 1992.

166. Whitley RJ, Lentnek A, McCracken GH, Sande MA, Scheld WM. Evaluation of new anti-infective agents for the treatment of viral encephalitis. Clin Infect Dis. 15 (Supp 1):S195-199, 1992.

167. Sande MA, Whitley RJ, McCracken GH, Lentnek AScheld WM. Evaluation of new anti-infective drugs for the treatment of toxoplasma encephalitis. Clin Infect Dis. 15(Supp 1):S200-205, 1992.

168. Trang JM, Kidd L, Gruber W, Storch G, Demmler G, Jacobs R, Dankner W, Starr S, Pass R, Stagno S, Alford C, Soong SJ, Whitley RJ, Sommadossi JP, and the NIAID Collaborative Antiviral Study Group. Linear single-dose pharmacokinetics of ganciclovir

in newborns with congenital cytomegalovirus infections. Clin Pharmacol Ther. 53:15-21, 1993.

169. Whitley RJ. Nucleoside antiviral therapy of human immunodeficiency virus infection: What does antiviral resistance mean - do we know? Current Opinion in Investigational Drugs 2:77-79, 1993.

170. Sarkar A, Koga J, Whitley RJ, Chatterjee S. Antiviral effect of the extract of culture medium of Lentinus edodes mycelia on the replication of herpes simplex virus type 1. Antiviral Res. 20:293-303, 1993.

171. Whitley RJ, Straus S. Therapy of varicella-zoster virus infections: Where do we stand? Infectious Disease in Clinical Practice. 2:100-108, 1993.

172. Griffiths, PD, Whitley, RJ. Viral infections in the immunocompromised host. Current Opinion in Infectious Diseases. 6:417-421, 1993.

173. Whitley RJ, Kern ER, Chatterjee S, Chou J, Roizman B. Replication, establishment of latency and induced reactivation of herpes simplex virus γ_1 34.5 deletion mutants in rodent models. J Clin Invest. 91:2837-2843, 1993.

174. Whitley RJ. Herpes-A Global Challenge: Neonatal herpes simplex virus infections. J Med Virol. 1 (Supp 1)13-21, 1993.

175. Whitley RJ. Famciclovir/penciclovir: Prospects for the future. Antiviral Chem Chemother. 4 (Suppl 1)65, 1993.

176. Saag MS, Emini EA, Laskin OL, Douglas J, Lapidus WI, Schleif WA, Whitley RJ, Hildebrand C, Byrnes VW, Kappes JC, Anderson KW, Massari FE, Shaw GM and L-697,661 Working Group. The nonnucleoside HIV-1 reverse transcriptase inhibitor L-697,661: Clinical activity and rapid selection for virus variants with reduced susceptibility. N Engl J Med. 329:1065-1072, 1993.

177. Mena W, Royal S, Pass RF, Whitley RJ, Philips JB III. Diabetes insipidus associated with congenital cytomegalovirus infection. J Pediatr. 122:911-913, 1993.

178. Norrby SR, Whitley RJ, and the European Working Party of the European Society of Clinical Microbiology and Infectious Diseases. Evaluation of new anti-infective drugs for the treatment of infection with human immunodeficiency virus. Clin Infect Dis. 17:794-801, 1993.

179. Whitley RJ. Prospects for vaccination against herpes simplex virus. Pediatr Ann. 22:726-732, 1993.

180. Whitley, RJ and Arvin, A. The natural history, pathogenesis, and treatment of neonatal herpes simplex virus infections. Semin Pediatr Infect Dis. 5:56-64, 1994.

181. Whitley RJ. Herpes simplex virus infections of women and their offsprings: Implications for a developed society. Proc Natl Acad Sci USA. 91:2441-2447, 1994.

182. Spring SB, Laughlin C, Arvin AM, Hay J, Straus SE, Whitley RJ, Gershon AA, Silverstein SJ. Varicella-zoster virus infection and post-herpetic neuralgia: New insights into pathogenesis and pain management. Ann Neurol 35 (Suppl):S2-S3, 1994.

183. Whitley, RJ. Neonatal herpes simplex virus infections: is there a role for immunoglobulin in disease prevention and therapy? Pediatr Infect Dis J. 13:432-439, 1994.

184. Whitley, RJ. Penciclovir/Famciclovir: parent and child in the treatment of herpes virus infections. Expert Opinion on Investigational Drugs. 3:759-761, 1994.

185. Gangopadhyay NN, Whitley RJ, Chatterjee S. A rapid protein A binding radioimmunoassay for the evaluation of antiviral agents. J Virol Methods. 48:273-279, 1994.

186. Whitley, R. J. Famciclovir for herpes zoster. The Medical Letter. 36:97-98. 1994.

187. Whitley, RJ. Viral encephalitis: diagnosis and treatment. CNS Drugs. 2:355-366, 1994.

188. Whitley RJ, Lakeman F. Herpes simplex infections of the central nervous system: Therapeutic and diagnostic considerations. Clin Infect Dis. 20:414-20, 1995.

189. Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J, Roizman B, Whitley RJ. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci (USA). 92:1411-1415, 1995.

190. Lakeman FD, Whitley RJ, NIAID Collaborative Antiviral Study Group. Diagnosis of herpes simplex encephalitis: Application of polymerase chain reaction to cerebrospinal fluid from brain biopsied patients and correlation with disease. J Infect Dis. 171:857-863, 1995.

191. Kimberlin DW and Whitley RJ. Antiviral resistance--An emerging problem. Antiviral Res. 26:365-368, 1995.

192. Kimberlin DW, Coen DM, Biron KK, Cohen JI, Lamb RA, McKinlay M, Emini EA,

Whitley RJ. Molecular mechanisms of antiviral resistance. Antiviral Res. 26:369-401, 1995.

193. Kimberlin DW, Spector SA, Hill EL, Biron KK, Hay AJ, Mayers DL, Whitley RJ. Assays for Antiviral drug resistance. Antiviral Res. 26:403-413, 1995.

194. Kimberlin DW, Kern ER, Sidwell RW, North TW, Whitley RJ. Models of Antiviral Resistance. Antiviral Res. 26:415-422, 1995.

195. Kimberlin DW, Crumpacker CS, Straus, SE, Biron KK, Drew L, Hayden FG, McKinlay M, Richman DD, Whitley RJ. Antiviral Resistance in Clinical Practice. Antiviral Res. 26:423-438, 1995.

196. Kimberlin DW Couch RB, Galasso, Richman DD, Whitley RJ. Research initiatives in studies of antiviral resistance and consensus points and recommendations. Antiviral Res. 26:439-452, 1995.

197. McCullers JA, Lakeman FJ, Whitley RJ. Human herpesvirus-6 is associated with focal encephalitis. Clin Infect Dis. 21:571-576, 1995.

198. Whitley, RJ. Evolution of therapy for herpes zoster: What's next? Curr Opin Infect Dis. 8:453-454, 1995.

199. Whitley RJ. Sorivudine. A promising drug for the treatment of varicella-zoster virus infection. Neurology. 45 (Suppl 8):S73-S75, 1995.

200. DeMets DL, Fleming TR, Whitley RJ, Childress JF, Ellenberg SS, Foulkes M, Mayer KH, O'Fallon J, Pollard RB, Rahal JJ, Sande M, Stephen Straus, Walters L, Whitley-Williams P. The Data and Safety Monitoring Board and acquired immune deficiency syndrome (AIDS) clinical trials. Controlled Clin Trials. 16:408-421, 1995.

201. Stewart J, Reef S, Pellet P, Whitley RJ. Herpesvirus Infections in persons infected with human immunodeficiency virus. Clin Infect Dis. 21:S114-S120, 1995.

202. Kimberlin D, Powell D, Gruber W, Diaz P, Arvin A, Kumar M, Jacobs R, Van Dyke R, Burchett S, Soong S-J, Lakeman F, Whitley R, NIAID Collaborative Antiviral Study Group. Administration of oral acyclovir suppressive therapy following neonatal herpes simplex virus disease limited to the skin, eyes, and mouth: results of a Phase I/II trial. Pediatr Infect Dis J. 15:247-254, 1996.

203. Kimberlin DW and Whitley RJ. Review: Antiviral resistance: Mechanisms, clinical significance, and future implications. J Antimicrob Chemother. 37:403-421, 1996.

204. Wood MJ, Kay R, Dworkin RH, Soong S-J, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: A Meta-analysis of placebo-controlled trials. Clin Infect Dis 22:341-347, 1996.

205. Whitley RJ and Darby G. Antiviral therapy: present approaches, clinical needs, and drug development strategies. Reviews in Contemporary Pharmacotherapy 7:91-107, 1996.

206. Whitley RJ, Gnann JW, Weiss, HL, Soong S-J. Unique clinical trial design: combination acyclovir plus prednisone therapy of localized zoster in the normal host. Antiviral Res. 29:67-68, 1996.

207. McCullers, J. A., Whitley, R. J. The natural history, pathogenesis, treatment of neonatal herpes simplex virus infections. Neonatal Monitor. 13:2-5, 1996.

208. Whitley RJ. Drug discovery for human immunodeficiency virus infection: conquests and hurdles J Antimicrobial Chemother. 37 (Suppl B):151-159, 1996.

209. Whitley RJ. Introduction. Seminars in Dermatology. 15 (Suppl 1):1-3, 1996.

210. Whitley RJ, Weiss H, Gnann JW, Tyring S, Sherrill L, Pollard, RB, Mertz GJ, Pappas P, Schleupner CJ, Hayden F, Wolf J, Soong S-J, NIAID Collaborative Antiviral Study Group. A randomized, placebo-controlled trial of acyclovir with and without steroids for the treatment of herpes zoster. Ann Intern Med. 125:376-383, 1996.

211. Yoshida M, Yamada M, Chatterjee S, Lakeman F, Nii S, Whitley RJ. A method for detection of HHV-6 antigens and its utilization for evaluating antiviral drugs. J Virol Methods. 58:137-143, 1996.

212. Zhou X-J, Gruber W, Demmler G, Jacobs R, Reuman P, Adler S, Shelton M, Pass R, Britt, B, Trang JM, Whitley RJ, Sommadossi J-P and the NIAID Collaborative Antiviral Study Group. Population Pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Antimicrob Agents Chemother. 40:2202-2205, 1996.

213. Whitley RJ. The past as prelude to the future: history, status, and future of antiviral drugs. Ann Pharmacother. 30:967-971, 1996.

214. Wintergerst U, Gangemi JD, Kern ER, Whitley RJ, Chatterjee S. Differential effect of recombinant human and mouse interferons on replication of herpes simplex virus type 1 in mouse cells. Antiviral Res. 32:27-34, 1996.

215. Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Roizman B, Whitley RJ. Application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA. 93:11313-11318, 1996.

216. Griffiths PD and Whitley RJ. The pathogenesis of AIDS: lessons learned from other medical conditions. Infect Agents Dis. 5:231-239, 1996.

217. van der Meer JTM, Drew WL, Bowden RA, Galasso GJ, Griffiths PD, Jabs DA, Katlama C, Spector SA, Whitley RJ. Summary of international consensus symposium on advances in the diagnosis, treatment and prophylaxis of cytomegalovirus infection. Antiviral Res. 32:119-140, 1996.

218. Kimberlin DK, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DW, Burchett SK, Jacobs RF, Starr SE, Whitley RJ and the NIAID Collaborative Antiviral Study Group. Application polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. J Infect Dis. 174:1162-1167, 1996.

219. Dworkin RH, Carrington D, Cunningham A, Kost RG, Levin MJ, McKendrick MW, Oxman MN, Rentier B, Schmader KE, Tappeiner G, Wassilew SW, Whitley RJ. Mini review: Assessment of pain in herpes: Lessons learned from antiviral trials. Antiviral Res. 33:73-85, 1997.

220. Cassady KA, Whitley RJ. New therapeutics approaches to the alphaherpes infections. J Antimicrob Chemother. 39:119-128, 1997.

221. Whitley RJ. Introduction. J Acquir Immune Defic Synd Hum Retrovirol. 14:vii, 1997.

222. Whitley RJ. Open Discussion. J Acquir Immune Defic Syndr Hum Retrovirol. 14:S36-S38, 1997.

223. Whitley RJ and Kimberlin DW. Treatment of viral infections during pregnancy and the neonatal period. Clin Perinatol. 24:267-283, 1997.

224. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ,. Evaluation of genetically engineered herpes viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 57:1502-1509, 1997.

225. Whitley RJ, Cloud G, Gruber W, Storch MD, Demmler MD, Jacobs RF, Dankner W, Spector SA, Starr S, Pass RF, Stagno S, Britt WJ, Alford C, Soong S-J, Zhou X-J, Sherrill L, FitzGerald JM, Sommadossi J-P, and the NIAID Collaborative Antiviral Study Group. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: Results of a Phase II Study. J Infect Dis. 175:1080-1086, 1997.

226. Whitley RJ and Kimberlin DW. Prophylaxis and treatment of herpesvirus infections in children. Semin Pediatr Infect Dis. 8:196-204, 1997.

227. Mennemeyer ST, Cyr LP, Whitley RJ. Antiviral therapy for neonatal herpes simplex virus: A cost-effectiveness analysis. Am J Manag Care. 3:1551-1558, 1997.

228. Whitley RJ. The management of herpesvirus infections in individuals with HIV/AIDS. Antivir Ther. 2(Suppl 2):25-28, 1997.

229. Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY, Roizman B, Whitley RJ. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex virus that express murine interleukins. Gene Therapy. 5:121-130, 1998.

230. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis. 26:541-553, 1998.

231. Gnann JW, Jr. Crumpacker CS, Lalezari JP, Smith JA, Tyring SK, Baum KF, Pollard RB, Joseph WP, Mertz GJ, Steigbiegel RT, Cloud GA, Soong S-J, Sherrill LC, DeHertogh DA, Laughlin CA, Whitley RJ, and the NIAID Collaborative Antiviral Study Group (CASG)/AIDS Clinical Trials Group (ACTG) Herpes Zoster Study Group. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients; results from a randomized controlled clinical trial. Antimicrob Agents Chemother. 42:1139-1145, 1998.

232. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, Hardy WD, Polis MA, Deutsch TA, Feinberg J, Spector SA, Walmsley S, Drew WL, Powderly WG, Griffiths PD, Benson CA, Kessler HA. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS. Arch Intern Med. 152:957-969, 1998.

233. Stuart JWTC, Boucher CAB, Cooper DA, Galasso GJ, Richman DD, Thomas HC, Whitley RJ. Summary of the III International consensus symposium on combined antiviral therapy. Antiviral Res. 38:75-93, 1998.

234. Domingues RB, Lakeman FD, Mayo MS, Whitley RJ. Application of competitive PCR to cerebrospinal fluid samples from patients with herpes simplex encephalitis. J Clin Microbiol. 36:2229-2234, 1998.

235. Kimberlin DF, Weller KS, Whitley RJ, Andrews WW, Hauth JC, Lakeman F, Miller G. Pharmacokinetics of oral valaciclovir and acyclovir in late pregnancy. Am J Obstet Gynecol. 179:846-851, 1998.

236. Kimberlin DW and Whitley RJ. Human herpesvirus-6. Neurologic implications of a newly-described viral pathogen. J Neurovirol. 4:474-485, 1998.

237. Yoshida M, Yamada M, Tsukazaki T, Chatterjee S, Lakeman FD, Nii S, Whitley RJ. Comparison of antiviral compounds against human herpesvirus-6 and -7. Antiviral Res. 40:73-84, 1998.

238. Whitley RJ, Shukla S, Crooks RJ. The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis. 178 (Suppl 1):S71-S75, 1998.

239. Whitley RJ, Weiss HL, Soong S-J, Gnann JW. Herpes zoster: risk categories for persistent pain. J Infect Dis. 179:9-15, 1999.

240. Whitley RJ. A new role for herpes simplex virus? IDCP. 16:93-96, 1999.

241. Martin DF, Dunn JP, Davis JL, Duker JS, Engstrom RE Jr., Friedberg DN, Jaffe GJ, Kuppermann BD, Polis MA, Whitley RJ, Wolitz RA, Benson CA for the Internaitonal AIDS Society--USA. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society--USA Panel. Am J Ophthalmol. 127:329-339, 1999.

242. Whitley RJ and DW Kimberlin. Viral Encephalitis. Pediatr Rev. 20:192-198, 1999.

243. Harrison RA, Soong S-J, Weiss HL, Gnann JW Jr, Whitley RJ. A mixed model for factors predicttive of pain in AIDS patients with herpes zoster. J Pain Symptom Manage. 17:410-417, 1999.

244. Advani SJ, Chung SM, Yan SM, Gillespie GY, Markert JM, Whitley RJ, Roizman B, Weichselbaum RR. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 59:2055-2088, 1999.

245. Bradley JD, Kataoka Y, Advani S, Chung SM, Arani RB, Gillespie GY, Whitley RJ, Markert JM, Roizman B, Weichselbaum RR. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res 5:1517-1522, 1999.

246. Cassady KA, Whitley RJ. Encephalitis: new thoughts on pathogenesis and diagnostics. Curr Infect Dis Rep. 1:178-186, 1999.

247. Rotbart HA, McCracken GH Jr., Whitley RJ, Modlin JF, Cascino M, Shah S, Blum D. Clinical significance of enteroviruses in serious summer febrile illness of children. Pediatr Infect Dis J. 18:869-874, 1999.

248. Wintergerst U, Gangemi JD, Whitley RJ, Chatterjee S, Kern ER. Effect of recombinant human interferon α B/D (rHu-IFN-α B/D) in combination with acyclovir in experimental HSV-1 encephalitis. Antiviral Res. 44:75-78, 1999.

249. Whitley RJ. Gnann JW. Herpes zoster: focus on treatment in older adults. Antiviral Res. 44:146-154, 1999.

250. Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ. Genetically-engineered HSV in the treatment of glioma: A Review. Rev Med Virol. 10:17-30, 2000.

251. Parker J, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing interleukin 12 in the treatment of experimental murine tumors. Proc Natl Acad Sci USA. 97:2208-2213, 2000.

252. Whitley RJ, MacDonald N, Asher DM, and the Committee on Infectious Diseases. Technical Report: Transmissible Spongiform encephalopathies: a review for pediatricians. Pediatrics 106:1160-1165, 2000.

253. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 20:127-133. 2001.

254. Markert JM, Parker JN, Gillespie GY, Whitley RJ. Genetically engineered human herpes simplex virus in treatment of brain tumors. Herpes. 8:17-22, 2001.

255. Roizman B and Whitley RJ. The nine ages of herpes simplex virus. Herpes. 8:23-27, 2001.

256. Whitley RJ, Roizman B. Herpes simplex viruses: from structure to function. Lancet. 357:1513-1518, 2001.

257. Whitley RJ, Miller RL. Immunologic approach to herpes simplex virus. Viral Immunol. 14:111-118, 2001.

258. Arani RB, Soong S-J, Weiss HL, Wood MJ, Fiddian PA, Gnann JW, Whitley R Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med. 20:2429-2439, 2001.

259. Kimberlin DW, Lin C-Y, Jacobs RF, Powell DA, Frenkel LM, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, deSierra TM, Soong S-J, Kiell J, Lakeman FD, Whitley RJ and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study

Group. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 108:223-229, 2001.

260. Kimberlin DW, Lin C-Y, Jacobs RF, Powell DA, Corey L, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, de Sierra TM, Weller S, Soong S-J, Kiell J, Lakeman FD, Whitley RJ and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 108:230-238, 2001.

261. Whitley RJ. Herpes simplex virus infection. Semin Pediatr Infect Dis 13:6-11, 2002.

262. Whitley RJ and Gnann JW. Viral encephalitis: familiar infections and emerging pathogens. Lancet. 359:507-514, 2002.

263. Chung S-M, Advani SJ, Bradley JD, Kataoka Y, Vashistha K, Yan SY, Markert JM, Gillespie GY, Whitley RJ, Roizman B, Weichselbaum RR. The use of genetically herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther. 9:75-80, 2002

264. Whitley RJ. Herpes simplex virus in children. Curr Treat Options Neurol. 4:231-237, 2002.

265. Desmond RA, Weiss HL, Arani RB, Soong S-J, Wood MJ, Fiddian PA, Gnann JW, Whitley RJ. Clinical Applications for Change-Point Analysis of Herpes Zoster Pain. J Pain Symptom Manage 23:510-516, 2002.

266. Whitley RJ, Roizman B. Herpes simplex viruses: is a vaccine tenable? J Clin Invest 110:145-151, 2002.

267. Gnann JW and Whitley RJ. Herpes zoster. N Engl J Med 347:340-346, 2002.

268. Advani SJ, Weichselbaum RR, Whitley RJ, Roizman B. Friendly fire: Redirecting herpes simplex virus-1 for therapeutic application. Clin Microbiol Infect 8:551-563, 2002.

269. Whitley RJ. Introduction. J Infect Dis. 186 (Suppl 1):S1-S2, 2002.

270. Whitley RJ. Smallpox: A potential agent of bioterrorism. Antiviral Res 57: 7-12, 2003.

271. Abzug MJ, Cloud G, Bradley J, Sanchez PJ, Romero J, Powell D, Lepow M, Mani C, Capparelli eV, Blount S, Lakeman F, Whitley RJ, Kimberlin DW, National Institute of Allergy and Infectious Diseases and the Collaborative Antiviral Study Group. Double-Blind, placebo-controlled trial of pleconaril in infants with enterovirus meningitis.

Pediatr Infect Dis J 22:335-341, 20003.

272. Kimberlin DW, Lin C-Y, Sanchez PJ, Demmler GJ, Dankner W, Shelton MD, Jacobs RF, Vaudry W, Kiell JM, Soong S-J, Whitley RJ, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Effect of ganciclovir on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trial. J Pediatr 143:16-25, 2003.

Articles in Press

1. Whitley RJ. Critical Drug Appraisal: Famciclovir. Drug Therapy.

Original Articles-Submitted for Publication:

1. Ennis DM, Lackey PC, Jernigan DB, Good JK, Lakeman Fl, Whitley RJ, Richey CM, Hook EW. High prevalence of non-gonococcal, non-chlamydia urethritis in association with genital ulcer disease in men. Clin Infect Dis.

2. Brown ZA, Wald A, Corey L, Whitley R, Arvin A, Prober C, Hitchcock P. Type-specific serologic tests for herpes simplex virus: Use during routine prenatal care. Obstet Gynecol.

3. Weiss HL, Soong-SJ, Gnann JW, Whitley RJ, NIAID Collaborative Antiviral Study Group. Assessment of severity of herpes zoster pain among immunocompetent adults: an analysis using area under the curve. J Infect Dis.

4. Weiss HL, Desmond RA, Soong-S-J, Wood MJ, Gnann, Jr. JW, Whitley RJ. The natural history of herpes zoster pain in immunocompromised and immoncompetent patients.

5. Gober EH, Randall SH, Markert JM, Parker JN, He B, Perbal B, Roizman B, Whitley RJ, Gillespie GY. Increased efficacy of an IL-12 secreting HSV in a syngeneic intracranial murine glioma model suitable for immunologic or non-immunologic evaluation of mutant HSV-1 therapy.

Book Chapters

1. Whitley RJ, Chien LT, Nahmias AJ, Buchanan RA and Alford CA Jr: Adenine arabinoside therapy of neonatal herpetic infections. In: Adenine Arabinoside: An Antiviral Agent, D Pavan-Langston, Robert A Buchanan and Charles A Alford Jr (eds), Raven Press (New York), 1975, pp 225-235.

2. Baublis JV, Whitley RJ, Chien LT and Alford CA Jr: Treatment of cytomegalovirus infection in infants and adults. In: Adenine Arabinoside: An Antiviral Agent, D Pavan-Langston, Robert A Buchanan, and Charles A Alford Jr (eds), Raven Press (New York), 1975, pp 247-260.

3. Chien LT, Whitley RJ, Charamella LJ, Buchanan RA, Cannon NJ, Dismukes WE and Alford CA Jr: Clinical and virologic studies with systemic administration of adenine arabinoside in severe, progressive mucocutaneous herpes simplex virus infection. In: Adenine Arabinoside: An Antiviral Agent, D Pavan-Langston, Robert A Buchanan and Charles A Alford Jr (eds), Raven Press (New York), 1975, pp 205-224.

4. Luby JP, Johnson MR, Buchanan RA, Chien LT, Whitley RJ, and Alford CA Jr: Adenine arabinoside therapy of varicella-zoster virus infections: Summary of phase II studies. In: Adenine Arabinoside: An Antiviral Agent, D Pavan-Langston, Robert A Buchanan, Charles A Alford Jr (eds), Raven Press (New York), 1975, pp 237-246.

5. Whitley RJ, Alford CA Jr: Chronic intrauterine infections. In: Pediatric Therapy 5th Edition, Harry C Shirkey (ed), CV Mosby Company (St. Louis), 1975, pp 411-416.

6. Whitley RJ, Chien LT and Alford CA Jr: Neonatal herpes simplex virus infection. In: International Ophthalmology Clinics: Ocular Viral Disease, D Pavan-Langston (ed), Little, Brown and Co (Boston), Vol 15, No 4, 1975, pp 141-149.

7. Alford CA Jr and Whitley RJ: Treatment of infections due to herpesvirus in humans: A critical review of the state of the art. In: Antivirals with Clinical Potential, Thomas C Merigan (ed), University of Chicago Press, 1976, pp 101-108.

8. Ch'ien LT, Whitley RJ, Alford CA Jr, Galasso GJ and the Collaborative Study Group: Adenine arabinoside for therapy of herpes zoster in immunosuppressed patients: Preliminary results of a collaborative study. In: Antivirals with Clinical Potential, Thomas C Merigan (ed), University of Chicago Press, 1976, pp 184-191.

9. Whitley RJ and Alford CA Jr: Chronic intrauterine and perinatal infections. In: Antiviral Agents and Viral Diseases of Man, GJ Galasso, TC Merigan and RA Buchanan (eds), Raven Press (New York) 1979, pp 541-604.

10. Tucker BA and Whitley RJ: Current thoughts on the management of chickenpox. In: Current Therapy, Howard F Conn (ed), WB Saunders Co (Philadelphia), 1979, pp 9-12.

11. Whitley RJ and Alford CA Jr: Chronic intrauterine infections. In: Pediatric Therapy, 6th Edition, Harry C Shirkey (ed), CV Mosby Co (St Louis), 1980, pp 87-393.

12. Nahmias AJ and Whitley RJ: Herpes simplex infections. In: Current Pediatric Therapy, Gellis and Kagan (eds), WB Saunders Co (Philadelphia), 1980, pp 86-589.

13. Whitley RJ and Alford CA Jr: Parenteral antiviral chemotherapy of human herpesviruses. In: The Human Herpesviruses: An Interdisciplinary Perspective, A Nahmias, W Dowdle, R Schinazi (eds) Elsevier Press (New York), 1981, pp 478-490.

14. Whitley RJ and Alford CA Jr: Preventive and therapeutic approaches to the newborn infant with perinatal viral and toxoplasma infections. In: Clinics in Perinatology, S Plotkin, S Starr (eds), WB Saunders Co (Philadelphia), 1981, pp 591-604.

15. Whitley RJ: Neonatal herpes simplex virus infection. In: The Merck Manual, 14th Edition, Robert Berkow (ed), Merck Sharp and Dohme Research Laboratories (New Jersey), 1982, pp 147-148.

16. Whitley RJ: Therapeutic and diagnostic approaches to children with herpes simplex and varicella-zoster virus infections. In: MTA-Pediatric, JR Prous (ed), International Publishers in Sciences and Medicine (Barcelona, Spain), 1982.

17. Whitley RJ and Alford CA: Therapy for herpesvirus infections in childhood. In: Pediatrics Update, 1984 Edition, AJ Moss (ed), Elsevier Science Publishing Company (New York), 1983, pp 215-230.

18. Whitley RJ and Crist WM: Supportive care: management of infections. In: Cancer Therapy in Children, C Pochedly (ed), Charles B Slack Publishers Incorporated (New Jersey), 1983.

19. Whitley RJ, and Alford CA Jr: Towards therapy and prevention of herpetic infections. In: Viral Infections in Pregnancy, MS Amsety (ed), Grune & Stratton, Inc. (Orlando), 1984, pp 197-224.

20. Whitley RJ: Varicella-zoster virus infections. In: Antiviral Agents and Man, 2nd Edition, G Galasso, T Merigan and R Buchanan (eds), Raven Press (New York), 1984, pp 517-543.

21. Whitley RJ, and Morawetz RB: Herpes simplex virus infections. In: Neurosurgery, RH Wilkins, SS Rengachary (eds), McGraw Hill Book Company (New York), 1984, pp 1987-1993.

22. Whitley RJ: Epidemiology of herpes simplex virus. In: The Herpesviruses, Volume 3, B Roizman (ed), Plenum Publishing Company, New York, 1985, pp 1-44.

23. Whitley RJ: A perspective on the therapy of human herpesvirus infections. In: The Herpesviruses, Volume 4, B Roizman and C Lopez (eds), Plenum Publishing Company, 1985, pp 39-370.

24. Nahmias AJ, Coleman M, Becker T, Schwahn M, Pereira L, and Whitley RJ: The (un)natural history of herpes simplex in neonates. In: The Herpesviruses, Volume 4, B Roizman and C Lopez (eds), Plenum Publishing Company, 1985.

25. Barnes DW, and Whitley RJ: CNS disease associated with varicella-zoster virus and herpes simplex virus infections. In: Neurologic Clinics, B Frank (ed), WB Saunders, Company (Philadelphia), 1986, pp 265-283.

26. Whitley RJ, and Barnes DW: Herpes simplex virus infections. In: Current Therapy in Infectious Diseases, EH Kass and R Platt (eds), BC Decker, Inc. (Philadelphia), 1986, pp 376-381.

27. Whitley RJ and Hutto SC: Therapy of viral infections in pediatrics. In: Advances in Pediatric Infectious Diseases, S Aronoff, W Hughes, S Kohl, W Speck, and E Wald (eds), Year Book Medical Publishers (Illinois), pp 35-56, 1986.

28. Whitley RJ: Therapeutic approaches to herpes simplex encephalitis and neonatal herpes simplex virus infections. In: Antiviral Chemotherapy, John Mills (ed), Elsevier Science Publishing, Co (New York), pp 155-166, 1986.

29. Whitley RJ: Therapeutic advances for severe and life-threatening herpes simplex virus infections. In: Human Herpesvirus Infections, C Lopez and B Roizman (eds), Raven Press (New York), pp 153-164, 1986.

30. Whitley RJ: Rational imperative for the development of antiviral therapy. In: Approaches to Antiviral Agents, MR Harnden (ed), Macmillan Press (London), pp 3-11, 1986.

31. Whitley RJ: Therapeutic approaches to life-threatening herpes simplex and varicella-zoster infections in the immunocompromised hosts. In: Herpesviruses and Virus Chemotherapy, R Kono and A. Nakajima (eds), Excerpta Medica (Amsterdam), pp 157-161, 1986.

32. Nahmias AJ, Keyserling HL, and Whitley R: Changing patterns of neonatal herpes - as affected by antiviral therapy and other factors. In: Herpesviruses and Virus Chemotherapy, R Kono and A. Nakajima, (eds), Excerpta Medica (Amsterdam), pp 145-149, 1986.

33. Whitley RJ: Herpesvirus infections in the immunocompromised host: diagnosis and management. In: Infections in the Immunocompromised Host: Laboratory Diagnosis and Treatment, P Actor, A Evangelista, K Poupard and E Hinks (eds), Plenum Publishing Corporation (New York), pp 95-118, 1986.

34. Whitley RJ: Varicella-zoster virus infections. In: Harrison's Principles of Internal Medicine, E Braunwald, KJ Isselbacher, RG Petersdorf, JD Wilson, JB Martin, AS Fauchi (eds), McGraw Hill Publishing (New York), pp 689-692, 1986.

35. Whitley RJ: Neonatal herpes simplex virus infection. In: The Merck Manual, 15th Edition, Robert Berkow (ed), Merck, Sharp, and Dohme Research Laboratories (New Jersey), pp 1912-1913, 1987

36. Whitley RJ: Therapy of varicella-zoster virus infections. In: The Natural History of Varicella-Zoster Virus, Richard Hyman (ed), CRC Press (Florida), pp 163-179, 1987.

37. Whitley RJ: Approaches to therapy of viral infections. In: Advances in Pediatrics, Volume 34, L Barness (ed), Year Book Medical Publishers (Illinois), pp 89-110, 1987.

38. Baldwin S, Stagno S, and Whitley RJ: Transfusion associated viral infections. In: Current Problems in Pediatrics, JD Lockhart (ed), Year Book Medical Publishers (Chicago), pp 395-443, 1987.

39. Whitley RJ: Herpes simplex virus infections of pregnancy and the newborn. In: 1988 McGraw-Hill Yearbook of Science and Technology, SP Parker (ed), McGraw-Hill Book Company (New York), 1987.

40. Whitley RJ: Vidarabine therapy of herpesvirus infections in childhood. In: Antimicrobial Therapy in Infants and Childhood, G Koren, CG Prober, and R Gold, Marcel Dekker, Inc. (New York), pp 565-577, 1988.

41. Whitley RJ: Diagnosis and treatment of herpes simplex encephalitis. In: Clinical Use of Antiviral Drugs, E DeClercq (ed), Martinus Nijhoff Publishers, (Netherlands), pp 49-66, 1988.

42. Whitley RJ: Herpes simplex virus. In: Hospital Acquired Infection in the Pediatric Patient, L Donowitz (ed), Williams & Wilkins, Publishers (Baltimore), pp 160-173, 1988.

43. Whitley RJ: Neonatal herpes simplex virus infections. In: Clinics In Perinatology, R Behrman and RM Kliegman (ed), WB Saunders Company, (Philadelphia), pp 903-916, 1988.

44. Whitley RJ: Natural history and pathogenesis of neonatal herpes simplex virus infections. In: Annals of the New York Academy of Sciences, Vol. 549, R. Kundsin, L. Folk and S. Hipp, (eds), The New York Academy of Sciences, (New York), pp 103-117, 1988.

45. Keyserling H, Kodsi R, Whitley R, Nahmias AJ: Opinions of infectious disease experts in obstetrics and pediatrics on issues related to perinatal HIV infection. In: AIDS in Children, Adolescents and Heterosexual Adults; An Interdisciplinary Approach to Prevention. RF Schinazi, AJ Nahmias, (eds), Elsevier Science Publishing Company, (New York), pp 254-256, 1988.

46. Whitley RJ: Herpes Simplex Virus Infection of the Newborn. In: Antiviral Chemotherapy, 2nd Edition, J Mills, L Corey (eds), Elsevier Science Publishing, (New York), pp 37-56, 1989.

47. Saag MS, Decker D, Campbell SA, Leuther MD, Brown WE, Crain M, Whitley RJ, Hahn BH, and Shaw GM. Replication of HIV-1 in vivo: Plasma viremia. Retroviruses of Human AIDS and Related Animal Diseases, 4e Girard M, Valette L, eds. Colloque des Cent Gardes. Pasteur Vaccines, Marnes-La-Coquette, Paris France 37-42, 1989.

48. Goldsmith SM, Whitley RJ: Therapy of encephalitis with acyclovir. In: Acyclovir Therapy for Herpesvirus Infection. DA Baker, (ed), Marcel Dekker, Inc., Publisher, (New York), pp 213-231, 1990.

49. Baldwin S, Whitley, RJ: Acyclovir therapy in the newborn. In: Acyclovir Therapy for Herpesvirus Infection. DA Baker, (ed), Marcel Dekker, Inc., Publisher, (New York), pp 151-203, 1990.

50. Stagno S, Whitley RJ: Herpesvirus infection in the neonate and children. In: Sexually Transmitted Diseases, 2nd Edition, W Stamms, Holmes, Mardh, Sparling, Wiesner, Cates, Lemon, (eds), McGraw-Hill, Publishers (New York), pp 863, 1990.

51. Whitley RJ: Varicella-zoster virus. In: Principles and Practices of Infectious Diseases, 3rd Edition, G. Mandell, R. Gordon, and J. Bennett (eds), Churchill Livingston Inc., (New York), pp 1153-1159, 1990.

52. Whitley RJ: Herpes simplex virus. In: Virology, 2nd Edition, BN Fields, DM Knipe, R Chanock, M Hirsch, J Melnick, T Monath, B Roizman, (eds), Raven Press, (New York),

pp 1843-1887, 1990.

53. Whitley RJ: Cercopithecine Herpes Virus 1 (B Virus). In: Virology, 2nd Edition, BN Fields, DM Knipe, R Chanock, M Hirsch, J Melnick, T Monath, B Roizman, (eds), Raven Press, (New York), pp 2063-2075, 1990.

54. Whitley RJ: Varicella-zoster virus infections. In: Antiviral Agents and Viral Diseases of Man, 3rd Edition, Galasso, Merigan, Whitley (eds), Raven Press (New York), pp 235-263, 1990.

55. Whitley RJ, Goldsmith S, Gnann J: Herpesviruses in the immunocompromised host. In: Control of Virus Diseases, NJ Dimmock, PD Griffiths, CR Madeley, (ed), Cambridge University Press, (England), pp 315-339, 1990.

56. Whitley RJ: Herpes simplex virus infections. In: Infectious Diseases of the Fetus and Newborn Infants, Third Edition. J Remington and J Klein (ed), WB Saunders Company, (Philadelphia), pp 282-305, 1990.

57. Whitley RJ, Middlebrooks M, Gnann JW Jr: Acyclovir: The past ten years. In: Immunobiology and Prophylaxis of Human Herpesvirus Infections C Lopez, R Mori, B Roizman, R Whitley, (eds), Plenum Publishing Corporation (New York), pp 243-254, 1990.

58. Whitley RJ, Meignier B: Vaccines against herpes simplex infections. In: New Generation Vaccines. GC Woodrow, MM Levine (eds). Marcel Dekkar Inc, Publishers (New York), pp 825-854, 1990.

59. Whitley RJ, Goldenberg RL: Infectious disease in the prenatal period and recommendations for screening. In: New Perspectives on Prenatal Care. IR Merkatz, JE Thompson (eds). Elsevier Science Publishing Company, Inc. (New York), pp 363-406, 1990.

60. Goldsmith SM, Whitley RJ: Herpes simplex encephalitis. In: Infections of the Central Nervous System. HP Lambert (ed). BC Decker, Publisher (Philadelphia), pp 283-299, 1991.

61. Whitley RJ: Herpes Simplex Virus (Gingivostomatitis). In: Infection Control in the Child Care Center and Preschool. LG Donowitz (ed), Williams and Wilkins (Baltimore), pp 170-172, 1991.

62. Middlebrooks M, Whitley RJ: Herpes viruses. In: Medical Microbiology. S Baron, T Albrech (eds), Churchill Livingston Publishers, (New York), pp 865-879, 1991.

63. Schlitt M, Chronister RB, Whitley RJ. Pathogenesis and pathophysiology of viral infections of the central nervous system. In: Infections of the Central Nervous System. WM Scheld, RJ Whitley, DT Durack (eds), Raven Press, (New York), pp 7-18, 1991.

64. Whitley RJ, Schlitt M: Encephalitis caused by herpesviruses, including B virus. In: Infections of the Central Nervous System. WM Scheld, RJ Whitley, DT Durack (eds), Raven Press, (New York), pp 41-86, 1991.

65. Whitley RJ: Arthropod borne encephalitis. In: Infections of the Central Nervous System. WM Scheld, RJ Whitley, DT Durack (eds), Raven Press, (New York), pp 87-112, 1991.

66. Whitley RJ, Middlebrooks M. Rabies. In: Infections of the Central Nervous System. WM Scheld, RJ Whitley, DT Durack (eds), Raven Press, (New York), pp 127-144, 1991.

67. Whitley RJ, Stagno S: Perinatal viral infections. In: Infections of the Central Nervous System. WM Scheld, RJ Whitley, DT Durack (eds), Raven Press, New York), pp 167-200, 1991.

68. Whitley RJ. Herpes simplex virus infections of the central nervous system: Encephalitis and neonatal herpes. In: Drug. EM Sorkin (ed) ADIS Press Limited, (New Zealand), Vol. 42, pp 406-427, 1991.

69. Whitley RJ. Therapy of herpes simplex virus infections of the central nervous system: Neonatal herpes and herpes simplex encephalitis. In: Seminars in Pediatric Infectious Diseases. RD Feigin (ed), WB Saunders Company (Philadelphia), Vol 2, pp 263-269, 1991.

70. Lau YR, Whitley RJ. Evaluation of ribavirin for treatment of respiratory syncytial virus. In: Seminars in Pediatric Infectious Diseases. RD Feigin (ed), WB Saunders Company), (Philadelphia), Vol 2, pp 279-284, 1991.

71. Whitley RJ. Therapy for herpes simplex virus infections of the central nervous system. In: Treatment of Serious Infections in the 1990's. RK Root, MA Sande (eds). Churchill Livingstone (New York), pp 133-148, 1991.

72. Middlebrooks M, Whitley RJ. Antiviral therapy. In: Cecil Textbook of Medicine, 19th Edition, JB Wyngaarden, LH Smith, JC Bennett, F Plum (eds), WB Saunders Company (Philadelphia), pp 1801-1806, 1991.

73. Middlebrooks M, Whitley RJ. Herpes simplex virus infections. In: Cecil Textbook of Medicine, 19th Edition, JB Wyngaarden, LH Smith, JC Bennett, F Plum (eds), WB Saunders Company (Philadelphia), pp 1831-1835, 1991.

74. Whitley RJ, Meignier B. Herpes simplex vaccines. In: Vaccines: New Approaches to Immunological Problems. RW Ellis (ed), Butterworth Publishers (Massachusetts), pp 223-254, 1991.

75. Goldsmith S, Whitley RJ. Antiviral drugs. In: Infectious Diseases in Medicine and Surgery. SL Gorbach, JG Bartlett, NR Blacklow (eds), WB Saunders Company (Philadelphia), pp 289-306, 1991.

76. Whitley RJ. Varicella-zoster virus infections. In: Harrison's Principles of internal Medicine, 12th Edition, RG Petersforf, E Braunwald, AS Fauci, KJ Isselbacker, JB Martin, RK Root, JD Wilson (eds). McGraw-Hill Book Company (New York), pp 686-689, 1991.

77. Whitley RJ. Neonatal herpes simplex virus infection. In: The Merck Manual, 16th Edition, R Berkow (ed), Merck, Sharp, and Dohme Research Laboratories (New York), pp 2037-2039, 1992.

78. Whitley RJ. Varicella-zoster virus infections. In: Practical Diagnosis of Viral Infections. GJ Galasso, RJ Whitley, TC Merigan (eds), Raven Press, Ltd. (New York), pp 109-119, 1992.

79. Norrby SR, Whitley RJ. General guidelines for the treatment of infections of the central nervous system. Evaluation of new anti-infective drugs for the treatment of acute bacterial meningitis. In: European Guidelines for the Clinical Evaluation of Anti-Infective Drugs Products. TR Beam, Jr, DN Gilbert, CM Kunin with modifications by a European Working Party (eds), pp 32-51, 1993.

80. McCracken GH, Sande MA, Lentnek A,Whitley RJ, Scheld WM. General guidelines for the evaluation of new anti-infective drugs for the treatment of the central nervous system. In: European Guidelines for the Clinical Evaluation of Anti-Infective Drugs Products. TR Beam, Jr, DN Gilbert, CM Kunin with modifications by a European Working Party (eds), pp 202-220, 1993.

81. Whitley RJ, Kreth HW. Principles of antiviral therapy. In: Pediatric Therapy, 3rd Edition, HF Eichenwald, J Stroder (eds), Mosby (St Louis), pp 636-648, 1993.

82. Whitley RJ, Gnann JW Jr. Acyclovir: A model for future antiviral drugs. In: Acyclovir: The Landmark Papers. RJ Whitley, JW Gnann JR (eds), Science Press (London), pp ix-xxi, 1993.

83. Lakeman F, Whitley RJ. Herpes simplex encephalitis: Overview and diagnostic considerations. In: Antiviral Chemotherapy, III. J Mills, L Corey (eds), PTR Prentice-Hall (New Jersey), pp 21-31, 1993.

84. Whitley RJ, Gnann JW, Jr. The epidemiology and clinical manifestations of herpes simplex virus infection. In: The Human Herpesviruses. B Roizman, RJ Whitley, C Lopez (eds). Raven Press (New York), pp 69-105, 1993.

85. Whitley RJ. The biology of B. Virus (Cercopithecine Virus 1). In: The Human Herpesviruses. B Roizman, RJ Whitley, C Lopez (eds). Raven Press (New York), pp 317-328, 1993.

86. Whitley RJ, Gnann JW, Jr. Antiviral Therapy. In: The Human Herpesviruses. B Roizman, RJ Whitley, C Lopez (eds). Raven Press (New York), pp 329-348, 1993.

87. Whitley RJ. Herpes simplex virus (Gingivostomatitis). In: Infection Control in the Child Care Center and Preschool. LG Donowitz (ed), Williams and Wilkins (Baltimore), pp 164-166, 1993.

88. Whitley RJ. Varicella-zoster virus infections. In: Harrison's Principles of Internal Medicine, 13th Edition. KJ Isselbacke, E. Graunwald, JD Wilson, JB Martin, AS Fauci, DL Kasper (eds). McGraw-Hill Book Company (New York), pp 787-790, 1994.

89. Jue S, Whitley RJ. Herpesvirus infections in children with HIV. In: Herpesvirus Infections in Pediatric AIDS Patients, 2nd Edition. PA Pizzo, CM Wilfert (eds), Williams and Wilkins Publishers (Baltimore), pp 345-364, 1994.

90. Whitley RJ. Herpes simplex virus infections. Herpesvirus Infections. R Glaser, JE Jones (eds). Marcel Dekker Inc (New York), pp 1-57, 1994.

91. Whitley RJ, Kreth HW. Principles of pediatric antiviral therapy. In: Pediatric Therapy. 3rd Edition. HF Eichenwald, J Stroder (eds). BC Mosby--Year Book (St. Louis, Missouri), pp 636-648, 1993.

92. Whitley RJ. Vaccines directed against herpes simplex virus. In: Strategies for Pediatric Vaccines: Conventional and Molecular Approaches. Report of the 104th Ross Conference on Pediatric Research Ross Products Division, Abbott Laboratories (Columbus, Ohio), pp 133-141, 1994.

93. Arvin A, Whitley RJ. Herpes simplex virus infection. In: Infectious Diseases of the Fetus and Newborn Infants, Fourth Edition. J Remington and J Klein (ed) WB Saunders Company (Philadelphia), pp 354-376, 1995.

94. Whitley RJ. Varicella-zoster virus infection. In: Principles and Practice of Infectious Diseases. Fourth Edition. GL Mandell, JE Bennett, and R Dolin (eds). Churchill Livingstone (New York), pp 1345-1351, 1995.

95. Whitley RJ. Herpes simplex virus infections of women and their offspring: implications for a developed society. Infectious Diseases in an Age of Change. National Academy Press (Washington, D.C.), pp 171-188, 1995.

96. Whitley RJ. Perinatal herpes simplex virus infections. In: Clinical Management of Herpes Virus. Sacks, SL, Straus SE, Whitley RJ, Griffiths PD (eds). IOS Press (Washington, D.C.), pp 101-116, 1995.

97. Jue SJ and Whitley RJ. Herpes simplex virus infections. In: Gellis & Kagan's Current Pediatric Therapy, FD Burg, JR Ingelfinger, ER Wald (eds). W. B. Saunders Company (Philadelphia), pp 642-645, 1995.

98. Whitley RJ, Morawetz RB. Herpes simplex virus infections. In: Neurosurgery. Second Edition, RH Wilkins and SS Rengachary (eds). McGraw-Hill (New York), 3367-3383, 1995.

99. Whitley RJ. Herpes simplex virus. In: Fields Virology. BN Fields, DM Knipe, PM Howley, RM Chanock, JL Melnick, TP Monath, B Roizman, SE Straus (eds), Lippincott- Raven Publishers (Philadelphia), 2297-2342, 1996

100. Whitley RJ. Cercopithecine Herpes Virus 1 (B Virus). In: Fields Virology. BN Fields, DM Knipe, PM Howley, RM Chanock, JL Melnick, TP Monath, B Roizman, SE Straus (eds), Lippincott- Raven Publishers (Philadelphia), pp 2623-2634, 1996.

101. Whitley RJ: Antiviral Therapy (Non-AIDS). In: Cecil Textbook of Medicine, 20th Edition, JC Bennett, F Plum (eds), WB Saunders Company (Philadelphia), pp 1742-1747, 1996.

102. Whitley RJ: Herpes simplex virus infections. In: Cecil Textbook of Medicine, 20th Edition, JC Bennett, F Plum (eds), WB Saunders Company (Philadelphia), pp 1770-1774, 1996.

103. Whitley RJ. Antiviral therapeutics. In: Current Infectious Disease Drugs. Andriole (ed), Current Medicine (Philadelphia), pp 249-277, 1996.

104. Whitley RJ: Prevention and treatment of varicella-zoster virus infections in immunocompromised patients. In: Le Infezioni da Virus Varicella-Zoster. G Rocchi (ed), Il Pensiero Scientifico Editore (Rome, Italy), pp 103-119, 1996.

105. Whitley RJ: Prevention and treatment of varicella-zoster virus infections in immunocompromised patients. In: Le Infezioni da Virus Varicella-Zoster Aspetti Di Rillievo in età Pediatrica. G Rocchi (ed), Il Pensiero Scientifico Editore (Rome, Italy), pp

149-165, 1996.

106. Kimberlin DW, Whitley RJ. Herpes simplex virus. In: Current Therapy of Infectious Disease. D. Schlossberg (ed), Mosby-Year Book (Philadelphia), pp 494-498, 1996.

107. Whitley RJ. Herpesviruses. In: Medical Microbiology, Fourth Edition. S. Baron (ed), University of Texas Medical Branch at Galveston (Galveston, Texas), pp 823-837, 1996.

108. Kimberlin DW, Kimberlin DF, Whitley RJ. The treatment, management, prevention of neonatal herpes simplex virus infections. In: Genital and Neonatal Herpes. LR Stanberry (ed), John Wiley & Sons, Ltd. (Sussex, England), pp 209-236, 1996.

109. Whitley RJ. Sorivudine: A potent inhibitor of varicella zoster virus replication. In: Antiviral Chemotherapy 4: New Directions for Clinical Application and Research. J Mills, PA Volberding, L Corey. Plenum Press. New York, pp 41-44, 1996.

110. Arvin AM, Whitley R, Straus SE, Pollard RB, Mertz GJ. Summary of panel discussion about antiviral therapy for zoster. In: Antiviral Chemotherapy 4: New Directions for Clinical Application and Research. J Mills, PA Volberding, L Corey. Plenum Press. New York, pp 45-47, 1996.

111. Durack DT, Whitley RJ, Scheld WM. Introduction: Approach to the patient with Central nervous system infection. In: Scheld WM, Whitley RJ, Durack DT. (Eds) Infections of the Central Nervous System, second edition. Lippincott-Raven Publishers (Philadelphia), pp 1-4, 1997.

112. Cassady KA, Whitley RJ. Pathogenesis and pathophysiology of the central nervous system. In: Scheld WM, Whitley RJ, Durack DT (eds). Infections of the Central Nervous System, second edition. Lippincott-Raven Publishers (Philadelphia), pp 7-22, 1997.

113. Whitley RJ. Herpes simplex virus. In: Scheld WM, Whitley RJ, Durack DT. (Eds) Infections of the Central Nervous System, second edition. Lippincott-Raven Publishers. (Philadelphia), pp 73-89, 1997.

114. Gnann JW, Jr. and Whitley RJ. Neurologic manifestations of varicella and herpes zoster. In: Scheld WM, Whitley RJ, Durack DT. (Eds) Infections of the Central Nervous System, second edition. Lippincott-Raven Publishers (Philadelphia), pp 91-105, 1997.

115. Whitley RJ. B Virus. In: Scheld WM, Whitley RJ, Durack DT. (Eds) Infections of the Central Nervous System, second edition. Lippincott-Raven Publishers (Philadelphia), pp 139-145, 1997.

116. Whitley RJ. Arthropod-borne encephalitides. In: Scheld WM, Whitley RJ, Durack DT. (Eds) Infections of the Central Nervous System, second edition. Lippincott-Raven Publishers (Philadelphia), pp 147-168, 1997.

117. Whitley RJ. Rabies. In: Scheld WM, Whitley RJ, Durack DT. (Eds) Infections of the Central Nervous System, second edition. Lippincott-Raven Publishers (Philadelphia), pp 181-198, 1997.

118. Whitley RJ and Stagno S. Perinatal viral infections. In: Scheld WM, Whitley RJ, Durack DT. (Eds) Infections of the Central Nervous System, second edition. Lippincott-Raven Publishers (Philadelphia), pp 223-253, 1997.

119. Richman DD, Whitley RJ, Hayden FG. Introduction. Richman DD, Whitley RJ, Hayden FG (eds). Clinical Virology. Churchill Livingstone (New York), pp 1-4, 1997.

120. Cassady KA, Whitley RJ. Viral CNS infections. Richman DD, Whitley RJ, Hayden FG (eds) Clinical Virology Churchill Livingstone (New York), pp 35-53, 1997.

121. Whitley RJ and Roizman B. Herpes Simplex Virus. Richman DD, Whitley RJ, Hayden FG (eds). Clinical Virology Churchill Livingstone (New York), pp 375-410, 1997.

122. Whitley RJ. B-virus. Richman DD, Whitley RJ, Hayden FG (eds) Clinical Virology Churchill Livingstone (New York), pp 411-419, 1997.

123. Whitley RJ. Herpes simplex virus (gingivostomatitis). In: Donowitz LG (ed). Infection Control in the Child Care Center and Preschool. Third Edition. Williams & Wilkins Publishers (Baltimore), pp 162-164,1997.

124. Whitley RJ. Antiviral drug development for HIV infection: history, status, and future of antiviral drug. In: Aly R, Beutner KR, Maiback H (eds). Cutaneous Infection and Therapy. Marcel Dekker, Inc. (New York), pp 267-276, 1997.

125. Report of the Committee on Infectious Diseases. Hepatitis C, pp 260-264; EBV, pp 199-201; Antiviral therapy, pp 634-636; HIV, pp 279-304; HSV, pp 266-276. In: Red Book, 24th Edition. Committee on Infectious Diseases, American Academy of Pediatrics. Georges Peter, ed. 1997.

126. Whitley RJ: Herpes simplex vaccines. In: New Generation Vaccines, 2nd edition. MM Levine, GC Woodrow, JB Kaper, Cobon GS (eds.). Marcel Dekkar Inc, Publishers (New York) pp 727-747,1997.

127. Whitley RJ, Griffiths PD. Cytomegalovirus infections in the immunocompromised host. In: Antiviral Agents and Human Viral Diseases, 4th Edition, GJ Galasso, RJ

Whitley, TC Merigan, (eds). Lippincott-Raven Publishers (Philadelphia), pp 257-278, 1997.

128. Whitley RJ: Varicella-zoster virus infections. In: Antiviral Agents and HumanViral Diseases, 4th Edition, GJ Galasso, RJ Whitley, TC Merigan, (eds). Lippincott-Raven Publishers (Philadelphia), pp 279-304, 1997.

129. Whitley RJ and Arvin A. Herpes simplex infections of the central nervous system. In: In Defense of the Brain. Peterson PK and Remington JS (eds). Blackwell Science (Cambridge), pp 258-272, 1997.

130. Whitley RJ. Varicella-zoster virus infections. In: Harrison's Principles of internal Medicine, 14th Edition, AS Fauci, E Braunwald, KJ Isselbacker, JD Wilson, JB Martin, DL Kasper, SL Hauser, DL Longo, (eds). McGraw-Hill Book Company (New York), pp 1086-1089, 1997.

131. Kimberlin DW and Whitley RJ. Herpes Simplex Virus. In: Current Therapy in Adult Medicine, Fourth Edition. JP Kassirer and HL Greene II . Mosby (St. Louis), pp 327-330, 1997.

132. Whitley RJ. Antiviral therapy. In Infectious Diseases. 2nd Ed. Gorbach SL, Bartlett JG, Blacklow NR (eds) WB Saunders Co. (Philadelphia), pp 330-350, 1998.

133. Field HJ, Whitley RJ. Antiviral Chemotherapy. Topley and Wilson's Microbiology and Microbial Infections. Ninth Edition. L Collier, A Balows, M Sussman. Edward Arnold (London), pp 989-1010, 1998.

134. Whitley RJ. Herpes simplex virus. Public Health & Preventive Medicine. Wallace RB (ed). Appleton K& Lange (Stamford), pp 191-195, 1998.

135. Jue SJ and Whitley RJ. Herpes simplex virus infections. Gellis & Kagan's Current Pediatric Therapy. Burg, FD, Wald ER, Ingelfinger JR, Polin RA. (eds). W. B. Saunders Company (Philadelphia), pp 117-121, 1999.

136. Stagno S and Whitley RJ. Herpesvirus infections in neonates and children: cytomegalovirus and herpes simplex virus. Sexually Transmitted Diseases Third Edition. Holmes KK, Mardh P-A, Sparling PF, Lemon SM, Stamm WE, Piot P, Wasserheit JN (eds). McGraw-Hill (New York), pp 1191-1212, 1999.

137. Frizzell RT and Whitley RJ. Encephalitis. Clinical Infectious Diseases: A Practical Approach. Root RK, Waldvogel F, Corey L, Stamm WE (eds). Oxford University Press (New York), pp 703-714, 1999.

138. Whitley RJ and Gnann JW. Therapeutic approaches to the management of herpes zoster. Antiviral Chemotherapy 5. Mills J, Volberding PA, Corey L (eds). Kluwer Academic/Plenum Publishers (New York), pp 159-165, 1999.

139. Cassady KA and Whitley RJ. Acute and Chronic Encephalitis. In: Infectious Diseases. Armstrong D and Cohen J (eds). Mosby (London), Section 2, 16.1-16.8., 1999.

140. Whitley RJ. Approaches to the treatment of varicella-zoster virus infections. In: Varicella-Zoster Virus. Molecular Biology, Pathogenesis, and Clinical Aspects. Wolff MH, Schünemann S, Schmidt A. (eds). Karger (Basel), pp 158-172, 1999.

141. Whitley RJ. Herpes simplex virus (gingivostomatitis). In: Donowitz LG (ed). Infection Control in the Child Care Center and Preschool. Fourth Edition. Williams & Wilkins Publishers (Baltimore), pp 170-172, 1999.

142. Whitley RJ. Varicella-zoster Virus. In: Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. Fifth Edition. Churchill Livingstone (Philadelphia), pp 1580-1586, 2000.

143. Whitley RJ. Introduction. In: Whitley RJ (ed). Optimizing the Management of Genital Herpes. Royal Society (London) pp 1-3, 2000.

144. Report of the Committee on Infectious Diseases. Herpes simplex. In: Pickering LK, ed. Red Book 2000, 25th Edition. American Academy of Pediatrics (Elk Grove), pp 309-318, 2000.

145. Whitley RJ: Herpes simplex virus infections. In: Cecil Textbook of Medicine, 21th Edition, Goldman L, JC Bennett (eds), WB Saunders Company (Philadelphia), pp 1817-1814, 2000.

146. Whitley RJ: Antiviral Therapy (Non-AIDS). In: Cecil Textbook of Medicine, 21th Edition, Goldman L, JC Bennett (eds), WB Saunders Company (Philadelphia), pp 1784-1790, 2000.

147. Whitley RJ. Treatment of varicella. Varicella Zoster Virus: Virology and Clinical Management. In: Arvin AM and Gershon AA (eds.) Cambridge University Press (Cambridge, UK), pp 385-395, 2000.

148. Whitley RJ: The Treatment, Management, and prevention of neonatal herpes simplex virus infections (Trattamento, gestione e prevenzione dell'infezione neonatale da virus herpes simplex). Il Virus, L'Infezioni E Il Controllo. In: A Volipi (ed), Il Pensiero Scientifico Editore (Rome, Italy), pp 79-102.2000

149. Whitley RJ. Antiviral Agents. In: M Alexander, Bloom BR, Hopwood D, Hull R, Iglewski BH, Laskin AI, Oliver SG, Schaechter M, Summers WC (eds). Encyclopedia of Microbiology, Second Edition. Academic Press (San Diego), pp 286-310, 2000.

150. Kimberlin DW, Whitley RJ. Herpes simplex virus. In: D. Schlossberg (ed), Current Therapy of Infectious Disease, Second Edition. Mosby (Philadelphia), pp 586-590, 2001.

151. Whitley RJ. Varicella-zoster virus infections. In: Harrison's Principles of Internal Medicine, 15th Edition, E Braunwald, AS Fauci, DL Kasper, SL Hauser, DL Longo, JL Jameson, (eds). McGraw-Hill Book Company (New York), pp 1106-1108, 2001.

152. Kimberlin DW, Whitley RJ. Herpes simplex infections. In: Elzouki AY, Harfi HA, Nazer H. Textbook of Clinical Pediatrics. Lippincott Williams and Wilkins (Philadelphia), pp. 362-371, 2001.

153. Whitley RJ. Herpes zoster: natural history, diagnosis and therapy. In: C. P. N. Watson and A. A. Arvin (eds). Herpes Zoster and Postherpetic Neuralgia, 2nd Edition.Elsevier Science (The Netherlands), pp 65-78, 2001.

154. Whitley RJ. Herpes simplex virus (gingivostomatitis). In: Donowitz LG (ed). Infection Control in the Child Care Center and Preschool. Fifth Edition. Lippincott Williams & Wilkins Publishers (Baltimore), pp 171-173, 2001.

155. Whitley RJ. Herpes simplex virus. In: Knipe DM, Howley PM, Griffin D, Lamb R, Martin M, Straus SE (eds), Fields Virology, Fourth Edition. Lippincott- Williams & Wilkins (Philadelphia), pp 2461-2509, 2001.

156. Whitley RJ, Hilliard JK. Cercopithecine Herpes Virus 1 (B Virus). In: Knipe DM, Howley PM, Griffin D, Lamb R, Martin M, Straus SE (eds), Fields Virology, Fourth Edition. Lippincott Williams & Wilkins (Philadelphia), pp 2835-2848, 2001.

157. Arvin AM and Whitley RJ. Herpes simplex virus infection. In: Remington JS, Klein JO (eds). Infectious Diseases of the Fetus & Newborn Infant, Fifth Edition. WB Saunders Co. (Philadelphia), pp 425-446, 2001.

158. Whitley RJ. Antiviral therapy in the management of post-eradication infectious disease outbreaks. In: Knobler S, Lederberg J, Pray LA (Eds.); Forum on Emerging Infections. Considerations for Viral Disease Eradication: Lessons Learned and Future Strategies: Workshop Summary. National Academy Press (Washington, D.C.), pp121-140, 2002.

159. Whitley RJ, Roizman B. Herpes simplex viruses. In: . Creighton TE (ed). Encyclopedia of Molecular Medicine. John Wiley & Sons, Inc. (New York), pp 1617-1622, 2002.

160. Whitley RJ and Griffiths PD. Herpesviruses: An Introduction with a focus of herpes simplex virus. In: Boucher C, Cooper D, Katzenstein D, Galasso G. Practical Guidelines in Antiviral Therapy. Elsevier (Amsterdam), pp 127-149, 2002.

161. Griffiths PD and Whitley RJ. Cytomegalovirus. In: Boucher C, Cooper D, Katzenstein D, Galasso G.(eds) Practical Guidelines in Antiviral Therapy. Elsevier {Amsterdam), pp 151-171, 2002.

162. Richman DD, Whitley RJ, Hayden FG. Introduction. In: Richman DD, Whitley RJ, Hayden FG.(Eds) Clinical Virology, Second Edition. ASM Press (Washington, D. C.), pp 1-4, 2002.

163. Cassady KA, Whitley RJ. Viral central nervous system infections. In: Richman DD, Whitley RJ, Hayden FG.(Eds) Clinical Virology, Second Edition. ASM Press (Washington, D. C.), pp 27-44, 2002.

164. Whitley RJ, Roizman B. Herpes simplex virus. In: Richman DD, Whitley RJ, Hayden FG.(Eds) Clinical Virology, Second Edition. ASM Press (Washington, D. C.), pp 375-401, 2002.

165. Whitley RJ, Hilliard J. Cercopithecine herpesvirus (B Virus). In: Richman DD, Whitley RJ, Hayden FG.(Eds) Clinical Virology, Second Edition. ASM Press (Washington, D. C.), 403-411, 2002.

166. Whitley RJ, Kimberlin D. Antiviral Agents. In: Burg FD, Ingelfinger JR, Polin RA, Gershon A. Gellis and Kagan's Current Pediatric Therapy 17. W. B. Saunders Co., (Philadelphia), pp 244-256, 2002.

167. Whitley RJ, Gnann JW. Herpes simplex virus. Tyring (ed). Mucocutaneous Manifestations of Viral Diseases. Marcel Dekker, Inc. (New York), pp 69-117, 2002.

168. Haukenes, Whitley RJ. Laboratory Diagnosis of virus infections. In: Haaheim LR, Pattison JR, Whitley R (eds). A Practical Guide to Clinical Virology, 2nd Edition.John Wiley & Sons, Ltd. West Sussex, England, pp 15-18, 2002.

169. Oxford JS, Whitley RJ. Antiviral Drugs. In: Haaheim LR, Pattison JR, Whitley R (eds). A Practical Guide to Clinical Virology, 2nd Edition.John Wiley & Sons, Ltd. West Sussex, England, pp 21-35, 2002.

170. Whitley RJ, Shaw, Human T-lymphotropic virus type I and II. In: Haaheim LR, Pattison JR, Whitley R (eds). A Practical Guide to Clinical Virology, 2nd Edition.John Wiley & Sons, Ltd. West Sussex, England, pp 221-224, 2002.

171. Whitley RJ, Stagno S. Herpesvirus infections in the neonate and children. In: Rudolph CD, Rudolph AM, Hostetter MK, Lister G, Siegel NJ (eds). Rudolph's Pediatrics, 21st Edition. McGraw-Hill, New York, pp 169-174, 2002.

172. Whitley RJ, Morawetz RB. Herpes simplex encephalitis. In: Batjer HH, Loftus CM. Textbook of Neurological Surgery. Lippincott Williams & Wilkins, Philadelphia, 3196-3204, 2002.

173. Whitley RJ. Herpes simplex virus (gingivostomatitis). In: Grossman LB (ed). Infection Control in the Child Care Center and Preschool. Sixth Edition. Lippincott Williams & Wilkins Publishers (Baltimore), pp 179-181, 2002.

174. Cassady K, Gnann JW, Whitley RJ. Viral infections of the central nervous system.. In: Baddour LM and Gorbach SL. Therapy of Infectious Diseases. Saunders (New York), pp 237-260, 2003.

175. Greenwood D, Whitley R. Modes of action. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ. Antibiotic & Chemotherapy, 8th Edition. Churchill Livingstone (Edinburgh), pp 11-24, 2003.

176. Whitley R. Antiviral agents. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ. Antibiotic & Chemotherapy, 8th Edition. Churchill Livingstone (Edinburgh), pp 494-509, 2003.

177. Whitley RJ. Management strategies for herpes simplex viruses in cancer patients and bone marrow transplant recipients. In: Wingard JR and Bowden RA (eds). *Management of Infections in Oncology Patients*. Martin Dunitz Taylor & Francis Group (London), pp 223-232, 2003.

178.

Book Chapters--In Press

1. Whitley RJ, Hitchcok P, Biglan A, Farmer M. Biomedical interventions. In: STDs in Adolescents: Challenges for the 21st Century. Hitchock P, Boruch R, Flay B, Berkley S, Kanouse D, Whitley R, Darroch J (eds). Oxford University Press, Inc. (New York).

2. Whitley RJ. Herpesviruses. In: Medical Microbiology, Fifth Edition. S. Baron (ed), University of Texas Medical Branch at Galveston (Galveston, Texas).

3. Whitley RJ: Herpes simplex virus infections. In: Cecil Textbook of Medicine, 22nd Edition, Goldman L, JC Bennett (eds), WB Saunders Company (Philadelphia).

4. Whitley RJ: Antiviral Therapy (Non-AIDS). In: Cecil Textbook of Medicine, 22nd Edition, Goldman L, JC Bennett (eds), WB Saunders Company (Philadelphia).

5. Whitley RJ: Introduction to viral disease. In: Cecil Textbook of Medicine, 22nd Edition, Goldman L, JC Bennett (eds), WB Saunders Company (Philadelphia).

6. Whitley RJ. Introduction. Infectious Diseases, 3rd Edition. In: Gorbach SL, Blacklow NR, Bartlett JG. Lippincott Williams & Wilkins (Philadelphia).

7. Whitley RJ. Antiviral Therapy. Infectious Diseases, 3rd Edition. In: Gorbach SL, Blacklow NR, Bartlett JG. Lippincott Williams & Wilkins (Philadelphia).

8. Whitley RJ, RB. Herpes simplex virus infections. Neurosurgery, Third Edition. In: Rengachary SS, Maciunas RJ, Wilkins RH (eds). McGraw-Hill.

9. Whitley RJ. Viral Infections of the CNS. Krugman's Infectious Diseases of Children, 11/e. Harcourt Health Sciences, W. B. Saunders, Inc. (Philadelphia).

10. Whitley RJ: Herpes simplex vaccines. In: New Generation Vaccines, 2nd edition. MM Levine, GC Woodrow, JB Kaper, Cobon GS (eds.). Marcel Dekkar Inc, Publishers (New York).

11. Whitley RJ. Viral Infections of the CNS. Infectious Diseases, second edition. Cohen J and Powderly WG (eds). Elsevier.

12. Whitley RJ. Varicella-zoster virus infections. In: Harrison's Principles of Internal Medicine, 16th Edition, DL Kasper, E Braunwald, AS Fauci, SL Hauser, DL Longo, JL Jameson, (eds). McGraw-Hill Book Company (New York).

13. Whitley RJ. Human herpes virus. In: Encyclopedia of the Neurological Sciences. Academic Press (New York)

14. Cassady KA, Whitley RJ. Pathogenesis and pathophysiology of the central nervous system. In: Scheld WM, Mara, C, Whitley RJ (eds). Infections of the Central Nervous System, second edition. Lippincott Williams & Wilkins (Philadelphia).

15. Whitley RJ. Herpes simplex virus. In: Scheld WM, Mara, C, Whitley RJ (Eds) Infections of the Central Nervous System, second edition. Lippincott Williams & Wilkins. (Philadelphia).

16. Gnann JW, Jr. and Whitley RJ. Neurologic manifestations of varicella and herpes zoster. In: Scheld WM, Mara C, Whitley RJ (Eds) Infections of the Central Nervous System, second edition. Lippincott Williams & Wilkins (Philadelphia).

17. Whitley RJ. B Virus. In: Scheld WM, Mara C, Whitley RJ (Eds) Infections of the Central Nervous System, second edition. Lippincott Williams & Wilkins (Philadelphia), pp 139-145, 1997.

Editorials and Short Communications

1. Whitley RJ: Problems and approaches to antiviral therapy of herpes simplex infections. Guidelines to Antibiotic Therapy, 3, Spring/Summer, 1977.

2. Letter to Editor: N Engl J Med, 297:1288, 1977

3. Whitley RJ and Alford CA Jr: Encephalitis and adenine arabinoside: an indictment without fact. Hastings Center Report, August, 1979.

4. Letter to Editor: JAMA, 244:1035, 1979.

5. Letter to Editor: N Engl J Med, 304:1237, 1981.

6. Letter to Editor: The Lancet, 1:1013, 1982.

7. Alexander WJ, Gnann JW Jr and Whitley RJ: Progress report: genital herpes infection in Alabama. Al J Med Sci, 19:240, 1982.

8. Whitley RJ and Alford CA Jr: Diagnosis of herpes simplex encephalitis. JAMA, 248:547, 1982.

9. Furlow TW, Whitley RJ and Wilmes FJ: Repeated suppression of Creutzfeldt-Jakob disease with vidarabine: report of a case. Lancet, 2:564-565, 1982.

10. Furlow TW, Whitley RJ and Wilmes FJ: Remissions repetees au cours dun cas de maladie de Creutfeldt Jakob traitee par la vidarabine. Le Journal International De Medecine, 7:60-61, 1983.

11. Whitley RJ, Soong SJ, Dolin R, Betts R, Linnemann C and Alford CA Jr: Letter to the Editor. N Engl J Med, 308:526-527, 1983.

12. Volpi A, Whitley RJ, Ceballos R and Stagno S: Rapid diagnosis of pneumonia due to cytomegalovirus with specific monoclonal antibodies. J Infect Dis, 147:1119-1120, 1983.

13. Whitley RJ, Barton NH, Gnann JW Jr: Therapy of human herpesvirus infections. Clinical Microbiology Newsletter. Elsevier Publishing Company Inc. 6:15, 1984.

14. Whitley RJ, Soong SJ, Alford CA, Hirsch MS, Schooley R, Oxman MN, Connor JD, Betts R, Dolin R and Reichman RC: Design of therapeutic studies in herpes simplex encephalitis. Lancet, 8405:285, 1985.

15. Whitley RJ: Treatment of herpesvirus infections. N Engl J Med, 310:654, 1984.

16. Overall JC, Whitley RJ, Yeager AS, McCracken GH Jr and Nelson JD: Prophylactic or anticipatory antiviral therapy for newborns exposed to herpes simplex infections. Ped Infect Dis, 3:193-195, 1984.

17. Whitley RJ: Letter to the Editor. J Infect Dis, 151:971, 1985.

18. Whitley RJ: Parvovirus infection. N Engl J Med, 313:111-112, 1985.

19. Cauda R, Laghi V, Ortona L and Whitley RJ: Delta Hepatitis - an overview. International Contributions. Al J Med Sci, 23:433-436, 1986.

20. Whitley RJ, Morgan P, Lakeman FD: Herpes Simplex Virus Infections: An Overview. Syva Monitor, 4:1-4, 1986.

21. Whitley RJ: Letter to the Editor. Am J Med, 83:194-195, 1987.

22. Whitley RJ: Ganciclovir--have we established clinical value in the treatment of CMV infections? Ann Int Med, 108:452-454, 1987.

23. Arvin A, Johnson RT, Whitley RJ, Nelson JD and McCracken GJ: Consensus: management of the patient with herpes simplex encephalitis. Ped Infect Dis, 6:2-5, 1987.

24. Benton JW and Whitley RJ: Letter to the Editor. Ped Infect Dis, 7:699-700, 1987.

25. Whitley RJ: The frustrations of therapy of herpes simplex virus infections of the central nervous system. JAMA, 259:1067, 1988.

26. Bell DSH, Clements RS, Cutter GR, and Whitley RJ: Condylomata acuminata in IDDM. Diabetes Care, 11:295-296, 1988.

27. Whitley RJ: Varicella-zoster virus infections: chronic disease in the immunocompromised host: evidence for persistent excretion of virus. Ped Infect Dis, 8:584-585, 1989.

28. Whitley RJ: Varicella-zoster virus infections. In: Antiviral Agents and Viral Diseases of Man, 3rd Edition, Galasso, Merigan, Whitley (eds), Raven Press (New York), pp 235-263, 1990. Synopsis appeared in Current Contents, Life Sciences, Raven Press, Vol. 33, No. 22, May 14, 1990.

29. Whitley RJ: Chickenpox: Where do we stand with treatment? J of Peds, 116(4):587, 1990.

30. Whitley RJ. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. Pediatric Digest 7:29-30, 1991.

31. Antiviral Agents and Viral Diseases of Man, 3rd Edition, Galasso GJ, Whitley RJ, Merigan TC (eds), Raven Press (New York), 1991. Review appeared in ADVANCE for Medical Laboratory Professionals, November, 1991.

32. Whitley, RJ. Review of AIDS and Other Sexually Transmitted Diseases in Adolescent Medicine. Rev Infect Dis. 13:530-531, 1991.

33. Whitley RJ. A US overview of zoster and acyclovir. The Management of Varicella Zoster. Highlights of a symposium of Royal Society of Medicine, London. Jeffries D, editor, April 8, 1991.

34. Whitley RJ. Management of recurrence of herpes simplex virus infection in young infants. Ped Infect Dis J, Vol. 11, No. 3, 249, 1992.

35. Whitley RJ. Rigor in clinical trials. Infectious Agents and Diseases,1:119-120, 1992.

36. Whitley RJ. Antiviral Therapy: The Time Has Come. J Med Vir. 1(Supp. 1)1, 1993.

37. Whitley RJ. Panel Discussion - The Operation of Data Monitoring Committees. Statistics in Medicine. Control of Clinical Trials, 1994.

38. Whitley RJ. Antiviral resistance: do we know what it means? Current Opinion in Infectious Diseases. 7:671-673, 1994.

39. Whitley RJ. Herpes--The challenge continues. IHMF Focus. Guidelines and Recommendations from the Inaugural Meeting of the IHMF (November, 1993, Monte Carlo) pp 5-6, 1994.

40. Whitley RJ. Milestones in antiherpes therapy. IHMF Focus. Guidelines and Recommendations from the Inaugural Meeting of the IHMF (November, 1993, Monte Carlo) pp 9-10, 1994.

41. Whitley, RJ. Emerging therapies for varicella-zoster virus infections. VZV Focus. 2:4, Winter 1994/Spring 1995.

42. Whitley RJ, Gnann JW. Editorial Response: Herpes zoster in patients with human immunodeficiency virus infection--An ever expanding spectrum of disease. Clin Infect Dis. 14:989-990, 1995.

43. Whitley RJ. Editorial Review. Evolution of therapy for herpes zoster: What's next? Curr Opin Infect Dis. 8:453-454, 1995.

44. Whitley RJ. Editorial Comment. Advances in the treatment of cytomegalovirus retinitis in patients with AIDS. Curr Opin Infect Dis. 9:411-412, 1996.

45. Whitley RJ. Shingles. Bottom Line/Health. 1997.

46. Hellinger E and Whitley RJ. An improved treatment strategy for herpes zoster. Emergency Medicine. April, 1997, 125-126.

47. Rotbart HA, Ahmed A, Hickey S, Dagan R, McCracken GH, Whitley RJ, Modlin JF, Cascino M, O'Connell JF, Menegus MA, Blum D. Brief Reports. Diagnosis of enterovirus infection by polymerase chain reaction of multiple specimen types. The Ped Infect Dis J. 16:409-411, 1997.

48. Whitley RJ. A foot in the door. Herpes. 4:54, 1997.

49. Whitley RJ. Letter to Editor: Lancet. 352:651. 1998

50. Whitley RJ and Holland GN. Cytomegalovirus retinitis--evolving therapies in a new era. N Engl J. Med. 340:1109-1110, 1999.

51. Whitley RJ. Our evolving knowledge of herpesviruses. Herpes. 7:59, 2000.

52. AAP Committee on Infectious Diseases, 2000-2001, Abramson JS, Baker CJ, Fisher MC, Gerber MA, Meissner HC, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ. Pediatrics. 108:1392, 2001.

53. Whitley RJ. Editorial. Valtrex Achievements in Perspective, Malta, November 2000. J Infect Dis Supplement, 2002 in press

54. Whitley RJ. Review & Outlook. The Sars Crisis. The Wall Street Journal. June 19, 2003.

Abstracts

1. Whitley RJ, Parlett RC and Alford CA: Estrogenic effects on rubella infected and uninfected cells. Bacteriologic Proceedings ASM, Minneapolis, MN 1971.

2. Whitley RJ, Parlett RC and Alford CA: Estrogenic effects on rubella infected and uninfected cells. Bacteriologic Proceedings ASM, Birmingham, AL 1971.

3. Whitley RJ and Alford CA Jr: Mechanisms of antiviral chemotherapy. American Academy of Dermatology, Chicago, IL 1973.

4. Chien LT, Whitley RJ, Nahmias AJ, Buchanan RA and Alford CA Jr: Adenine arabinoside (ara-A) and neonatal herpes simplex virus infection. Southern Society for Pediatric Research, 1974.

5. Chien LT, Whitley RJ, Nahmias AJ, Buchanan RA and Alford CA Jr: Herpes simplex virus (HSV) infection in neonates, treated with adenine arabinoside (ara-A). Society for Pediatric Research, 1974.

6. Whitley RJ, Alford CA Jr, Chien LT and Galasso G: Factors influencing the response of immunosuppressed persons with herpes-zoster (V-Z) to adenine arabinoside (ara-A) therapy. Symposium on Antivirals with Clinical Potential, Stanford University, Stanford, CA 1975.

7. Chien LT, Whitley RJ, Alford CA Jr, Galasso G and Dolin R: Controlled studies of adenine arabinoside in the immunosuppressed with zoster. Symposium on Antivirals with Clinical Potential, Stanford University, Stanford, CA 1975.

8. Chien LT, Whitley RJ, Alford CA Jr and Galasso G: Adenine arabinoside (ara-A) and herpes zoster (VZ) in the immunosuppressed - a crossover control study. Third International Congress for Virology, Madrid, Spain 1975.

9. Whitley RJ, Alford CA Jr, Chien LT, Galasso G and Dolin R: Factors influencing the response of immunosuppressed persons with herpes-zoster (VZ) to adenine arabinoside (ara-A) therapy. 15th ICAAC, Chemotherapy, Washington DC 1975.

10. Chien LT, Whitley RJ, Alford CA Jr, Galasso G and Dolin R: Adenine arabinoside (ara-A) and herpes-zoster (VZ) in the immunosuppressed - a crossover control study. 15th ICAAC, Chemotherapy, Washington DC 1975.

11. Long WK, Whitley RJ, Lakeman AD, Field SS, Reynolds DW, Diethelm AG and Alford CA: Excretion of cytomegalovirus and herpes simplex in renal transplant recipients. 16th

ICAAC, Chicago, IL 1976.

12. Whitley RJ and Alford CA: Recent clinical advances with adenine arabinoside. Pan American Medical Association, 50th Anniversary Congress, Hollywood, FL 1976.

13. Whitley RJ, Dolin R, Galasso GJ, Chien LT, Alford CA Jr and the Collaborative Antiviral Study Group: Adenine arabinoside therapy of herpes simplex encephalitis: NIAID Collaborative Antiviral Study Group. Society for Pediatric Research, San Francisco, CA 1977.

14. Whitley RJ, Dolin R, Galasso GJ, Alford CA and the NIAID Collaborative Antiviral Study Group: Adenine arabinoside therapy of varicella-zoster in immunocompromised patients. Society for Pediatric Research, San Francisco, CA 1977.

15. Whitley RJ, Dolin R, Galasso G, Chien L, Alford CA Jr and the Collaborative Antiviral Study Group: Adenine arabinoside therapy of herpes simplex encephalitis: NIAID Collaborative Antiviral Study Group. American Society for Microbiology, New Orleans, LA 1977.

16. Mazur MH, Whitley RJ, Alford CA Jr and Dolin R: Antibody to varicella-zoster (VZ) virus detected by immune adherence and indirect immunofluorescence in patients with VZ infections. 17th ICAAC, New York City, NY 1977.

17. Chen AB, Ben-Porat T, Whitley RJ and Kaplan AS: Detection of herpes viral antigens in cerebrospinal fluids of patients with herpetic encephalitis. American Society for Microbiology, Las Vegas, NV 1978.

18. Whitley RJ, Dolin R, Galasso G, Alford CA Jr: Adenine arabinoside therapy of herpes simplex encephalitis: NIAID Collaborative Antiviral Study Group. International Congress of Virology, The Hague, Netherlands 1978.

19. Whitley R, Mazur M, Dolin R, Soong SJ and Alford CA: Antibody response in immunocompromised patients with varicella-zoster virus (VZV) infections18th ICAAC, Atlanta, GA 1978.

20. Tucker B, Kinkel A, Petrick T, Cobbs CG, Whelchel J and Whitley RJ: The pharmacokinetics of adenine arabinoside 5' monophosphate (ara-AMP). 18th ICAAC, Atlanta, GA 1978.

21. Whelchel JD, Pass RF, Diethelm AG, Whitley RJ and Alford CA Jr: Effect of primary and recurrent cytomegalovirus infections upon graft and patient survival after renal transplantation. Fifth Annual Scientific Meeting of the American Society of Transplant Surgeons, Chicago, IL 1979.

22. de Miranda P, Whitley RJ, Blum MR and Keeney RE: Pharmacokinetics of the antiviral drug acyclovir (zovirax) in man. 19th ICAAC Boston, MA 1979.

23. Whitley RJ, Nahmias AJ, Soong SJ, Galasso GJ, Alford CA Jr and the NIAID Collaborative Antiviral Study Group: Adenine arabinoside therapy of neonatal herpes simplex virus infection. Society for Pediatric Research, San Antonio, TX 1980.

24. Nahmias AJ, Visintine AM, Whitley RJ and Alford CA: The natural history of neonatal herpes simplex virus (HSV) infection. Society for Pediatric Research, San Antonio, TX 1980.

30. 25. Whitley RJ, Blum R, de Miranda P, Keeney RE, Barton N, Cobbs CG, Kirk LE, Many W, Page D and Elion G: Pharmacology and clinical experience with acyclovir (ACV) in humans. 20th ICAAC, New Orleans, LA 1980.

26. Whitley R, Soong SJ, Hirsch M, Karchmer AW, Dolin R, Galasso G, Alford CA and the NIAID Antiviral Study Group: Herpes simplex encephalitis (HSE): Vidarabine (Vira-A) therapy. 20th ICAAC, New Orleans, LA 1980.

27. Many W, Schmidt R, Whelchel J, Diethelm A, Cobbs CG and Whitley R: Herpes simplex esophagitis in renal transplant patient. 20th ICAAC, New Orleans, LA 1980.

28. Alford CA and Whitley RJ: Chemotherapy of herpetic infections - the struggle for the beginning. The International Workshop on Herpesviruses, Bologna, Italy 1981.

29. Whitley R, Soong SJ, Galasso G, Alford C and the NIAID Collaborative Antiviral Study Group: Vidarabine therapy of herpes zoster infection in immunocompromised patients. Fifth International Congress of Virology, Strasbourg, France 1981.

30. Whitley R, Soong SJ, Dolin R, Betts R, Linnemann C, Galasso G, Alford CA and the NIAID Collaborative Antiviral Study Group: Vidarabine (vira-A) therapy of herpes zoster infections in immunocompromised patients. 21st ICAAC, 1981.

31. Whitley R, Hilty M, Haynes R, Alford C, Soong SJ and the NIAID Collaborative Antiviral Study Group: Vidarabine (vira-A) therapy in chickenpox in immunosuppressed children. 21st ICAAC, 1981.

32. Straus SE, Smith HA, Owens J, Pizzo P, Hay J and Whitley R: Molecular epidemiologic studies of varicella-zoster virus (VZV) infections. 21st ICAAC, 1981.

33. Brasfield, DM, Stagno S, Whitley RJ and Tiller RE: Infant Pneumonitis associated with CMV, chlamydia, pneumocystis and ureplasma: 12 month follow-up. Society for Pediatric Research, Washington, DC 1982.

34. de Miranda P, Whitley RJ, Barton N, Page D, Creagh-Kirk T, Liao S, Blum R: Systemic absorption and pharmacokinetics of acyclovir (acv) (zovirax) capsules in immunocompromised patients with herpesvirus infections. 22nd ICAAC, Miami Beach, FL 1982.

35. Coleman M, Pereira L, Nahmias A, Bailey P, Dondero D and Whitley RJ: Immune responses of neonates and children to purified herpes simplex virus (HSV) glycoproteins. International Symposium on Recent Developments in Perinatal and Childhood Infections. Jerusalem, Israel 1982.

36. McCann WP, Hall LM, Siler W, Whitley RJ, Furner RL, Hafer LM and Barton N: Plasma arabinosyladenine (ara-A) levels in man. 67th Annual Meeting Federation of American Societies for Experimental Biology and Guest Societies, Chicago, IL 1983.

37. Whitley RJ, Barton NH, Levin M, Welchel J, Diethelm AG, Collins E, Kartus P, Davis G, Keeney R and Soong S: Topical acyclovir, ACV, Therapy of mucocutaneous herpes simplex virus, HSV, infections in the immunocompromised host. 23rd ICAAC, Las Vegas, NV 1983.

38. Chatterjee S, Lakeman AD, Whitley RJ and Hunter E: Effect of cloned human leukocyte and fibroblast interferons on the replication and cell fusion induced by herpes simplex virus. 23rd ICAAC, Las Vegas, NV 1983.

39. Whitley RJ, Barton NH, Welchel J, Diethelm AG, Curtis J, Luke R and Kulkarni AS: Plasma pharmacokinetics of bromovinyl deoxyuridine (BVDU) after oral administration to humans. 23rd ICAAC, Las Vegas, NV 1983.

40. Lakeman AD, Nahmias AJ and Whitley RJ: Restriction enzyme analysis of DNA from recurrent genital HSV-2 isolates. 23rd ICAAC, Las Vegas, NV 1983.

41. Chatterjee S, Hunter E and Whitley RJ: Effect of human interferons on the morphogenesis and infectivity of herpes simplex virus. Sixth International Congress of Virology, Sendai, Japan 1984.

42. Chatterjee S, Hunter E, and Whitley RJ: Effect of cloned human interferons on the infectivity of herpes simplex virus. 1984 Symposium on Medical Virology, Orange, California 1984.

43. Peacock J, Kaplowitz L, Sparling F, Durack D, Gnann J, Whitley RJ, Lovett M, Bryson Y, Klein R and Friedman-Kien A: Intravenous acyclovir in the therapy of first episode genital herpes: a multi-center trial. 24th ICAAC, Washington, DC 1984.

44. Gnann JW, Whitley RF, Reichman R, Wolinsky S, Nahmias AJ, Keyserling H: Controlled trial of parenteral interferon alpha$_2$ in the treatment of recurrent genital herpes, 24th ICAAC, 1984.

45. Whitley RJ: Treatment of herpesvirus infections in high risk patient populations. Pharmacological and Clinical Approaches to Herpesvirus and Virus Chemotherapy. Oiso, Japan 1984.

46. Nahmias AJ, Keyserling H and Whitley RJ: Changing patterns of neonatal herpes as affected by antiviral therapy and other factors. Pharmacological and Clinical Approaches to Herpesvirus and Virus Chemotherapy. Oiso, Japan 1984.

47. Kahlon J, Lakeman F, Nigida S, Ackermann M and Whitley RJ: Host response to specified polypeptides following primary and recurrent herpes simplex virus infections. American Society for Microbiology, Las Vegas, Nevada 1985.

48. Lakeman FD, Acoff R and Whitley RJ: Rapid diagnosis of genital herpes simplex infections using type specific monoclonal antibodies. American Society for Microbiology, Las Vegas, Nevada 1985.

49. Hutto C, Willett L, Yeager A and Whitley RJ: Congenital herpes simplex virus infection - early versus late gestational acquisition. Society for Pediatric Research, Washington, DC 1985.

50. Whitley RJ, Soong S, Alford C, Hirsch M, Schooley R, Hanley D, Nahmias A, Luby J, Aoki F and the NIAID Collaborative Antiviral Study Group: Treatment of biopsy-proven herpes simplex encephalitis: vidarabine versus acyclovir. Fourteenth International Congress of Chemotherapy, Kyoto, Japan 1985.

51. Whitley RJ, Soong SJ, Alford CA, Hirsch MS, Schooley R, Hanley D, Nahmias AJ and the NIAID Collaborative Antiviral Study Group: Treatment of biopsy-proven herpes simplex encephalitis: vidarabine versus acyclovir. American Federation for Clinical Research, Washington, DC 1985.

52. Whitley RJ, Hutto C, Corey L, Arvin A, Nahmias AJ, Alford CA Jr, Soong SJ and the NIAID Collaborative Antiviral Study Group: Changing presentation of neonatal herpes simplex virus (HSV) infections. 25th ICAAC, Minneapolis, MN 1985.

53. Corey L, Mohan K, Whitley, RJ and Stone F: Effect of viral type on the clinical outcome of CNS neonatal HSV infections. 25th ICAAC, Minneapolis, MN 1985.

54. Petty BG, Whitley RJ, Krasny HC, Liao S, Davis LG and Lietman PS: Pharmacokinetics and Tolerance of BW-A515U, a prodrug of acyclovir in healthy volunteers. 25th ICAAC,

Minneapolis, MN 1985.

55. Koga J, Chatterjee S, Whitley RJ: Synthesis and processing of herpes simplex virus glycoproteins. 1985 International Symposium on Medical Virology, 1985.

56. Tyring SK, Cauda R, Grossi C, Tilden AB, Sams WM Jr, Baron S and Whitley RJ: Peripheral blood mononuclear cells from patients with condyloma acuminatum exhibit decreased interleuken 2 and interleuken gamma production and depressed natural killer activity. 70th Annual Federation of American Societies for Experimental Biology and Guest Societies, 1986.

57. Schlitt M, Wilson E and Whitley RJ: Topographic and morphologic correlates in a rabbit model of HSE. 70th Annual Federation of American Societies for Experimental Biology and Guest Societies, 1986.

58. Whitley RJ, Arvin A, Corey L, Powell D, Plotkin S, Starr S, Alford CA, Connor J, Nahmias AJ, Soong SJ and the NIAID Collaborative Antiviral Study Group: Vidarabine versus acyclovir therapy of neonatal herpes simplex virus infection. Society for Pediatric Research, Washington, DC 1986.

59. Reichman RC, Bonnez W, Greisberger C, Whitley RJ, Tyring S, Miller L, Krueger GG, Corvath H, Wiedner M, Myers M and Dolin R: Treatment of condyloma acuminatum with intralesionally administered interferon: a multicenter, placebo-controlled trial, American Federation for Clinical Research, Washington, DC 1986.

60. Tyring SK, Cauda R, Grossi CE, Hatch KD, Sams WW Jr, Baron S and Whitley RJ: Peripheral blood mononuclear cells from patients with condyloma acuminata exhibit decreased interleukin 2 and interferon gamma production and depressed natural killer activity. European Society for Dermatological Research/Society for Investigative Dermatology, Geneva, Switzerland 1986.

61. Tyring SK, Cauda R, Grossi CE, Tilden AB, Hatch KD, Sams WW Jr, Baron S and Whitley RJ: Peripheral blood mononuclear cells from patients with condyloma acuminata exhibit decreased interleuken2 and interferon gamma production and depressed natural killer activity. Southern Branch of Society of Investigative Dermatology. Clinical Research, 34:267, 1986.

62. Kahlon J, Chatterjee S and Whitley RJ: Antibody response to specified polypeptides following neonatal herpes simplex virus, HSV infection. American Society for Virology, Santa Barbara, CA,, 1986.

63. Barnes DW, Britt W, Lakeman F, Whitley RJ: Urine cytomegalovirus (CMV) antigen detection. 26th ICAAC, New Orleans, LA 1986.

64. Soong SJ, Caddell GR, Alford CA, Whitley RJ and the NIAID Collaborative Antiviral Study Group: Utilization of brain biopsy for diagnostic evaluation of patients with herpes simplex encephalitis (HSE): a statistical model. 26th ICAAC, New Orleans, LA 1986.

65. Lakeman F, Loga J and Whitley RJ: Non-invasive assay of herpes simplex encephalitis: antigen detection in cerebrospinal fluid. 11th International Herpesvirus Workshop, Leeds, England 1986.

66. Chatterjee S, Koga J and Whitley RJ: Biological role of herpes simplex virus type 1 glycoproteins. 11th International Herpesvirus Workshop, Leeds, England 1986.

67. Whitley RJ: Therapy of life-threatening central nervous system herpes simplex virus infections. IXth International Congress of Infectious and Parasitic Diseases, Munich 1986.

68. Cauda R, Tilden AB, Prasthofer EF, Whitley RJ, Grossi CE: T-cell imbalances and NK activity in varicella-zoster infections. IXth International Congress of Infectious and Parasitic Diseases, Munich 1986.

69. Grossi CE, Whitley RJ and Tilden AB: Increased suppressor activity in herpes zoster patients. IXth International Congress of Infectious and Parasitic Diseases, Munich 1986.

70. Cauda R, Tilden AB, Grossi CE and Whitley RJ: Natural killing of varicella-zoster virus infected target cells: characterization of the effector cells. IXth International Congress of Infectious and Parasitic Diseases, Munich 1986.

71. Whitley, RJ, Arvin A, Corey L, Powell D, Plotkin S: Vidarabine versus acyclovir therapy of neonatal herpes simplex virus, HSV, infection. 2nd World Congress on Sexually Transmitted Diseases, Paris 1986.

72. Rodu B, Whitley RJ, Jones M, Lakeman AD, Romero de Leon E and Morgan P: Incidence of herpes simplex virus antibody titers in dental students. Biennial Congress, Edinburg, Scotland 1986.

73. Sommadossi JP, Barnes DW, Miller LR, Markiewicz MA and Whitley RJ: Novel pharmacologic strategies in the treatment of life-threatening infections: clinical experience with 9-(1,3-dihydroxy-2-propoxy-methyl) guanine (DHPG). American Federation of Clinical Research, San Diego, CA 1987.

74. Metcalf JF, Koga J, Chatterjee S and Whitley RJ: Protection against herpetic ocular disease by passive immunization with monoclonal antibodies to herpes simplex virus glycoproteins. ARVO 1987.

75. Whitley RJ: Varicella zoster virus infections. VIIth International Congress of Virology, Edmonton, Canada 1987.

76. Miller, L, Peets E, Whitley RJ and Tyring S: Interferon therapy of condyloma acuminatum (ca). 17th World Congress of Dermatology, Berlin 1987.

77. Chatterjee S, Shimizu M and Whitley RJ: Effect of cerulenin on the replication of herpes simplex virus type 1. American Society for Microbiology, Orlando, Florida 1987.

78. Tyring S, Cauda R, Whitley RJ, Hiramoto R, Ghanta V: Condyloma acuminatum patients successfully treated with interferon alpha exhibit enhanced lymphokine production and natural killer activity. Annual Federation of American Societies for Experimental Biology and Ghest Societies, 1986.

79. Whitley RJ, Arvin A, Corey L, Powell D, Plotkin S, Starr S, Nahmias A, Alford C, Caddell G, Soong SJ and the NIAID Collaborative Antiviral Study Group: Clinical factors which influence morbidity and mortality of herpes simplex virus infection. The Society for Pediatric Research, Washington, DC 1988.

80. Chatterjee S, Fabre V, Koga J and Whitley RJ: Isolation and partial characterization of monoclonal antibody against a HSV-2 nucleocapsid protein. American Society for Microbiology, Miami, Fl 1988.

81. Chatterjee S, Fabre V and Whitley RJ: Clinical isolates defective in the expression of surface glycoproteins of herpes simplex virus. American Society for Microbiology, Miami, Fl 1988.

82. Grimaldi LME, Roos RP, Manservigi R, Spear PG, Lakeman FD and Whitley RJ: Early diagnosis of herpes simplex virus encephalitis (HSVE) by an isoelectric focusing (IEF)-HSV-gB overlay technique. European Neurological Society, Nice, France 1988.

83. Cauda R, Laghi V, Ortona L, Whitley RJ: Immunologic alterations and recurrent herpes genitalis. The Immune Response to Viral Infections International Symposium. Florence, Italy, April 28-29, 1988.

84. Chatterjee S, Burns P, and Whitley RJ: Expression of herpes simplex virus type 1 glycoproteins in interferon-treated human neuroblastoma cells. 89th Annual Meeting of the American Society for Microbiology, New Orleans, Louisianna 1989.

85. Chatterjee S, Sarkar S, and Whitley RJ: Studies on the pathogenicity of herpes simplex virus isolates. 89th Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana 1989.

86. Chatterjee S, Nishimuro S, and Whitley RJ: Replication of herpes simplex virus in epidermal growth factor-treated human and monkey cells. International Herpesvirus Workshop, 1989.

87. Kahlon J, Whitley RJ: Antibody response of the newborn after herpes simplex virus infection. Adopted as Abstract from Pediatric Digest 6:7-8, 1989.

88. Whitley RJ: Antiviral therapy for HIV infection. The Children's Hospital Foundation Forum on Child Health. "Aids in Children". Memphis, Tennessee, November 16-17, 1989.

89. Whitley RJ: Therapy of herpes simplex virus infections of humans. UCLA Symposia on Molecular and Cellular Biology. Keystone, Colorado, March 31- April 5, 1989.

90. Goldsmith SM, Whitley RJ: A retrospective study of pregnant patients hospitalized with varicella. American Academy of Dermatology. Boston, Massachusetts, June 20-24, 1990.

91. Chatterjee S, Sarkar S, Koga J, Whitley RJ: Antiviral effects of the extract of culture medium of lentinus edodes mycelia on the replication of herpes simplex virus. VIIIth International Congress of Virology. Hindenburgdamm, Berlin, August 26-31, 1990.

92. Kahlon JB, Shannon WM, Brazier AD, Miller G, Schwartz J, Whitley RJ: Lack of inhibitory effect of SP-39304 (an antifungal agent) on the antiviral efficacy of AZT against HIV-in vitro. Third International Conference on Antiviral Research. Brussels, Belgium, April 22-27, 1990.

93. Daniels P, Watkins S, Kahlon J, Hart R, Horan A, Gullo V, Schwartz J, Whitley RJ, Shannon WM: Effect of a selected natural product from Schering-Plough Corporation on the Replication of HIV-1 as measured by CPE-Inhibition assays in infected cells. Third International Conference on Antiviral Research. Brussels, Belgium, April 22-27, 1990.

94. Kino T, Kern E, Britt W, Whitley R, Lakeman F: A rapid assay for cytomegalovirus antiviral sensitivity. Third International Conference on Antiviral Research. Brussels, Belgium, April 22-27, 1990.

95. Chatterjee S, Burns P, Whitley R, Kern E: Effect of HPMPC on the replication of herpes simplex virus type 1 in monkey kidney and human fibroblast cells. Third International Conference on Antiviral Research. Brussels, Belgium, April 22-27, 1990.

96. Chatterjee S, Nishimuro S, and Whitley RJ. Transport and expression of HSV-1 glycoproteins in tunicamycin-treated monkey kidney and human fibroblast cells.

American Society for Microbiology, Anaheim, California, May 7-9, 1990.

97. Whitley RJ: Treatment of disseminated varicella zoster infection in the immunocompromised host. Fourth International Antiviral Symposium: Clinical Pharmacological and Basic Aspects. Taipei, Taiwan, June 18-20, 1990.

98. Whitley RJ: Life Threatening Herpes Simplex Virus Infections. Fourth International Antiviral Symposium: Clinical Pharmacological and Basic Aspects. Taipei, Taiwan, June 18-20, 1990.

99. Whitley RJ: Clinical advances in antiviral therapy. Society of Industrial Microbiology. Orlando, Florida, July 31, 1990.

100. Nielsen LN, Chatterjee S, Whitley R: Apical and basolateral expression of HSV-1 glycoproteins in human neuroblastoma cells. The 15th International Herpesvirus Workshop. Washington, D.C., August 2, 1990.

101. Whitley RJ: Opportunistic herpesvirus infections. The 2nd International Conference of the Hospital Infection Society. Kensington, London, September 2-6, 1990.

102. Whitley RJ, Liu C, Pollard R, Hayden F, Mertz G, Linnemann C, Wright P, Peacock J, Laughlin C, Caddell G, Soong SJ, and the NIAID Collaborative Antiviral Study Group: Acyclovir versus vidarabine therapy of disseminated herpes zoster in the immunocompromised host. 30th ICAAC, Atlanta, GA, October 21-26, 1990.

103. Arvin A, Balfour H, Dunkle L, Feder H, Feldman S, Gershon A, Levy M, Hayden G, Rotbart H, Whitley R, McGuirt P: A double-blind, placebo-controlled trial of acyclovir treatment of chickenpox in healthy children. 30th ICAAC, Atlanta, GA, October 21-26, 1990.

104. Middlebrooks M, Holloway M, Blevins C, Lakeman A, Pappas P, Saag M, Tolpin M, Pollard R, Whitley R: Predictive value of positive cytomegalovirus (CMV) cultures in AIDS patients. 30th ICAAC, Atlanta, GA, October 21-26, 1990.

105. Balfour H Jr, Dunkle L, Feder H, Feldman S, Gershon A, Goldberg L, Hayden G, Levin M, Prober C, Whitley R, McGuirt P: Acyclovir (ACV) therapy of varicella in adolescents. 30th ICAAC, Atlanta, GA, October 21-26, 1990.

106. Perl TM, Haugen TH, Hollis R, Pfaller MA, Lakeman AD, Whitley RJ, Wenzel RP: Nosocomial transmission of herpes simplex-1 (HSV-1) in an intensive care unit (ICU): A need to reinforce isolation techniques? 30th ICAAC, Atlanta, GA, October 21-26, 1990.

107. Wahib M, Royal S, Pass R, Whitley R, Philips JB: Neurogenic diabetes insipidus (NDI)

associated with congenital cytomegalovirus (CMV) infection. Clinical Research. New Orleans, LA, January 30 - February 1, 1991.

108. Lakeman F, Blevins C, Whitley RJ: In vitro neutralization of cytomegalovirus (CMV) by a human monoclonal antibody, MSL-109. Clinical Research. New Orleans, LA, January 30 - February 1, 1991.

109. Chatterjee S, Burns P, Whitley RJ and Kern E. Inhibition of HSV-2 replication and glycoprotein expression in human fibroblast cells by HPMPC. Fourth International Conference on Antiviral Research, New Orleans, Louisiana, April 21-26, 1991.

110. Sanchez-Martinez D, Schmid DS, Whittington W, Brown D, Reeves WC, Chatterjee S, Whitley RJ, Pellett PE. Comparison of tests based on baculovirus expressed and immunoafinity purified glycoprotein G for detection of herpes simplex type specific antibodies. International Herpesvirus Workshop, Pacific Grove, California, July 7-10, 1991.

111. Nielsen LN, Whitley RJ, Chatterjee S. Herpes simplex virus type 1 induced changes in the organization of the intermediate filaments in human fibroblast and neuroblastoma cells. International Herpesvirus Workshop, Pacific Grove, California, July 7-10, 1991.

112. Amos CS, Pass RF, Stagno SB, Alford CA, Britt WJ, Whitley RJ: Unexpected exacerbation of retinitis after cessation of ganciclovir (DHPG) treatment of congenital CMV infection. 31st ICAAC, Chicago, Il., September 20 - October 2, 1991.

113. Whitley RJ, Lakeman AD, and the NIAID Collaborative Antiviral Study Group. Perinatal herpes simplex virus (HSV) infections. 31 ICAAC, Chicago, Il., 31st ICAAC, Chicago, Il., September 20 - October 2, 1991.

114. Isada NB, Johnson MP, Berry SM, Whitley R, Britt W, Haizgrave W, Evans MI. Multicompartment molecular in utero evaluation for congenital herpes simplex virus (HSV) and cytomegalovirus (CMV) and polymerase chain reaction (PCR). 1992 Society of Perinatal Obstetricians, Orlando, Florida, February 3 - 8, 1992.

115. Chatterjee S, Whitley RJ, Compans RW, Kern ER. Inhibition of virus-induced cell fusion by antivirals. Keystone Symposium on Molecular and Cellular Biology, Taos, New Mexico, February 28, 1992.

116. Kern ER, Vogt PE, Co MS, Kohl S, Whitley RJ. Treatment of herpes simplex virus type 2 infections in mice with murine and humanized monoclonal antibodies (MABS). International Society for Antiviral Research, Vancouver, B. C., Canada, March 8-13, 1992.

117. Pollard RB, Nokta MA, Pappas P, Holloway M, Borucki MJ, Wood DL, Zitelli AM, Tolpin MD, Nadler PI, and Whitley RJ. A Phase I/IIA study of a human monoclonal anti-cytomegalovirus antibody in patients with aids. International Society for Antiviral Research, Vancouver, B. C., Canada, March 8-13, 1992.

118. Chatterjee S, Burns P, Whitley RJ, Kern ER. Effect of CTC-23 on the replication of herpes simplex virus type 1 in human fibroblast cells. International Society for Antiviral Research, Vancouver, B. C., Canada, March 8-13, 1992.

119. Saag MS, Douglas J, Lapidus W, DeLoach LJ, Maples V, Laskin O, Massan F, Whitley RJ, Kappes J, Shaw G, Eminl E. Safety and relative antiretroviral activity of L697, L661 versus zidovudine in HIV-1 infected patients. VIII International Conference on AIDS/III STD World Congress, Amsterdam, Netherlands, July 19-24, 1992.

120. Whitley RJ. Therapeutic approaches to herpes simplex virus infection. IRBM Workshop on Molecular Basis of Viral Latency, Rome, Italy, May 10-13, 1992.

121. Whitley RJ. Herpes, a global challenge. Herpes - A Global Challenge Workshop. Berlin, June 4-6, 1992.

122. Cadoz M, Micoud M, Mallaret MR, Baccard C. Morand P, Chatel C, Meignier, Whitley RJ, Roizman B. Phase 1 trial of R7020: A live attenuated recombinant herpes simplex (HSV) candidate vaccine. 32nd ICAAC, Anaheim, California, October 11-14, 1992.

123. Jue S, Koanemon S, Rowe M, Laughlin C, Whitley R, and the NIAID Collaborative Antiviral Study Group. Neonatal herpes simplex virus (HSV) infections: A cost-benefit analysis of acyclovir therapy. 32nd ICAAC, Anaheim, California, October 11-14, 1992.

124. Boppana S, Alford C, Whitley R, Britt W. Altered antibody responses in congenital cytomegalovirus infection (C-CMV) treated with ganciclovir. 32nd ICAAC, Anaheim, California, October 11-14, 1992.

125. Trang JH, Kidd L, Soong SJ, Whitley RJ, Sommadossi JP. Linear pharmacokinetics of ganciclovir in infants and children with congenital cytomegalovirus infections. 7th Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, Texas, November 15-19, 1992.

126. Whitley RJ. Status, problems, and prospects of antiviral therapy for herpesvirus infections. First International Herpesvirus Symposium. Osaka, Japan, June 23-24, 1992.

127. Whitley RJ. Clinical virology and recent advances. SmithKlein Beecham Media Workshop. Paris, France, November 5-6, 1992.

128. Kern ER, Vogt PE, Palmer J, Whitley RJ, Co MS. Preclinical evaluation of murine and humanized monoclonal antibodies in experimental herpes simplex virus infections. The Third Annual IBC International Conference on Antibody Engineering. San Diego, California, December 14-16, 1992.

129. Gangopadhyay NN, Whitley, RJ, Chatterjee, S. Effect of human epidermal growth factor on the replication of human cytomegalovirus. American Society for Virology. Davis, California, July 10-14, 1993.

130. Mennemeyer ST, Whitley RJ, Cyr L. The value of neonatal herpes simplex infection prevention: Potential cost savings from vaccination protocols for a future vaccine. Economic Evaluation of Pharmaceuticals: Impacts on Administration and Policy Workshop. Association/Foundation for Health Services Research, Washington, D.C., June 27-29, 1993.

131. Mennemeyer ST, Whitley RJ, Cyr L. The value of neonatal herpes simplex infection prevention: Potential cost savings from vaccination protocols for a future vaccine. Primary Care: Cost, Quality and Effectiveness Workshop. Association/Foundation for Health Services Research, Washington, D. C., June 27-29, 1993.

132. Mennemeyer ST, Cyr L, Whitley RJ. Economic evaluation of neonatal herpes simplex virus infection therapy. APHA, San Francisco, California, October 24-28, 1993.

133. Mennemeyer ST, Cyr L, Whitley RJ. Using bootstrap estimators to test the sensitivity of cost effectiveness evaluations of therapy for neonatal herpes simplex virus infection. APHA, San Francisco, California, October 24-28, 1993.

134. Whitley RJ. Herpes simplex encephalitis: What's new in diagnosis, pathogenesis and treatment. Fifth Meeting of the Japanese Association of Antiviral Chemotherapy. Japan. January 26-27, 194.

135. Whitley RJ. Neonatal herpes simplex virus infections: tatus of therapy and future challenges. Whistler Herpesvirus Meeting. Whistler, Canada, January 29-February 2, 1994.

136. Jernigan DB, Ennis DM, Lackey PC, Chatterjee S, Whitley RJ, Hook III EW. Spectrum of herpes simplex virus infection in men attending a Birmingham sexually transmitted diseases clinic. Department of Medicine 10th Annual Trainee Research Symposium, Birmingham, Alabama, 1993.

137. Palmer J, Vogt PE, Co MS, Roizman B, Whitley RJ, Kern ER. Immunoprophylactic strategies for prevention of genital herpes simplex virus infections. Seventh International Society for Antiviral Research, Charleston, South Carolina, February 27-March 4, 1994.

138. Chatterjee S, Burns P, Gangemi JD, Whitley RJ. Effect of human recombinant and recombinant hybrid alpha-interferons on the replication of herpes simplex virus type 1 in human fibroblast and neuroblastoma cells. Seventh International Conference on Antiviral Research, Charleston, South Carolina, February 27-March 4, 1994.

139. Andreansky S, Whitley RJ, Chatterjee S. Role of HSV-1 mutant in cessation of protein synthesis in human and mouse glioma cells. 19th International Herpesvirus Workshop. Vancouver, B. C., Canada, July 31-August 5, 1994.

140. Legido A, Miles DK, Foley CM, Lischner H, Long S, Whitley R, Lakeman F, Grover WD. Relapse of herpes virus encephalitis after adequate acyclovir therapy. Child Neurology Society and International Child Neurology Assocaiton. San Francisco, California, October 2-8, 1994.

141. Lackey PC, Ennis DM, Duffy LB, Cassell GH, Whitley RJ, Hook EW III. Agents of urethritis in males attending a STD clinic. 34th ICAAC. Orlando, Florida, October 4-7, 1994.

142. Kimberlin DW, Kimberlin DE, Andrews WW, Lakeman Fd, DuBard MB, Soong SJ, Whitley RJ. Neonatal characteristics of infants born to women shedding herpes simplex virus (HSV) proximate to delivery. 2nd Annual Meeting of the IHMF, San Francisco, California, November 13-15, 1994.

143. Weiss H, Sherrill L, Soong SJ, Whitley RJ, Gnann J. Cost utility analysis of therapies for localized herpes zoster in the normal host. 2nd Annual Meeting of the IHMF, San Francisco, California, November 13-15, 1994.

144. Soroceanu L, Chatterjee S, Chambers R, Andreansky S, Chou J, Whitley RJ, Roizman B, Gillespie GY. Use of genetically engineered HSV-1 viruses in treatment of malignant intracerebral gliomas. Experimental Biology 95.

145. Whitley RJ, Weiss H, Gnann J, Tyring S, Wolf J, Pollard R, Mertz G, Pappas P, Laughlin C, Sherrill L, Hayden F, Schleupner C, Soong SJ, NIAID CASG. The efficacy of steroid and acyclovir therapy of herpes zoster in the elderly. International Society for Antiviral Research. Santa Fe, New Mexico, April 23-28, 1995.

146. Gnann J, Crumpacker C, Pollard R, Mertz G, Smith R, Steigbigel, Lalezari J, Cloud 2G, Soong S, Laughlin C, Whitley R, CASG/ACTG Zoster Study Group. Sorivudine (BV-araU) versus acyclovir for herpes zoster in HIV infected patients. The Clinical Research Meeting (AFCR), San Diego, California, May 5-8, 1995.

147. Whitley RJ, Weiss H.Gnann J, Tyring S, Wolf J, Pollard R, Mertz G, Pappas P, Laughlin

C, Sherrill L, Hayden F, Schleupner C, Soong SJ, NIAID CASG. The efficacy of steroid and acyclovir therapy of herpes zoster in the elderly. The Clinical Research Meeting (AFCR), San Diego, California, May 5-8, 1995. J Invest Med 1995;43:A114.

148. Kimberlin DW, Kimberlin DF, Andrews WW, Lakeman FD, DuBard MB, Soong S-J, Whitley RJ. Maternal and neonatal effects of genital herpes simplex virus (HSV) shedding proximate to delivery. The American Pediatric Society/The Society for Pediatric Research, San Diego, California, May 5-11, 1995.

149. Soong SJ, Whitley RJ. A comprehensive analysis of the effect of acyclovir versus placebo on herpes zoster pain. 35th ICAAC, San Francisco, California, September 17-20, 1995.

150. Kimberlin DW, Lakeman FD, Whitley RJ, NIAID CASG. Application of the polymerase chain reaction (PCR) to the diagnosis and management of neonatal herpes simplex virus (HSV) disease. 35th ICAAC, San Francisco, Califonria, September 17-20, 1995.

151. Dworkin, RH, Wood, MJ, Kay R, Cubed S, Sheffield, Soong S-J, Whitley RJ. A meta-analysis of placebo-controlled trials of acyclovir in acute herpes zoster: effect of treatment, age, and acute pain severity of persisting pain. American Pain Society, Los Angeles, California, November, 1995.

152. Lackey PC, Ennis DM, Cassell GH, Whitley RJ, Hook EW III. The Etiology of nongonococcal urethritis. Poster. Infectious Diseases Society of America, 1995.

153. Whitley RJ, Gnann JW, Jr, Weiss HL, Soong S-J. Unique clinical trial design combination acyclovir plus prednisone therapy of localized zoster in the normal host. Portugal, July 24-28, 1995.

154. Gnann J, Crumpacker C, Lalezari J, Smith J, Pollard R, Mertz G, Steigbigel R, Cloud G, Soong S-J, Laughlin C, Whitley R and the CASG ACTG Herpes Zoster Study Group. Sorivudine (BV-araU) versus acyclovir for herpes zoster in HIV-infected patients. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28-February 1, 1996.

155. Chatterjee S, Koga J, Whitley RJ. Antiviral effect of the extract of culture medium of Lentinus Edodes mycelia on the replication of human cytomegalovirus in human cells. Ninth International Conference on Antiviral Research, Urabandai, Fukushima, Japan, May 9-24, 1996.

156. Whitley RJ. Status of therapy for the management of VZV infections: A focus on chicken pox. 12th Regional Conference of Dermatology. Pattaya, Thailand, May 1-14, 1996.

157. Whitley R. J. New approaches to antiviral therapy in the immunocompromised. MASCC Symposium Supporte Care in Cancer. Toronto, Canada, June 19-22, 1996.

158. Whitley RJ. The behavior of $_1$ 34.5 herpes simplex virus mutants in tumor models. 3rd Japan Herpesvirus Infection Forum. Sapporo, Japan, August 23-24, 1996.

159. Ennis DM, Lackey PC, Good JK, Jernigan DB, Lakeman F, Whitley RJ, Richey CM, Hook EW III. The etiology of concomitant urethritis in men with genital ulcer disease (GUD). Infectious Diseases Society of America 34th Annual Meeting. New Orleans, Louisiana, September 18-20, 1996.

160. Rotbart H, McCracken G, Dagan R, Pichichero M, McLinn S, Whitley R, Modlin J,McCarty J, Cascino M, O'Connell J, Menegus M, Reidenberg B, Blum D. PCR of multiple specimen types in the diagnosis of outpatient enterovirus (EV) Infections. 36th ICAAC, New Orleans, Louisiana, September 13-16, 1996.

161. Whitley RJ. Therapeutic approaches to herpes zoster: Past and future. 12th International Roundtable "Nucleosides, Nucleotides, and their Biological application. La Jolla, California, September 14-19, 1996.

162. Kimberlin DW, Whitley RJ, Cloud G, Gruber W, Storch, Demmler GJ, Jacobs RF, Dankner W, Spector SA, Starr S, Pass RF, Stagno S, Britt WJ, Alford C, Soong SJ, and the NIAID CASG. Ganciclovir treatment of symptomatic congenital cytomegalovirus (CMV) Infection: Results of a Phase II Study. 6th International Cytomegalovirus Workshop, Orange Beach, Alabama, March 5-9, 1997.

163. Andreansky S, Gillespie GY, He B, Markert J, Parker J, VanCott J, McGhee J, Roizman B, Whitley RJ. Intracranial therapy in mice with $\gamma_1$34.5$^-$HSV-1 genetically engineered to express murine interleukins. 22nd International Herpesvirus Workshop, La Jolla, California, August 2-8, 1997.

164. Gnann J, Tyring S, Burdge D, Chandrasekar P, Wallace M, Beutner K, Weiss H, Soon S-J, Sherrill L, Laughlin C, Whitley R, and the CASG Herpes Zoster study Group. Oral antiviral therapy for herpes zoster in immunocompromised (IC) patients: sorivudine vs. acyclovir. Infectious Diseases Society of America 35th Annual Meeting. San Francisco, California, September 13-16, 1997.

165. Johnson, L. Laughlin C, Sawyer L, Gaither T, Gnann J, Kimberlin D, Whitley R., CASG. An established collaborative network for performance of multicentered clinical trials including chronic hepatitis B and C. AASLD Meeting on Chronic Viral Hepatitis. McLean, Virginia, June 27-28, 1997.

166. Andreansky S, Gillespie GY, He B, Markert J, Roizman B, Whitley. Murine glioma therapy with mutant herpes simplex viruses expressing murine interleukins. 12th International Conference on Brain Tumour Research and Therapy. Keble College, Oxford, United Kingdom. September 20-23, 1997.

167. Whitley RJ. Therapeutic advances in the management of herpes simplex and varicella zoster virus infections. The 8th International Conference on Immunobiology and Prophylaxis of Human Herpesvirus Infections. Mishima, Japan, October 6-8, 1997.

168. Whitley RJ. Management of herpes zoster in the normal host. New Directions in Antiviral Chemotherapy. San Francisco, California, November 13-15, 1997.

169. Whitley RJ. The immunocompromised host: Rational Antiviral Therapies. 3rd International Symposium on Febrile Neutropenia. San Francisco, California, December 10-13, 1997.

170. Kimberlin DF, Weller S, Andrews WW, Hauth JC, Whitley RJ, Lakeman F, Miller G, Goldenberg RL. Valaciclovir pharmacokinetics in late pregnancy. Society of Perinatal Obstetricians. Miami Beach, Florida, February 2-7, 1998.

171. Whitley RJ. Neonatal Herpes: New approaches to therapy. Whistler Herpesvirus Meeting, Whistler, Canada, February 7-10, 1998.

172. Whitley RJ. Cytomegalovirus infection: Is there a place for antiviral therapy. Whistler Herpesvirus Meeting, Whistler, Canada, February 7-10, 1998.

173. Parker JN, Markert JM, Gillespie GY, Roizman B, Whitley RJ. Characterization of genetically engineered herpes simplex viruses expressing murine cytokines interleukin-12 and granulocyte-macrophage colony stimulating factor. 23rd International Herpesvirus Working. York, England, August 1-7, 1998.

174. Whitley RJ. New antiviral drugs for the treatment of respiratory viral diseases: A focus on pleconaril. American College of Physicians Symposium. New Orleans, Louisiana, April 22, 1999.

175. Kimberlin DW, Jacobs RF, Powell DA, Corey L, Gruber G, Rathore M, Bradley J, Diaz P, Kumar M, Arvin A, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, Sierra T, Soong S-J, Lakeman FD, Whitley RJ, and the NAID Collaborative Antiviral Study Group. The safety and efficacy of high-dose (HD) acyclovir (ACV) in neonatal herpes simplex virus (HSV) infections. Society for Pediatric Research Meeting. San Francisco, California, May 1-4, 1999.

176. Parker JN, Zhang L, Hunter E, Whitley RJ. Recombinant herpes simplex virus as a

vector for HIV vaccines. New Concepts in HIV Vaccine Development Workshop, AVRC and NIH. Bethesda, Maryland, May 3-5, 1999.

177. Markert JM, Parker JN, Gillespie GY, Whitley RJ. Engineered HSV-1 expressing IL-12 or GM-CSF for experimental murine brain tumor therapy. American Society of Gene Therapy 2nd Annual Meeting. Washington, D.C., June 9-13, 1999.

178. Guffey MB, Luckett WS, Gillespie GY, Whitley RJ, Markert JM. Genetically engineered HSV-1 expressing bacterial cytosine deaminase for experimental murine brain tumor therapy. International Herpesvirus Workshop. Boston, Massachusetts. July 17-23, 1999.

179. Parker JN, Markert JM, Love CE, Gillespie GY, Whitley RJ. Engineered HSV-1 expressing IL-12 or GM-CSF for experimental murine brain tumor therapy. International Herpesvirus Workshop. Boston, Massachusetts, July 17-23, 1999.

180. Bharara S, Gillespie GY, Cocchi F, Campadelli-Fiume, Parker JN, Markert JM, Whitley RJ, Roizman B. Transuced expression of the herpesvirus Ig-Like Receptor by GL-261 glioma cells facilitates HSV entry. International Herpesvirus Workshop. Boston, Massachusetts, July 17-23, 1999.

181. Whitley RJ. Perinatal herpes simplex virus infections. 39th ICAAC, San Francisco, California, September 26-29, 1999.

182. Straus SE, Whitley RJ. Varicella and herpes zoster: management for the year 2000. 39th ICAAC, San Francisco, California, September 26-29, 1999

183. Reisinger K, Hayden F, Whitley R, Toronto TBD, Dutkowski R, IPE D, Mills R, Ward P. Oral oseltamivir is effective and safe in the treatment of children with acute influenza. IDSA, Philadelphia, Pennsylvania, November 21-28, 1999.

184. Whitley R, Dutkowski R, Ipe D, Mills R, Ward P. Safety and acceptability of oseltamivir liquid formulation in the treatment of influenza in children aged 1 to 12 years. 9th International Congress on Infectious Diseases (ICID), Buenos Aires, Argentina, April 10-13, 2000.

185. Whitley RJ. New approaches to neonatal herpes simplex virus infections. 9th International Congress on Infectious Diseases, Buenos Aires, Argentina, April 10-13, 2000.

186. Reisinger K, Hayden F, Whitley R, Dutkowski R, Ipe D, Mills R, Ward P. Oral oseltamivir is effective and safe in the treatment of children with acute influenza. ECCMID (European Congress Meeting on Infectious Diseases). Stockholm, Sweden. May 28-31, 2000.

187. Whitley RJ, Reisinger KS, Hayden FG, Dutkowski D, Ipe D, Mills R, Ward P. Oral oseltamivir is effective and safe in the treatment of influenza virus infections in children. ECCMID (European Congress Meeting on Infectious Diseases). Stockholm, Sweden. May 28-31, 2000.

188. Hayden F, Reisinger K, Whitley R, Dutkowski R, Ipe D, Ward P. Oseltamivir significantly reduces upper and lower respiratory complications of influenza that require antibiotic intervention. ECCMID (European Congress Meeting on Infectious Diseases). Stockholm, Sweden. May 28-31, 2000.

189. Hayden FG, Reisinger KS, Whitley RJ, Dutkowski R, Ipe D, Mills R and Ward P.. The impact of oseltamivir treatment on upper and lower respiratory tract complications of acute influenza in children. Florence 2000 World Congress on Lung Health. Florence, Italy. August 30-September 3, 2000.

190. Hayden FG, Reisinger KS, Whitley RJ, Dutkowski R, Ipe D, Mills R and Ward P. Oral oseltamivir is effective and safe in the treatment of influenza virus infection in children. Florence 2000 World Congress on Lung Health. Florence, Italy. August 30-September 3, 2000.

191. Hayden FG, Reisinger KS, Whitley R, Dutkowski R, Ipe D, Mills R, Ward P. Oral oseltamivir is effective and safe in children for the treatment of acute influenza A and B. ESWI Pediatrics, Crete. September 23- 28, 2000.

192. Winther B, Hayden FG, Whitley R, Reisinger K, Dutkowski R, Ipe D, Ward P, Mills R. Oral oseltamivir reduces the risk of developing acute otitis media following l, influenza infection in children. 40th ICAAC, Toronto, Canada. September 17-20, 2000.

193. Kimberlin DW, Lin C-Y, Sanchez P, Demmler G, Dankner W, Shelton M, Edwards, K, Jacobs RF, Robinson J, Wright J, Lakeman FD, Kiell JM, Soong S-J, Whitley RJ, and the NIAID CASG. Ganciclovir (GCV) treatment of symptomatic congenital cytomegalovirus (CMV) infections: Results of a Phase III randomized trial. 40th ICAAC, Toronto, Canada. September 17-20, 2000.

194. Whitley RJ. Antiretrovirals in children. 40th ICAAC, Toronto, Canada. September 17-20, 2000.

195. Whitley RJ. Perinatal herpes simplex virus infections. 40th ICAAC, Toroto, Canada. September 17-20, 2000.

196. Whitley RJ. Herpes simplex virus. 40th ICAAC, Toronto, Canada. September 17-20, 2000.

197. Reisinger K, Winther, B, Hayden F, Whitley R, Dutkowski R, Ipe D, Mills R, Ward P. Oral oseltamivir reduces the risk and severity of otitis media in preschool children. WONCA 2001.

198. Weiss H, Gnann J, Wood M, Fiddian P, Crooks J, Soong SJ, Whitley RJ. Application of a new phase-specific models in the evaluation of herpes zoster pain. The 4th International Conference on Varicella, Herpes Zoster and Post-herpetic neuralgia (PHN). La Jolla, California, March 3-5, 2001.

199. Whitley RJ. Clinical management of herpes today. 11th European Congress of Clinical Microbiology and Infectious Diseases. Istanbul, Turkey. April 1-4, 2001.

200. Parker JN, Markert JM, Gillespie GY, Whitley RJ. Engineered herpes simplex vaccine implications viruses expressing IL-12 or GM-CSG: Gene Therapy and Vaccine Implications. Fourth Annual Conference on Vaccine Research. April 23-25, 2001.

201. Kimberlin DW and Whitley RJ for the NIAID Collaborative Antiviral Study Group (CASG). 8th International CMV Workshop. Monterey, CA, May 19-25, 2001.

202. Bradford, RD, Kimberlin DW, Lakeman FD, Cloud G, Boppana SB, Britt WJ, Sanchez P, Demmler G, Dankner W, Shelton M, Jacobs RJ, Whitley RJ, and the NIAID Collaborative Antiviral Study Group (CASG). Baseline viremia in congenital cytomegalovirus (CMV) infection correlates with clinical outcome. IDSA. San Francisco, CA. October 25-28, 2001.

203. Ison MG, Gnann J, Treanor J, Nagy-Agren S, Whitley RJ, Elliott M, Hayden F, NIAID Collaborative Antiviral Study Group. Phase II Study of the safety and efficacy of nebulized zanamivir in patients with serious influenza virus infections. 41st ICAAC, Chicago, IL,. December, 16-18, 2001.

204. Whitley RJ. New therapeutic approaches CMV Symposium. 41st ICAAC, Chicago, IL, December, 16-18, 2001.

205. Whitley RJ. Virology of Picornavirus viral respiratory infections. 41st ICAAC, Chicago, IL, December, 16-18, 2001.

206. Whitley RJ. Taking on resistance: A losing battle or a winning stratagem? Keystone Symposia, Sante Fe, New Mexico. January 31-February 5, 2002.

207. Whitley RJ. Treatment and management of pain. Update 2002—Clinical Management of Viral Infection. Whistler Herpesvirus Meeting, Whistler, Canada, February 9-12, 2002.

208. Whitley RJ. Clinical management of human cytomegalovirus infection. American Association for the Advancement of Science. Boston, MA. February 14-19, 2002.

209. Whitley RJ. New antiviral compounds. ICAAC, San Diego, CA. September 27-30, 2002.

210. Whitley RJ. Prevention and treatment of zoster associated pain. 42nd ICAAC, San Diego, CA. September 27-30, 2002.

211. Horsbaugh BC, Gillespie Y, Whitley R, Peterkin JJ, Tufaro F. G207 and radiation. G207, an oncolytic HSV-1, combined with whole head irradiation significantly increases survival in a murine model of human glioma. International Cancer Gene Therapy Conference. San Diego, CA, December 12-14, 2002

212. Andrews W, Kimberlin D, Whitley R, Cliver S, Deeter R. Valaciclovir suppressive therapy in pregnant women reduces recurrent genital herpes (HSV): Results of a randomized trial. Society for Maternal-Fetal Medicine 23rd Annual Meeting. San Francisco, CA, February 3-8, 2003.

213. Parker* JN, Zajac A, Hunter E, Whitley RJ. Evaluation of a conditionally replication competent HSV expressing HIV-$1_{89.6}$ Gag as a vaccine for HIV. American Society for Gene Therapy, Washington, D.C., June 4-8, 2003.

214. Kimberlin DW, Lin C-Y, Sanchez P, Demmler G, Dankner W, Shelton M, Edwards K, Jacobs RF, Robinson J, Wright J, Lakeman FD, Kiell JM, Soong S-J, Whitley RJ, and the NIAID Collaborative Antiviral Study Group (CASG). Ganciclovir (GCV) Treatment of Symptomatic Congenital Cytomegalovirus (CMV) Infections: Results of a Phase III Randomized Trial. 43rd ICAAC. Chicago, Illinois, September 14-17, 2003.

215. Whitley RJ. West Nile virus clinical overvied prospects for development of therapeutics and a human vaccine. 43rd ICAAC. Chicago, Illinois, September 14-17, 2003.

216. Mertz GJ, Miedzinski L, Goade D, Pavia A, Hjlle B, Hansbarger CO, Levy H, Koster FT, Lindemulder A, Carpenter M, Zhang S, Riser L, Fernandez H, Laughlin CA, and Whitley RJ for the Collaborative Antiviral Study Group. Placebo-Controlled, Double Blind Trial of Intravenous Ribavirin for Hantavirus Cardiopulmonary Syndrome in the US and Canada. 43rd ICAAC. Chicago, Illinois, September 14-17, 2003.

217. Sizemore, Jr., A Hughes, A Lakeman, R Whitley, E Hook III. Herpes Simplex Virus 2 Serostatus Among Circumcised and Uncircumcised Men Attending an STD Clinic. 41st Annual Meeting of IDSA, San Diego, California, October 9-12, 2003.

Monographs

Wood M. How can the burden of zoster-associated pain be reduced? IHMF Forum (International Herpes Management Forum), 1993.

Whitley R. Diagnosis of herpesvirus infections. IHMF (International Herpes Management Forum), 1994.

Kroon S. Limiting the continued spread of genital herpes. IHMF (International Herpes Management Forum), 1994.

Kroon S, Whitley R. Can we improve management of perinatal HSV infections? IHMF (International Herpes Management Forum), 1995.

Conant MA, Wood MJ (eds.). Herpesvirus and HIV infection--co-factors and opportunistic Infections. IHMF (International Herpes Management Forum), 1995.

Wood MJ, Kroon S. Reducing the burden of zoster pain--update. IHMF (International Herpes Management Forum), 1995.

Sandstrom E, Whitley RJ. Genital and orofacial herpes simplex virus infections—clinical implications of latency. IHMF (International Herpes Management Forum) 3rd Annual Meeting, November 17-19, 1995.

Sivayathorn A, Whitley RJ (eds.) Herpesvirus infections in the immunocompromised hosti with HIV-Update. IHMF (International Herpes Management Forum) 4th Annual Meeting, November 9-10, 1996.

Whitley RJ, Weber T, Pass R. Herpesvirus infections in pregnancy IHMF (International Herpes Management Forum), 1999.

Whitley RJ. Optimizing the management of genital herpes. Roundtable Series 69. 1999.

Pass R, Weber T, Whitley RJ. Herpesvirus infections in pregnancy. IHMF (International Herpes Management Forum), 2000.

Whitley RJ and Meheus A. The public health significance of genital herpes. IHMF (International Herpes Management Forum), 2000.

Whitley RJ. The impact of antiviral medications on high-risk patients. Infectious Diseases in Children Monograph. Advances in Antiviral Medications. July, 2000.

Griffiths PD and Whitley RJ (eds.). The challenge of CMV infection and disease in transplantation

IHMF (International Herpes Management Forum), 2000.

Whitley RJ (ed). Introduction. p. 5. CMV 2000: The year in Review.

Whitley RJ (ed). Herpesvirus infections of the central nervous system. IHMF (International Herpes Management Forum), Management Strategies Workshop, Paris, France. February 26 – March 2, 2003.

Committee on Infectious Diseases Publications

Anonymous. Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn. Pediatrics. 99:645-50, 1997.

American Academy of Pediatrics, Committee on Infectious Diseases. Hepatitis C virus infection. Pediatrics. 101:481-5 Part 1, 1998.

Anonymous. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics, Committee on Infectious Diseases, Committee on Fetus and Newborn. Pediatrics. 102:1211-1216, 1998.

Abramson JS, Baker CJ, Fisher MC, Gerber MA, Meissner, HC, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ. Possible association of intussusception with rotavirus vaccination. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics 104(3 Pt 1):575, 1999.

Abramson JS, Baker CJ, Fisher MC, Gerber MA, Meissner, HC, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ. Prevention of hepatitis B in adolescents. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics 108:1392:1392, 2001.

3/5/97

I certify that this is a complete copy of the original.

NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006
BONDED THRU NOTARY PUBLIC UNDERWRITERS

DESIGN HSV VECTORS WITH EGR promoter - MULTIPLE CLONING SITE AND Poly A

I. CLONE EGR promoter into BamHI - S fragment HSV plasmid, which has been digested with BstE2 and BspE1.

A. PCR EGR fragment using Primers 5'-EGRp and 3'EGRp-PL (PL means polylinker)

B. -CUT WITH BstE2 and BspE1, LIGATE



II. CREATE EGR-pA plasmid by SUBCLONING polyA From CMVpAL/BL SK+ GMCSF USING XhoI - Screen By using BglII (Should cut out polyA)



III. To GENERATE egr-GMCSF, CUT OUT GM-CSF-polyA from CMV-pAL/BLSK(+) USING BAMHI, BglII and SUBclone into BglII site in HSV-egr. Screen using EcoRI/BglII





NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006
BONDED THRU NOTARY PUBLIC UNDERWRITERS

I certify that this is a complete copy of the original.
Terri Hicks

Timeline of the Construction of M002, a 34.5-deleted, tk+ HSV that expresses murine IL-12

12/30/96 Plasmids pBS-mp35 and pBS-mp40 received from Ueli Gubler, Ph.D., Hoffman-LaRoche

1/97 Construction of murine IL-12 bicistronic cassette into pBluescript (pBS-mIL-12) is initiated (page copy attached)

4/2/97 pBS-mIL-12 construction confirmed by restriction digest analysis

8/27/97 Construction of Egr-IL12 shuttle plasmid confirmed by restriction digest analysis

8/28/97 Co-transfection of R3659 with Egr-IL12 to construct 34.5-deleted, tk- HSV that expresses murine IL-12 (M001) is initiated

1/5/98 M001 confirmed by Southern blot analysis

4/1/98 IL-12 production by M001-infected Vero cells is confirmed

8/21/98 Construction of M002 completed after results of Southern blot hybridization show that tk gene has been successfully repaired to wildtype genotype (copy of dated gel attached)

I certify that this is a complete copy of the original.

Terri Rick
NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006
BONDED THRU NOTARY PUBLIC UNDERWRITERS

1/2/97 Added 10μL TE buffer to each tube of M_{35}, M_{40}, H_{35}, H_{40}

1/2/97 Transformed 1μL of each DNA into 40μL DH5α E. coli cells. Plated 100μL of cells on 1X plate by smearing. Incubated in 37°C, then put in 4°C.

1/6/97 Picked 3 colonies/plate and put each colony in 2mL LB/Ap. Warmed on shaker @ 37°C ON.

1/7/97 Obtained DNA from bacterial cells (1mL cells pelleted @ 8,000 rpm for 2 mins.) using QIAgen QIAprep Spin Protocol. Eluted DNA (each) w/ 100μL milli-Q H_2O.

1/8/97 Digested preps. of DNA:

M35 digest mix	M40 digest mix	H35 digest mix	H40 digest mix
1.5μL EcoR1 enzyme	3μL EcoR1 enzyme	3μL HindIII enzyme	3μL EcoR1 enzyme
1.5μL HindIII enzyme	3.5μL React 2 buffer	3.5μL React 2 buffer	3.5μL React 2 buffer
3.5μL React 2 buffer	28.5μL milli-QH_2O	28.5μL milli-QH_2O	~~28.5~~ 25μL milli-QH_2O
28.5μL milli-QH_2O			
35μL Total	35μL Total	35μL Total	35μL Total

Mixed mixes by vortexing and quick centrifuging.
Added 10μL mix + 10μL each DNA.
Incubated @ 37°C ~2½ hrs. Stored @4°C ON.

I certify that this is a complete copy of the original.

Terri Ricks

NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006
BONDED THRU NOTARY PUBLIC UNDERWRITERS

3/6/97 Transformed correct DNA from minipreps of M35, M40, H35, and H40 into E. coli cells.

Used: #1 M35 DNA (from 1/7/97)
#1 M40 DNA (from 1/7/97)
#2 H35 DNA (from 1/7/97)
#6 H40 DNA (from 1/13/97)

Transformed 1 µL each DNA into 75 µL DH5α E. coli cells. Plated 10 µL (in 90 µL milli-Q H_2O) onto 1X plates (LB w/Ap50). Incubated at 37°C ON.

3/6/97 Also transformed 1 µL pCITE 4a (+) DNA into 75 µL DH5α E. coli cells. Plated 10 µL (in 90 µL milli-Q H_2O) onto 1X plate (LB w/Ap50) Incubated at 37°C ON.

3/6/97 Performed digests of IL-12 subunits miniprep DNAs:

M35 digest:
3 µL #1 DNA (1/7/97)
1 µL NcoI
1 µL EcoRI
3 µL React 3 buffer (10x)
22 µL milli-Q H_2O
30 µL Total

M40 digest:
3 µL #1 DNA (1/7/97)
1 µL HindIII
1 µL BamHI
1.5 µL React 3 buffer (10x)
1.5 µL React 2 buffer (10x)
22 µL milli-Q H_2O
30 µL Total

H35 digest:
2 µL #2 DNA (1/7/97)
1 µL PstI
2 µL React 2 buffer
15 µL milli-Q H_2O
20 µL Total

H35 digest:
2 µL H35 #2 DNA (1/7/97)
1 µL XhoI
2 µL React 2 buffer (10x)
15 µL milli-Q H_2O
20 µL Total

H35 digest:
2 µL #2 DNA (1/7/97)
1 µL PstI
1 µL XhoI
3 µL React 2 buffer (10x)
23 µL milli-Q H_2O
30 µL Total

H40 digest:
2 µL #6 DNA
3 µL React 2 buf
1 µL XbaI
1 µL HindIII
23 µL milli-Q H_2O
30 µL Total

Mixed digests by vortexing and centrifuging.
Incubated @ 37°C for ~2 hrs.
Added 2 µL sample buffer/tube and mixed.
Mixed and quick-centrifuge.
Ran on 1% agarose gel.

Results: All cut correctly.

Mp35 should have ~645-bp fragment, and it does.

Mp40 should have ~1.1-bp fragment, and it does.

Hp35 cut w/ PstI should yield ~900-bp fragment, and it does.

Hp35 cut w/ XhoI should yield ~1090-bp fragment, and it does.

Hp35 double-digest w/ PstI and XhoI should yield ~900-bp fragment, and it does.

Hp40 should have ~1040-bp fragment, and it does.



1 = Mp35 cut w/ NcoI and EcoRI
2 = Mp40 cut w/ HindIII and BamHI
3 = Hp35 cut w/ PstI
4 = Hp35 cut w/ XhoI
5 = Hp35 cut w/ PstI and XhoI
6 = Hp40 cut w/ XbaI and HindIII

I certify that this is a complete copy of the original.

Terri Hicks

NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006
BONDED THRU NOTARY PUBLIC UNDERWRITERS



I certify that this is a complete copy of the original.

NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006
BONDED THRU NOTARY PUBLIC UNDERWRITERS

Timeline of the Construction of M012, a $\gamma_1$34.5-deleted, tk+ HSV that expresses bacterial cytosine deaminase

06/19/98	Received pCD2 clone from ATCC.
7/2/98	Construction of shuttle vector Egr-CD is initiated by Brad Guffey
7/17/98	Construction of shuttle vector is completed
7/22/98	Construction of M011, $\gamma_1$34.5-deleted HSV that expresses CD initiated.
8/98	M011 confirmed by Southern blot analysis.
9/18/98	Repair of tk gene in M011 initiated (construction of M012)
1/99	M012 completed (see page 78, WL II notebook)

I certify that this is a complete copy of the original.

NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006
BONDED THRU NOTARY PUBLIC UNDERWRITERS

Preparation of CD probe template from ATCC pCD2 1-12-99

- a 1.7kb fragment of the E.coli cytidine deaminase gene will be recovered from the ATCC plasmid pCD2. This fragment was subcloned into pBH478 by Brad Guffey & used in construction of the tk(-) virus. The 1.7kb fragment is released by BamHI-EcoRI digestion:

pCD2, 1.1µg/µl	2.5µl
10x R3	5µl
BamHI (10U/µl)	1µl
EcoRI (10U/µl)	1µl
H_2O	40.5µl
	50µl

1.7kb = 1.65×10^{-18} g/copy
want = 500ng = 3.0×10^{11} copies
pCD2 = 7.4kb
= 8.16×10^{-18} g/copy
$\times$ 3.0×10^{11} copies
2.4µg

- 37° overnight
- electrophorese on 1% preparative gel
- excise 1.7kb band & elute with Qiagen
- quantitate purified fragment on 1% agarose, 3/30µl against 1µl LMDL, 2000bp @ 50ng
0.5µl LMDL, " 25ng

1. 0.5µl LMDL
2. 3µl 1.7kb BamHI-EcoRI ~ 10ng/µl
3. 1µl LMDL

1 2 3

Stripping the Membrane
- the blot of PCR3 (tk(-) BamHI digests previously probed for tk will be stripped & re-probed for CD
- incubate blot in 0.5% SDS @ 100°C for 10'
- rinse in 100mM Tris pH8 for 5' @ RT
- cut ½" off bottom of membrane so it would fit in both carrier

Probe Labelling
- 5ng/µl wanted in kept. Plan on labelling 300ng 1.7kb CD frag

I certify that this is a complete copy of the original.
Cheri Nicholas

NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2000
BONDED THRU NOTARY PUBLIC UNDERWRITERS

- add following reaction components in order on ice:
  30 µl reaction buffer & mix
  Ce ul labelling reagent & mix
  30 µl X Lenther working soln & mix
- incubate 30' @ 37°
- add immediately to hyb

- Prehybridization & hybridization
  hyb buffer = Ce3ml
  add NaCl to 0.5M
  add blocking agent to 4%
  mix 1-2H
  - prehyb at least 15' @ 55°, actually about 1H
  - add probe in 1ml vol of hyb soln
  seal bag & hyb overnight @ 55°
- Washes
  - wash membrane 2x in primary wash buffer @ 55° for 15' ea
  - " " " secondary " " RT for 5' ea

Primary Wash Buffer (1l)

Urea	120g
SDS	1g
0.5M NaH_2PO_4 pH7	100ml
NaCl	8.7g
1.0m $MgCl_2$	10 ml

The CD-specific probe should hybridize to a 2.2kb BamHI fragment, containing the Epstein-Barr virus & CD gene. Of the 12 candidate viruses, only five appear to contain the CD gene:

pCD3tk(+) -3
pCD3tk(+) -4
pCD3tk(+) -6
pCD3tk(+) -7
pCD3tk(+) -9

These five clones will be used in subsequent activity assays.

NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006
BONDED THRU NOTARY PUBLIC UNDERWRITERS

I certify that this is a complete copy of the original.

I certify that this is a complete copy of the original.

Alexi Nicks

NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006
BONDED THRU NOTARY PUBLIC UNDERWRITERS

Timeline of the Construction of M1012, a $\gamma_1$34.5-deleted, RR1-deleted, tk+ HSV that expresses bacterial cytosine deaminase

10/15/02	Co-infection of M012 with M1000 initiated
4/25/03	Southern blot confirming construction of M1012
6/07/03	CD Activity in M1012 infected cells confirmed

=

CD40 / ~~PRT~~ PRT in $\gamma_1$34.5 / UL39

MO12 - CD40 in $\gamma_1$34.5

(M1000) 8309-βgal(8309-LacZ) LacZ in UL39

Coinfect MO12 + 8309-LacZ at
5:5, 5:4, 6:3, 5:2, 5:1 ratios

Pick LacZ producing colonies 1st round 10/20-21 2nd round
After several rounds, screen for purity
Southern Blot
probe - with $\gamma_1$34.5, CD plasmids
- with UL39 plasmid

~~Coinfect~~ MO12 LacZ and will have PacI sites flanking LacZ in the UL39 sequence.

Purify MO12 LacZ DNA and Cotransfect
& PART in PacI site of UL39 vector (make from vector

10/15/02 - CO- RSC15 Infected MO12 (2 MOI) and (M1000) 8309-LacZ (2 MOI) &
(1.6 MOI)
(1.2 MOI)
(0.8 MOI)
(0.4 MOI)

in .2 ml ifi. med.
inc 2 hr @ 37°C/5% ± rocking
Aspirated, washed, Added 2 ml growth med.
Incubate 24 hr

10/16/02 Harvested - added 2 ml sterile skim milk to each wells (All were infected) - froze @ -80°C in plate

Seed Vero @ 3×10^5/well in 6-well plates, incubate overnight

10/17/02 Infected ± 5:5 10^{-} → 10^{-4} in .2 ml ifi med
MO12/M1000 5:4 inc 2 hr @ 37°C ± rocking

NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006
BONDED THRU NOTARY PUBLIC UNDERWRITERS

I CERTIFY THIS IS A TRUE AND CORRECT COPY of the original.

+ H_2O
400µl Phenol/Chloroform/Isoamyl added
Shaken 1' gently
Cent 5' at R.T.
Transferred top layer to new tube
Added 40µl 3M Na OAc
Added 800µl 100% EtOH
-80°C 3/4 hr -> 1 hr
Cent 15' at 4°C
Asp carefully
Washed w/ 80% EtOH
Cent 5'
Asp carefully
Speed Vac dried
Resuspended in 15µl H_2O
Added 3µl 6X Loading Buffer
Loaded on 1% agarose gel, thin wells (20), 20 x 25 gel
300ml 1X TAE. 2L 1X TAE + 50µl EtBr = running buffer

Hind III gel
digests

①	②	③	④	⑤	⑥	⑦	⑧	⑨	⑩	⑪	⑫
1Kb	R8309	M1000	8111	8222	8311	8411	8412	2111	M012	F	λ + Hind
15µl	⊢ Hind III digests ———									⊣	
	18µl	18µl	18µl	18µl	18µl	18µl	18µl	18µl	18µl	18µl	12µl

Nco I digest - gel

①	②	③	④	⑤	⑥	⑦	⑧	⑨	⑩	⑪	⑫
1Kb	R8309	M1000	8111	8222	8311	8411	8412	2111	M012	F	λ (+ Hind III)
1.5µl	⊢ Nco I digests ———									⊣	
	18µl	18	18	18	18	18	18	18	18	18	

Run 125V, 3hr then 150V 2 - 2½ hr

Nco I digest gel stopped at 5:30 pm

Hind III stopped at 6:00 pm

I certify that this is a complete copy of the original.

NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006
BONDED THRU NOTARY PUBLIC UNDERWRITERS



M012/M1000 candidates V and VII digested probed:

I certify that this is a complete copy of the original.

NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006
BONDED THRU NOTARY PUBLIC UNDERWRITERS



I certify that this is a complete copy of the original.

NOTARY PUBLIC STATE OF ALABAMA AT LARGE
MY COMMISSION EXPIRES: May 12, 2006